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Abstract 
Primary sclerosing cholangitis (PSC) is a progressive chronic cholestatic liver disease, 
affecting young males predominantly.  It causes stricturing of the intrahepatic and 
extrahepatic bile ducts, often leading to biliary cirrhosis, with an increased risk of 
colorectal and hepato-biliary malignancy. It is commonly associated with 
inflammatory bowel disease (IBD). Specific medical therapy is ineffective and for 
patients who develop end-stage liver disease, liver transplantation remains the only 
definitive treatment option.  
 
The UK PSC study was set up in 2008 to recruit patients with PSC, to collect clinical 
data and DNA samples, to study phenotypic characteristics and the role of genetic risk 
factors in PSC.  To date, more than 2,000 patients have been recruited from UK 
hospitals, making it the largest independent PSC cohort worldwide. 
 
I studied the phenotypic characteristics of the cohort and identified an increased risk 
of requiring liver transplantation in patients with both intrahepatic and extrahepatic 
bile duct disease, in comparison to those with disease limited to intrahepatic ducts. 
Further study of the clinical and laboratory parameters, helped develop a UK PSC risk 
score, which allowed risk stratification of patients with PSC at the time of diagnosis. 
 
I performed a replication/candidate gene study followed by a genome wide 
association study in a cohort of  1,030 and 1,020 patients respectively with 5,162 
controls.  Genome-wide signficant association was identified at two novel loci: 10p15 
and 12q24, containing candidate genes Il2RA and SH2B3/ATXN2 respectively.  These 
genes have important roles in adaptive immune pathways, implicating an immue 
mediated disease process in the pathogenesis of PSC. As part of UK PSC, I also 
contributed to two large scale genome wide association studies in an international 
collaboration, which identified 13 novel loci associated with PSC. 
 
The UK PSC cohort is a unique national resource of patients with PSC and further 
deep phenotyping and quality of life studies are planned, in addition to undertaking 
clinical trials for novel therapeutic agents. The study of phenotypic characteristics and 
genetic association, undertaken in patients with PSC are described in this thesis. 
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Chapter 1: Introduction. 
 
 
Epidemiology of PSC 
 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, 
characterized by progressive inflammation and fibrosis of the intrahepatic and 
extrahepatic bile ducts (1).  PSC was first described by Delbet in 1924 (1) and 
then by Schwartz and Dale in a review of 6 patients with ulcerative colitis who 
developed inflammation of the bile ducts within as well as without the liver 
(2).  
 
The first population based study in PSC was undertaken in a well defined 
Norwegian population in 1998, with an estimated mean annual incidence and 
point prevalence of 1.3 per 100,000 person-years and 8.5 per 100,000 persons 
respectively (3).  Subsequent studies in the USA and UK have shown 
estimated incidence and prevalence rates of 0.41 – 0.9 per 100,000 person-
years and 3.85 – 13.6 per 100,000 persons respectively (4, 5).  PSC appears to 
be more prevalent in northern European countries, particularly Nordic 
countries (6). The most recent population based study performed in the 
Netherlands identified a mean incidence of 0.5 per 100,000 inhabitants 
(between 2000 and 2007) and a point prevalence of 6 per 100,000 inhabitants 
in a cohort of 590 well-characterised patients with PSC (7). PSC typically 
affects young males between the ages of 25 and 55 years; up to one third of 
affected patients are female (8). Male predominance in PSC was reported as 
early as 1966 (9) and has been confirmed in several follow-up studies (7). In 
contrast, a study by Takikawa et al, in Japanese patients concluded two 
distinct peaks in the age distribution at diagnosis: 20 – 30 years and 50 – 70 
years when compared with the west (10). The prevalence rates of PSC in 
Japan are much lower when compared with northern Europe or U.S.A, at 
around 0.095 per 10,000 (11). The reason for the geographical difference is 
not entirely clear, but could reflect considerable variability in describing the 
PSC phenotype accurately as well as difficulty in diagnosis.  It is apparent that 
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PSC differs considerably between various population groups and it is difficult 
to generalize about the epidemiological features based on any single 
population study alone. The main emphasis throughout this thesis however, 
will be based on studies done in the context of “Caucasian” (European & 
American) PSC cohorts, to allow a degree of homogeneity in the interpretation 
and conclusions of study findings across these sub-populations. 
 
Clinical features of PSC 
  
PSC should be considered in patients diagnosed with inflammatory bowel 
disease (IBD) who develop deranged (cholestatic) liver function tests (LFTs). 
Cholestasis is defined as decrease in bile flow, either due to impaired secretion 
from the hepatocytes or obstruction to bile flow within intrahepatic or 
extrahepatic bile ducts. However, the clinical presentation can vary 
considerably between different population sub-groups.  Chapman et al. and 
Wiesner et al were the first groups to describe the clinical characteristics in 
large cohorts of patients with PSC in 1980 (1, 12). One key feature that 
emerged from this study was that approximately 7 - 10% of patients were 
asymptomatic at diagnosis with a raised alkaline phosphatase (ALP) the only 
clue to the diagnosis.  
 
The largest single centre study by Boonstra et al. described the characteristics 
of 590 PSC patients (7): 64% of patients were male (male:female ratio 1.7: 1), 
with the mean age at diagnosis 38.9 years (1 standard deviation = 15.2).  It 
would be reasonable to conclude from this study and other reported studies 
that PSC typically affects young males, usually in their 3rd or 4th decade (13-
16).  Up to half of the patients are asymptomatic at diagnosis (13, 16).  The 
most prevalent symptom recorded is abdominal pain (35%), usually in the 
right upper quadrant, followed by jaundice (27 - 30%), pruritus (20 - 40%), 
fever (11 - 35%) and fatigue (17).  2 – 7% of patients may have stigmata of 
chronic liver disease at presentation such as ascites, oesophageal varices or 
variceal bleeding (13, 16). Findings at clinical examination are usually non-
specific and dependent upon the stage of disease, and include hepatomegaly 
(44 - 55%) and splenomegaly (29 - 30%) (17). 
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The serum alkaline phosphatase (ALP) is usually elevated, but is normal in up 
to 8.5% of patients (13).  Transient elevation of bilirubin level is common (≈ 
40%) (13, 16) and usually reflects a degree of cholangitis or dominant bile 
duct stenosis.   However, persistent conjugated hyperbilirubinaemia (for over 
3 months), is associated with a poor prognosis, but was seen in only 15% of 
patients in one study (16).  
 
Natural history of PSC 
 
The pathogenesis of PSC is poorly understood and the disease course notably 
unpredictable; this has led to an ever-increasing research interest in this 
condition.  The onset of PSC is usually insidious and patients tend to run a 
relatively stable course, at least in the early stages.  Deterioration in the 
clinical picture is often due to an episode of ascending cholangitis secondary 
to biliary stasis.  If treated promptly, patients usually make a full recovery to 
the pre-existing clinical state.  Repeated attacks of cholangitis might lead to 
the development of progressive bile duct stenosis or strictures.  Cholangitis is 
however, not a pre-requisite for the development of dominant strictures 
(discussed later in this chapter; page 45) and nearly half of patients with PSC 
have dominant strictures at follow-up (18).  
 
As with other cholestatic liver disorders, PSC may lead eventually to biliary 
cirrhosis.  However, only a small proportion (2 - 7%) of patients present with 
features of advanced liver disease at diagnosis (13, 16).  Until recently, the 
estimated median survival from diagnosis to either death or OLT was 
estimated to be between 9.6 and 18 years (13, 15, 16).  In the recent study by 
Boonstra et al. survival estimates were calculated for two separate PSC 
cohorts: a population based cohort (n = 140) and a tertiary referral centre 
cohort (n = 450) with the combined end-points of liver transplantation or PSC-
related death (7).  The population-based cohort had significantly extended 
survival when compared to the tertiary centre cohort (21.3 years versus 13.2 
years), confirming the referral bias noted in previous reports (7).  
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Patients with a persistent elevation of the serum conjugated bilirubin from 
presentation have a reduced median survival of just 30 months (16).  It is 
beyond doubt that the presence of sustained conjugated hyperbilirubinaemia 
marks the beginning of decompensated chronic liver disease.  In this context it 
is imperative to search for the presence of a dominant stricture or more sinister 
pathology, such as a superimposed cholangiocarcinoma (CCA), which may 
present with cholestatic jaundice. 
  
No therapy targeted at PSC has so far been shown to improve patient 
outcomes, other than liver transplantation.  
 
Diagnosis of PSC 
 
Defining PSC 
This section describes the criteria used to make a diagnosis of PSC in this 
thesis and is in accordance with national and international guidelines.  
PSC is diagnosed based on the following standard diagnostic criteria (19): 
 
A) The presence of cholestatic LFTs. 
B) The presence of intrahepatic and/or extrahepatic bile duct changes 
(including irregularity, narrowing, beading/segmental dilatation and/or 
stricturing) with endoscopic retrograde cholangio-pancreatography 
(ERCP), MR cholangiopancreatography (MRCP) or percutaneous 
transhepatic cholangiography (PTC). 
C) Histological changes consistent with PSC.  
 
Patients who have histological changes consistent with PSC but normal 
cholangiography are considered to have “small-duct PSC” (19). 
 
It is important to exclude all possible causes of secondary sclerosing 
cholangitis before a diagnosis of PSC can be considered secure.  Table 1.1 
lists the recognised causes of secondary sclerosing cholangitis, which can 
mimic both the clinical and the radiological features of PSC. 
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Table 1.1 Causes of secondary sclerosing cholangitis  
 
Choledocholithiasis 
Ischemic cholangiopathy 
Autoimmune pancreatitis/IgG4-associated cholangitis 
Intra-arterial chemotherapy 
Surgical biliary trauma 
HIV associated cholangiopathy 
Portal hypertensive biliopathy 
Cholangiocarcinoma 
Recurrent pyogenic cholangitis 
Eosinophilic cholangitis 
Histiocytosis X 
Recurrent pancreatitis 
Chronic ketamine use 
Ductal plate malformation 
 
 
Role of ERCP 
Cholangiographic assessment of the biliary tract is essential for a definite 
diagnosis of PSC.  Until the mid 1970s a definite diagnosis of PSC could only 
be made using operative cholangiography at laparotomy.  The advent of 
endoscopic retrograde cholangio-pancreatography (ERCP) in the late 1970s 
allowed the diagnosis to be made in a less invasive manner, but with similar 
sensitivity and specificity (20).  The characteristic cholangiographic findings 
include: multifocal, short, annular strictures alternating with normal or slightly 
dilated segments producing the classical beaded pattern of bile ducts (19, 21). 
A cholangiography based classification system - the “Amsterdam 
classification” (table 1.2) was first derived by Majoie et al. and subsequently 
modified by Rajaram et al. (22, 23).  Patients usually have both intrahepatic 
and extrahepatic changes: however up to 25% of patients have disease 
restricted to the intrahepatic ducts (16, 19).  Isolated extrahepatic disease is 
uncommon and seen in less than 5% of all patients (19).  However, ERCP is 
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an invasive procedure and is associated with complications such as 
pancreatitis, biliary sepsis, bleeding, perforation and aspiration (24).  
 
 
In the recent years, there has been a shift from using ERCP as a diagnostic 
tool to restricting its use for selected groups of patients who require 
therapeutic intervention to maximize the benefit to risk ratio.  Figures 1.1(a) 
and 1.1(b) show intrahepatic and both intra- and extrahepatic duct 
involvement in PSC respectively at ERCP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2. Amsterdam classification system for PSC based on 
cholangiography 
Morphologic type Cholangiography findings 
     Intrahepatic 
Type 0 No abnormalities. 
Type I Multiple strictures, normal calibre of the bile ducts or 
minimal dilatation. 
Type II Multiple short, band-like strictures, saccular dilatations, 
decreased arborisation. 
Type III Only central branches filled despite adequate filling 
pressure; severe pruning, one or more outpouchings. 
    Extrahepatic* 
Type 0 No abnormalities. 
Type I Irregular contour of extrahepatic ducts, without distant 
narrowing. 
Type II Segmental narrowing of extrahepatic ducts, with 
smooth or irregular margin. 
Type III Irregular narrowing and beading of the entire length of 
the common duct. 
Type IV The margin of the extrahepatic ducts is extremely 
irregular with diverticulum like out-pouching.  
*Extrahepatic ducts comprise the first order bile ducts (right or left main hepatic duct) and/or 
common bile duct at cholangiography allowing distinction between extrahepatic and 
intrahepatic disease. 
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(a) 
 
 
 
(b) 
Figure 1.1(a). ERCP showing intrahepatic bile duct beading and focal 
strictures with normal common bile duct; (b) intrahepatic and extrahepatic 
multifocal biliary strictures due to PSC. 
(C Y Ponsioen et al. (15); Copyright © BMJ Publishing Group Ltd & British Society of Gastroenterology. All rights 
reserved.) 
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Role of MRCP 
With the introduction of MRCP in the early 1990s, its sensitivity and 
specificity were found to be comparable to ERCP in evaluating patients with 
suspected biliary tract diseases (25).  Cholangiographic changes similar to that 
seen on ERCP, as described above, are considered diagnostic.  A recent meta-
analysis by Dave et al. concluded that the higher sensitivity (86%) and 
specificity (94%) obtained at MRCP for the diagnosing of PSC, allowed 
recommendation of MRCP as the first line investigation in patients with 
suspected PSC (26).  However, where patients are unable to have MRCP, or 
require therapeutic intervention or when MRCP findings are inconclusive, 
ERCP is the preferred investigation.  
 
Reporter variability is undoubtedly a concern but is likely to diminish with 
increased availability and experience of MRCP in the clinical setting.  
 
The main advantages of MRCP over an ERCP are: 
a) It is non-invasive and avoids the use of ionizing radiations.   
b) Lower risk of significant complications. 
c) Reduced cost.  
d) It allows complete visualization of the biliary tree (intrahepatic and 
extrahepatic) irrespective of the presence of an obstructive large bile duct 
lesion. 
 
Figures 1.2(a) and 1.2(b) depict the characteristic cholangiographic changes 
seen within the biliary tree at MRCP. 
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Figure 1.2(a). Cholangiography shows stricturing and beading of the intrahepatic 
ducts (arrow 1) with a normal appearing common bile duct (CBD).  
 
 
 
 
Figure 1.2(b). Cholangiography shows a severe hilar stricture involving the 
common hepatic duct (arrow 1) with marked dilatation of intrahepatic ducts 
(arrow 2).  
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Role of Liver biopsy and histological features of PSC 
The classic histological hallmark of PSC is the presence of concentric onion 
skin-type periductal fibrosis.  Other features that may be present include: 
portal fibrosis (60 - 80%), portal lymphocyte infiltration (69%), ductopenia 
with bile ductular proliferation (8 - 55%), cholestasis (7 - 50%) (17).  
Figure 1.3 shows the characteristic histological changes pathognomonic of 
PSC.  
 
 
Figure 1.3. Liver histology showing lymphocytic infiltrate and concentric onion 
skin fibrosis. 
 
Given the focal nature of PSC, liver biopsy specimens may not be a true 
representation of the pathological changes occurring in affected segments 
(sampling variation).  In a retrospective study of patients with PSC confirmed 
by cholangiography, liver biopsy failed to add any useful diagnostic 
information (27). Moreover, a normal liver biopsy does not per se exclude 
PSC.  As a consequence, routine liver biopsy is not recommended for patients 
with suspected PSC (19).  It does however, have a role in patients with 
suspected PSC who might have early disease or those with normal 
cholangiography (to exclude small-duct PSC) and to help exclude co-existing 
liver disorders.  
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Serological markers in PSC 
 
Serum autoantibodies form an important part of the routine diagnostic work-
up of various immune mediated chronic liver disorders such as primary biliary 
cholangitis (PBC), autoimmune cholangitis, autoimmune hepatitis (AIH) as 
well as PSC.  However, with few exceptions antibodies are not specific for 
any single disease.  
 
Several autoantibodies have been studied in PSC but most of these have very 
low diagnostic specificity.  The most relevant and prevalent of these is the 
perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA), seen in 26 - 94% 
of patients with PSC (28) and this may even have a diagnostic role (29).  The 
classical cytoplasmic ANCA (c-ANCA) and p-ANCA are directed against 
antigenic proteins found within the cytoplasm of human neutrophils.  They are 
typically found in patients with systemic vasculitis, but have also been 
reported in AIH and ulcerative colitis (UC) (30).  Another distinct type of 
ANCA known as “atypical” p-ANCA shows broad heterogeneous rim-like 
staining of the nuclear periphery associated with multiple intra-nuclear 
fluorescent foci (30).  It is now clear that the atypical p-ANCA in fact 
represents anti-neutrophil nuclear antibodies and not the classical anti-
neutrophil cytoplasmic antibodies (30). It is this atypical p-ANCA, which is 
associated most closely with PSC.  
 
Unlike c-ANCA and p-ANCA, the auto-antigen for atypical p-ANCA was 
identified only recently.  Terjung et al. identified Beta-tubulin isotype 5 
(TBB5) as the ANCA autoantigen associated with both PSC and AIH (31).  It 
is important to note that autoantibody titres (including that of atypical p-
ANCA) do not often correlate with disease activity, the extent of organ 
involvement or with immunosuppressive therapy (29).  
 
Based on the present evidence, a case cannot be made to use tests for 
autoantibodies in the diagnosis, stratification or monitoring of disease 
progression in patients with PSC.  However, their presence can be used as 
circumstantial evidence of a co-existing immune-mediated process. 
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A list of various serum autoantibodies present in patients with PSC is shown 
in table 1.3.    
 
Table 1.3. Serum autoantibodies present in patients with PSC 
Antibody Prevalence 
Anti-neutrophil cytoplasmic antibody (ANCA) 
(c-ANCA; p-ANCA and atypical p-ANCA) 
26 - 94% 
Anti-nuclear antibody (ANA) 7 - 77% 
Anti-smooth muscle antibody (SMA) 13 - 20% 
Anti-endothelial cell antibody  35% 
Anti-cardiolipin antibody  4 - 66% 
Anti-thyroperoxidase antibody 7 - 16% 
Thyroglobulin antibody 4% 
Rheumatoid factor 15% 
adapted from Chapman et al. (19) 
 
 
Immune-mediated disease associations in PSC 
 
There may be a role for an immune-mediated process in the pathogenesis of 
PSC (discussed later in this chapter).  This association is further strengthened 
by the presence of various immune-mediated diseases in PSC patients and is 
discussed below. 
  
Inflammatory bowel disease 
 
Prevalence of IBD 
PSC is often diagnosed in patients suffering with IBD (usually UC), who 
develop cholestatic LFT’s. PSC is associated strongly with IBD, with a 
reported prevalence of IBD in the northern European PSC population of 
between 60 and 80% (1, 13, 32).  The prevalence of IBD is significantly lower 
in Asia (20 - 50%) (33). The most common IBD phenotype observed in PSC is 
UC, present in 80 - 90% of patients with IBD (34).  Crohn’s disease (CD) is 
seen in up to 13% of cases and almost all of these have colonic involvement 
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(Crohn’s colitis) (34, 35).  Only 2 - 7.5% of patients with UC and 3.4% with 
CD appear to have co-existing PSC (34, 36). 
 
It is important to note that not all patients with UC or CD are screened 
routinely for PSC and these figures are likely to underestimate the prevalence 
of PSC in the IBD population.  This is elucidated very well in a recent study 
by Lunder et al. (37), in which 322 patients with UC were screened by MRCP 
for 20 years.  A total of 7.4% patients were found to have features of PSC, of 
which only 2.2% had a prior diagnosis of PSC.  It is possible that a proportion 
of patients with early PSC have normal liver biochemistry and so there is low 
clinical suspicion, until an ALP elevation becomes apparent.    
 
Diagnostic timeline for IBD 
The diagnosis of IBD precedes the diagnosis of PSC in most cases (19). 
However, there is no specific relationship between the onset of either of the 
two diseases and de novo cases of IBD are well recognized in patients after 
liver transplantation for PSC (38).  Conversely, PSC can also develop several 
years after UC in patients who have undergone colectomy (1, 39).  
 
PSC-IBD phenotype 
The IBD associated with PSC (PSC-IBD) is considered indistinguishable from 
that of IBD in general, both in terms of endoscopic as well as histo-
pathological findings.  However, some phenotypic characteristics are seen 
more commonly in patients with PSC, suggesting that PSC-IBD may represent 
a distinct sub-type of IBD, distinct from UC and Crohn’s disease (35). 
 
Table 1.4 lists the key phenotypic features of UC seen in patients with PSC. 
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Table 1.4. Features of IBD seen in patients with PSC. 
Pan-colitis with rectal sparing 
Backwash ileitis 
Quiescent disease course 
Predominance of right sided inflammatory activity 
Increased risk of colorectal cancer 
Increased risk of pouchitis in patients with ileal pouch anal 
anastomosis following colectomy 
Increased risk of peri-stomal varices in patients with 
ileostomy following colectomy 
 
 
Non-IBD immune-mediated diseases associated with PSC 
In a recent cohort study of 241 patients with PSC, the prevalence of non-IBD 
immune-mediated disease was 25%.  6% had features of autoimmune hepatitis 
(discussed on page 34) and the remaining (20%) had one or more extra-
hepatic, non-IBD diseases with sarcoidosis, thyroid disease and type 1 
diabetes the most prevalent (40).   Other less common diseases reported in 
association with PSC patients and present in 0.4% - 2% of cases overall, 
include coeliac disease, rheumatoid arthritis, psoriasis, vitiligo and systemic 
lupus erythematosus (SLE) (40, 41).  
 
 
Clinical variants in PSC 
 
The diagnosis of PSC encompasses all cases of cholangiopathy in which 
secondary causes have been excluded.  However, there are three distinct 
categories of patients, who despite having cholangiopathy differ from the 
usual clinical pattern of PSC either in terms of their imaging, biochemical 
parameters, treatment response or prognosis.  Thus attempts should be made to 
confirm or exclude these clinical variants.  
 
These include small-duct PSC; IgG4 associated cholangitis and PSC-AIH 
overlap and are discussed in more detail below.  Whether these clinical 
phenotypes are part of the spectrum of PSC or distinct entities remains 
unclear.  
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Small-duct PSC 
Cholangiography (ERCP, MRCP or PTC) can identify changes occurring only 
in the large bile ducts (> 100 μm in diameter), comprising ducts distal to the 
septal ducts.  A cholangiopathy restricted to smaller bile ducts (interlobular 
and proximal septal bile ducts) can only be identified at liver biopsy and 
where MRCP or ERCP findings are considered normal, is a phenotypic variant 
of PSC and termed small-duct PSC (42).  
 
True estimates of the incidence and prevalence of small-duct PSC remain 
largely unknown, but is estimated to be between 5 and 23% of all patients with 
PSC (43-45). In a recent large multi-centre study (published since the work 
described in this thesis was undertaken) with 7121 PSC cases, 3.4% of 
patients were diagnosed as having small-duct PSC (46).  
 
The diagnostic criteria for small-duct PSC include: 
A) Cholestatic liver biochemistry of otherwise unknown aetiology. 
B) Normal cholangiography.   
C) Liver histology consistent with PSC. 
D) An absence of any risk factor for secondary sclerosing cholangitis (Table 
1.1). 
 
In general the clinical course of PSC is highly variable, but includes 
significant co-morbidity, with reduced survival consequent to progressive 
chronic liver disease and in some, a need for liver transplantation.  In contrast, 
patients with small-duct PSC, tend towards a more benign clinical course with 
a significantly reduced risk of progression and superimposed malignancy.  
 
In a large series of 83 patients with small-duct PSC patients followed for 7.4 
years, liver transplant-free survival was significantly longer compared to well-
matched patients with large-duct PSC (13 years versus 10 years) (44).  Similar 
rates of IBD were seen in both the groups.  None of the patients in the series 
developed cholangiocarcinoma, which is seen in almost a third of patients with 
large-duct PSC.  Only 15.6% of patients with small-duct disease underwent 
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liver transplantation or died, demonstrating a much better prognosis in this 
group.  
 
It is estimated that approximately 20% of such patients will progress to large 
duct involvement (44, 45), but it is unclear if small-duct PSC is part of the 
same clinical spectrum as large-duct disease.  Since the pathogenesis for both 
disorders is unknown it is uncertain if these differ and this remains an area of 
active research. 
 
IgG4-related disease 
IgG4-related disease is a group of multisystem fibro-inflammatory disorders 
and has generated significant clinical interest in the last decade.  This has led 
to the identification of robust biochemical and histo-pathological criteria to 
diagnose these conditions (47). Hepatic involvement is common and can be 
classified as: 
- IgG4-related sclerosing cholangitis (IgG4-SC)  
- IgG4-related hepatopathy 
- IgG-related autoimmune hepatitis    
 
IgG4-related sclerosing cholangitis (IgG4-SC), is the most common hepatic 
manifestation and has recently been recognized as a distinct clinical entity and 
can mimic PSC. Amongst various other causes of secondary sclerosing 
cholangitis, it is perhaps the most important to recognise because of its 
responsiveness to therapy. Serum IgG4 is raised (> 1.4g/l) in most but can be 
normal in up to 20% of patients and levels > 5.6g/l give a specificity and 
positive predictive value of 100% for differentiating IgG4-SC from PSC (48).  
 
IgG4-SC is often associated with autoimmune pancreatitis (AIP) and is 
characterized by stricturing of the distal (intra-pancreatic) common bile duct 
(49).  However, strictures involving other parts of biliary tree are often seen 
and can be indistinguishable radiologically from those in more classical PSC. 
IgG4-SC can be classified into sub-types based on cholangiogram findings 
(Table 1.5). Abnormalities of the pancreas include diffuse enlargement 
(atrophy in chronic cases), sausage shaped pancreas, a peri-pancreatic halo 
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and irregular pancreatic duct and are often present.  By definition the serum 
IgG4 is elevated and is highly specific for the condition but is not diagnostic 
as it can be raised in other diseases.  A cut-off greater than two times upper 
limit of normal is considered significant but up to 30% of AIP cases can have 
normal IgG4 levels (50).  Histopathological examination remains the gold 
standard for diagnosis.  Characteristic features include a lymphoplasmacytic 
infiltrate organized in a storiform pattern, obliterative phlebitis and a mild-to-
moderate eosinophilic infiltrate.  In addition, more than 30 IgG4 positive 
plasma cells per high-power field and a more than 50% ratio of IgG4 to IgG, 
provides compelling evidence of an IgG4-related disease (47).  IgG4-related 
systemic diseases, including AIP and IgG4-SC, show dramatic responses to 
corticosteroid therapy with improved outcomes and corticosteroids are the 
treatment of choice in routine clinical practice.  Figure 1.4 (a) and (b) shows 
cholangiographic response to steroid treatment in a patient with IgG4-SC (49).  
 
Table 1.5. IgG4-SC sub-classification based on cholangiogram. 
Subtype Biliary involvement 
Type 1 Distal common bile duct (CBD) stricture 
Type 2a 
 
Type 2b 
 
Diffuse intrahepatic cholangiopathy and a lower 
CBD stricture with prestenotic dilatation 
Diffuse intrahepatic cholangiopathy and a lower 
CBD stricture without prestenotic dilatation 
Type 3 Hilar and distal CBD stricture 
Type 4 Hilar stricture 
adapted from Culver et al. (51) 
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(a) 
 
(b) 
Figure 1.4(a). ERCP showing intrahepatic and hilar strictures in a patient with 
raised serum IgG4. (b) Repeat ERCP after 3 months of corticosteroid 
treatment showing marked improvement in biliary strictures.  
Images taken from Webster et al. (49).  
 
Raised serum IgG4 levels are seen in 9 – 36% of patients with PSC (52, 53) 
and an increased number of intra-hepatic IgG4 positive plasma cells were 
found in 23% of explanted livers from patients with PSC undergoing liver 
transplantation and not thought beforehand to have IgG4-SC (49). PSC 
patients with raised IgG4 can be distinguished from those with IgG4-SC using 
an IgG1:IgG4 ratio > 0.24 with a sensitivity of 86% and specificity of 95% 
(48). 
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The role of IgG4 in disease pathogenesis is unclear at present; raised levels 
could merely be secondary to the inflammatory response but patients with 
PSC and a raised IgG4 may run a more progressive course (54).  It is evident 
that a mild elevation of the serum IgG4 is present in a small proportion of 
patients with PSC and does not indicate the presence of IgG4-related disease 
(IgG4-SC +/- AIP).  
  
Conversely, some patients with IgG4-SC may be misdiagnosed as having 
PSC.  The importance of distinguishing IgG4-SC from PSC cannot be 
overemphasized for the simple reason that the former condition is 
corticosteroid-responsive and the latter is not.  If left untreated, IgG4-SC can 
progress quickly to hepatic failure in months (55) and biliary cirrhosis/chronic 
liver disease in longstanding cases.  There are no clear-cut laboratory tests at 
present that would allow definitive distinction between these two conditions 
and emphasis should be laid on the presence of morphological features and 
other circumstantial evidence.  If these are present, then a trial of 
corticosteroid therapy may be considered.    
 
PSC with autoimmune features (“Overlap syndrome”) 
As highlighted previously in this chapter (on page 26), several autoantibodies 
are prevalent in patients with PSC but none has sufficient specificity for use as 
a diagnostic or prognostic marker for PSC.  The lack of a specific auto-antigen 
with a corresponding antibody, male predominance and the lack of response to 
immunosuppressive treatment make it difficult to call PSC a classical 
autoimmune disease.  
 
However, a small proportion of patients with PSC also have features of 
autoimmune hepatitis (AIH).  These groups of patients are sometimes referred 
to having ‘overlap syndrome’.  The overlapping features include symptoms, 
clinical findings, biochemical tests, variety of immunological findings, as well 
as histology.  A position paper from the International autoimmune hepatitis 
group (IAIHG) discourages the use of term ‘overlap syndrome’; instead, each 
diagnosis should be considered separately.  Diagnosis of PSC should be made 
on the standard criteria and if features of autoimmune hepatitis are present, 
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then patient has PSC with features of autoimmune hepatitis (56).  The 
prevalence of PSC in patients with AIH has been reported to be between 1.7 
and 12% in recent studies (57, 58).  
 
It is possible that the two conditions occur sequentially (usually AIH precedes 
PSC) and this is commonly seen in adult transition of patients with paediatric 
AIH.  However, in the prospective study by Gregorio et al., which evaluated 
55 children with serological features of AIH, 50% of these cases already had 
features of cholangiopathy at MRCP and were labeled as having autoimmune 
sclerosing cholangitis (59).  An alternative possibility is that PSC and AIH 
occur concurrently due to a predisposition to immune mediated diseases in 
PSC (e.g. thyroid disease and type 1 diabetes mellitus).  ‘Overlap’ at 
presentation is often seen in younger patients (< 25 years) (54) and when 
present, the first therapeutic approach should be immunosuppression (19).  
 
 
Malignancy in PSC 
 
As with most other chronic inflammatory disease states, which are known to 
promote carcinogenesis, PSC is also associated with an increased risk of 
malignancy and this represents the major cause of mortality.  
 
The most commonly reported malignancies are those of the biliary tract and 
colorectal mucosa.  However, malignancy affecting other organs have been 
reported (60).  In a recent study (published in 2017) by Weismuller et al. 21% 
of patients with PSC developed HPB malignancy over a 20-year period from 
diagnosis (46).  The majority of these were cholangiocarcinoma, with a third 
diagnosed within the first year of PSC diagnosis.  
 
Several risk factors have been postulated to increase the risk of neoplastic 
transformation including older age, alcohol consumption as well as the 
duration of co-existent IBD, but none have been validated and are of limited 
utility in clinical practice.  The most commonly reported malignancies are 
discussed in this section. 
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Cholangiocarcinoma  
Cholangiocarcinoma (CCA) is by far the most common malignancy reported 
in patients with PSC, with an estimated prevalence of between 5 and 20% (13, 
60-62).  CCA often develops considerably sooner (in the 5th decade) in 
patients with PSC when compared to those without PSC (usually in the 7th 
decade) and up to half of patients with CCA are diagnosed in the first year 
following the diagnosis of PSC (61, 63).  This suggests that prior to the 
manifestation of CCA, PSC may have been present but sub-clinical until the 
evolution of cholestasis.  
 
Beyond the first year of diagnosis of PSC, the annual incidence of CCA is 
between 0.5 and 1.5% per year (64).  Diagnosing CCA is often challenging, as 
it grows longitudinally with early perineural and pervascular invasion (65) and 
typically presents as a bile duct stricture (rather than a mass) usually at the 
hilum.  
 
As many as 50% of patients with PSC develop a dominant bile duct stricture 
(discussed on page 45). In most the cause is inflammation alone, but CCA is 
reported in this context in 5 to 20% of cases (66).  Clinical difficulty arises as 
the images in the presence or absence of superimposed CCA may be identical.  
The diagnosis of CCA should always be considered in a PSC patient with 
recent clinical deterioration in the form of obstructive jaundice, worsening 
pruritus, cholangitis or weight loss.  
 
No single test can reliably exclude CCA and results can be inconclusive 
despite repeated tests.  The carbohydrate antigen 19-9 (CA 19-9) is often 
measured as part of routine clinical follow up in PSC. Values over 130 U/ml 
have a sensitivity of 79% and specificity of 98% in diagnosing CCA (66), but 
the results should be always be interpreted with caution as the Ca19-9 is often 
raised markedly in patients with bacterial cholangitis.  
 
The EASL and AASLD guidelines do not recommend any biochemical or 
imaging modality to screen for CCA in patients with PSC due to lack of 
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evidence. Other tests that are routinely undertaken to investigate suspected 
CCA include MRI with MRCP, triple phase CT liver, ERCP +/- 
cholangioscopy, with biopsy or brushings and EUS.  The prognosis is 
extremely poor with a median survival of only 5 months after diagnosis (67). 
 
Gallbladder disease and malignancy 
An increased risk of gallbladder (GB) disease including stones, cholecystitis, 
polyps and neoplasia is well established in patients with PSC (68-73). 
Cholecystectomy is undertaken more often in this population in as many as 20 
to 25% of patients (74).  In a recent study 25% of patients were found to have 
gallstones and cholecystitis (irrespective of the gender) and another 6% of 
cases had a mass lesion within the GB (73).  More than half of the cases with a 
mass lesion were subsequently confirmed to have GB carcinoma.  In contrast, 
only 0.2 to 20% of the general population with a mass lesion develop 
carcinoma (73).  
 
Furthermore, GB polyps < 1.0 cm in size in the general population are 
unlikely to develop malignancy (75).  This is in contrast to the risk in PSC, 
which appears to be present independent of polyp size.  In a study in PSC by 
Said et al. 9/53 (13%) GB specimens were found to demonstrate dysplasia, 
despite the absence of a mass lesion on pre-operative imaging (73).   
It is possible that GB carcinoma also follows the inflammation-dysplasia-
carcinoma sequence and so it is recommended currently to refer patients with 
PSC patients and a GB mass lesion of any size for cholecystectomy (19, 73).  
It is assumed that chronic cholestasis is one risk factor for developing pigment 
gallstones, which are the variety seen most often in patients with PSC, but the 
precise mechanism remains elusive.  
 
Colorectal malignancy 
Studies have consistently shown an increased risk of colorectal cancer (CRC) 
in patients with PSC and co-existing IBD.  This risk is increased for patients 
suffering with UC as well as CD and appears to be significantly higher than 
the risk of developing CRC in patients with IBD alone (76, 77).  The absolute 
cumulative risk of CRC in a group of patients with PSC and UC has been 
 38 
estimated to be 9%, 31% and 50% after suffering with UC for 10, 20 and 25 
years respectively, in comparison to a risk of 2%, 5% and 10% for patients 
with UC alone at the same time points (78).  A recent population based study 
has provided further evidence of an increased CRC risk with an estimated 
odds ratio (OR) of 6.9 (79). 
 
One of the plausible explanations for the increased susceptibility may be the 
relatively quiescent nature of UC in PSC patients, allowing it to remain covert 
for a number of years, until PSC is diagnosed. However, the exact 
pathological basis of increased risk is unexplained. 
 
Hepatocellular carcinoma 
Patients with PSC who progress to cirrhosis are also at increased risk of 
developing hepatocellular carcinoma (HCC) in between 1.5 and 4% of cases 
(60, 80).  Such patients should be managed according to the same guidelines 
for patients with HCC developing due to cirrhosis of any cause.  
 
Pancreatic cancer 
An increased risk of pancreatic carcinoma in PSC was first described in a 
case-control study by Bergquist et al. in 2002 (80).  5/604 (0.8%) patients 
were found to have pancreatic cancer giving a standard incidence ratio of 14.3.  
More recently, 5/200 (2.5%) patients were found to have pancreatic cancer, all 
of whom died within 5 years of diagnosis.  No differences were seen with 
respect to the age at diagnosis of pancreatic cancer in comparison to the 
general population (60). 
 
 
Pathogenesis of PSC – Current views and hypotheses 
 
The pathogenic mechanisms leading to the development of PSC remain poorly 
understood, but are likely to be multifactorial.  There is evidence to support an 
immune-mediated basis to the development of PSC, involving a complex 
interplay between innate and adaptive immune responses.  According to this 
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hypothesis PSC results from exposure of a genetically susceptible individual 
to one or a combination of unidentified environmental factors. 
 
There are several aspects of immune function that differ between patients with 
PSC and both healthy individuals and patients with other varieties of liver 
injury.  Some of these differences may provide insight into the pathogenesis of 
the condition and in turn might guide future therapy.   
 
Immunological changes in PSC 
Immunological changes that occur in PSC at the cellular level have largely 
been studied on liver biopsy specimens from patients with established PSC.  
As such, it is difficult to study the cellular immune responses that take place in 
the earlier stages of the evolution of PSC; these early changes may be more 
relevant than the later changes in determining any role of the immune system 
in PSC.  Moreover, given the patchy intra-hepatic involvement in PSC, the 
changes seen on a liver biopsy specimen may not reflect or represent the 
underlying disease process accurately.  A role for both innate as well as 
adaptive immune response in PSC has been proposed. 
 
An organ specific, T-cell infiltrate is characteristic in patients with 
autoimmune diseases.  In PSC, a mononuclear cell infiltrate (predominantly 
both CD4+ and CD8+ T-cells) and an increased proportion of natural killer 
(NK) cells is typical, especially within and surrounding portal tracts (81, 82).  
However, the role of lymphocytes in mediating the pathological changes of 
PSC has not been well established.  There is increased production of tumour 
necrosis factor-α (TNF-α) and IL-1β by liver derived lymphocytes; liver 
derived lymphocytes in PSC have been shown to produce higher levels of 
TNF-α at different stages of the disease in comparison to patients with PBC, 
suggesting the presence of a TNF-α rich environment, irrespective of disease 
stage (83, 84).  The stimulus to drive lymphocytes to produce cytokines in 
PSC is not known.  However, the proliferative and functional capacity of 
intrahepatic T-lymphocytes and NK cells is impaired in patients with PSC 
(83).  Whether that is a direct consequence of exposure to high levels of TNF-
α, or some other mechanism, is not clear. 
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It is noteworthy that genetic variation (polymorphisms) within the TNF-α gene 
has been associated with certain inflammatory and immune-mediated diseases, 
although this association has not yet been observed in PSC.  
 
Leaky gut hypothesis 
The atypical p-ANCA seen in patients with PSC cross-reacts with human beta-
tubulin isotype 5 and the bacterial protein FtsZ expressed by intestinal flora 
(85).  The strong association of PSC with IBD (mainly UC) has led to the 
hypothesis that the initial trigger in PSC could be exposure of liver cells to 
bacterial cell wall products and/or PAMPs, which enter the portal circulation 
through a permeable intestinal mucosa resulting in an aberrant immune 
response.  Macrophages (Kupffer cells) and dendritic cells are activated 
through the pattern recognition receptors (PRRs) resulting in phagocytosis and 
subsequent production of inflammatory cytokines and chemokines (including 
IL-12, TNFα, IL-1β and CXCL8) (86).  The resulting activation of natural 
killer (NK) cells and lymphocyte recruitment results in a pro-inflammatory 
and a pro-fibrotic environment.  In addition, exposure to bacterial cell wall 
products may result in disruption of tight junctions within the biliary epithelial 
cells, thereby exposing them to toxic effects of bile acids and subsequently 
inflammation and fibrosis (87).  
 
Aberrant lymphocyte homing 
Although the leaky gut hypothesis is plausible, it does not fully explain the 
development of PSC in patients who have previously undergone total 
colectomy i.e. the absence of a diseased colon.  It has been postulated that 
lymphocytes activated in the gut undergo entero-hepatic circulation and 
mediate hepatic inflammation leading to the development of PSC (88).  
Usually, intestinal mucosal lymphocytes express integrin α4/β7, which binds 
to its ligand mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) 
expressed on the mesenteric endothelium, thereby ensuring intestinal homing 
of activated T-lymphocytes.  In inflammatory liver diseases (including PSC) 
increased expression of MAdCAM-1 and vascular adhesion protein-1 (VAP-
1) is seen in the hepatic portal endothelium, allowing liver recruitment of 
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lymphocytes activated in the intestine and expressing integrin α4/β7 (89).  
Memory cells activated in the intestine remain in circulation and may mediate 
hepatic inflammation, even in the absence of a diseased colon.  
 
 
Bile acid toxicity  
Some animal models of biliary transporter abnormalities have been shown to 
develop a phenotype resembling PSC.  The most commonly studied amongst 
these is the phospholipid transporter - multidrug resistance protein 2 (mdr2) 
knock-out mouse, which develops inflammation and progressive fibrosis of 
the bile ducts following bile acid toxicity (90). 
 
Abnormalities in the human bile acid transporter genes ABCB4 (encodes 
MDR3) and ABCB11 (encodes bile salt export pump) typically cause intra-
hepatic cholestasis but variants at these loci have not yet been found to be 
associated with PSC.  However, patients with PBC who happen to have 
variants at the MDR3 locus tend to have a more severe disease course, which 
is most likely a consequence of hepatotoxicity secondary to persistent 
cholestasis (91).  It is possible that patients with cholestatic liver disease such 
as PSC or PBC, who have mutations in the bile acid transporter genes, develop 
a more severe disease phenotype, but a causal relationship has not been 
established. 
 
Gut microbiome 
The gut microbiome in PSC has been studied using 16S rRNA sequencing and 
has shown an overall reduction in bacterial diversity and altered abundance of 
certain bacteria compared with healthy controls. No causal link has been 
established yet between altered gut microbiome and development of PSC, but 
immune dysregulation may play a part.      
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Treatment of PSC 
 
Despite recent advances in understanding the pathogenesis of PSC, one might 
say without fear of contradiction that little progress has been made in 
developing effective medical therapy for PSC.   Liver transplantation offers 
the only chance of cure.  Several drugs have been studied in PSC patients 
including immunosuppressive drugs (including corticosteroids, calcineurin 
inhibitors, azathioprine and methotrexate); anti-fibrotic drugs (colchicine, 
pentoxyphylline, D-penicillamine and pirfenidone); and anti-TNF drugs 
(Infliximab and Etanercept).  But none alter disease progression or improve 
liver related outcomes (92-95). 
 
In contrast, systemic corticosteroid therapy has a major role in patients with 
proven AIH/PSC overlap syndrome or IgG4-SC as discussed above. 
 
Role of UDCA in treatment of PSC 
The most widely studied therapeutic approach in PSC is UDCA.  It is a di-
hydroxy bile acid, which constitutes ~ 3% of human bile acid pool and 
undergoes enterohepatic circulation from the distal small bowel.  Enrichment 
of the bile acid pool with UDCA can be achieved with systemic therapy.  
UDCA protects hepatocytes and cholangiocytes from the toxic effects of 
hydrophobic bile acids present in cholestatic liver disease by detoxification, 
facilitation of bile acid secretion as well as inhibition of apoptosis (96).  
UDCA has been studied at varying doses in patients with PSC (7 to 28 
mg/Kg/day) and although there was biochemical and histological 
improvement in some studies, almost all were underpowered to detect a 
survival benefit (97, 98). 
 
A recent randomized controlled trial investigated high dose (28 to 30 
mg/kg/day) UDCA in 150 patients with PSC, but the trial had to be terminated 
early due to a higher risk of death, need for liver transplantation and adverse 
effects in the UDCA treated arm (99). 
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A meta-analysis of 8 randomised controlled trials (5 using a standard dose ≤ 
15mg/Kg/day and 3 using high dose > 15mg/Kg/day) involving 567 patients, 
revealed biochemical improvement in UDCA treated patients but no effect on 
survival.  Limitations of all the studies were the small total number of patients 
and short follow-up periods (3 months to 6 years).  There was insufficient 
evidence to support the use of UDCA in PSC (100).   
 
Role of UDCA in chemoprevention of colorectal cancer 
A chemopreventive role of UDCA has been suggested to reduce the risk of 
colorectal dysplasia and/or cancer in patients with PSC and IBD.  However, 
these studies have been limited by sample size (50 to 100).  In a recent study 
Lindstrom et al. looked at colonic epithelial dysplasia and cancer-free survival 
in 98 patients with PSC and IBD randomised to treatment with UDCA or 
placebo for 5 years and followed for a median of 12 years.  No effect of 
UDCA was seen with either dysplasia or cancer prevention (log rank p-value 
= 0.73) (101). 
 
Singh et al. (102) performed a meta-analysis of 8 studies involving 763 
patients with both PSC and IBD but again, did not identify a protective effect 
of UDCA use on colorectal neoplasia (defined as colorectal cancer and/or any 
dysplasia) prevention.  However, significant protective association was seen 
for prevention of advanced colorectal neoplasia (defined as high-grade 
dysplasia and/or colorectal cancer) in UDCA treated patients.  The studies 
included in the meta-analysis had significant heterogeneity and the median 
duration of exposure to UDCA was only 3.5 years so the results need to be 
interpreted with caution and further long-term randomised trials are needed to 
determine a role for UDCA in prevention of colorectal neoplasia.  
 
EASL and AASLD recommendations for UDCA use 
Due to limited evidence at present, the EASL guidelines do not make a 
specific recommendation for the general use of UDCA in PSC.  However, 
based on suggestive but limited evidence, EASL supports the use of UDCA 
for chemoprevention of colorectal cancer in high-risk groups, such as those 
with a strong family history of colorectal cancer, previous colorectal neoplasia 
 44 
or longstanding ulcerative colitis (103).  The AASLD guidelines do not 
recommend the use of UDCA in PSC (19). 
 
 
Novel therapeutic agents 
 
24-norursodeoxycholic acid 
24-norUDCA was compared with placebo in 161 patients with PSC with 
raised ALP for 12 weeks in a randomised control phase II trial (104). It 
significantly reduced ALP level compared to placebo with a very favourable 
safety profile. Phase III trials are currently in progress.  
It has been shown to reduce the production of toxic bile acids in-vitro and 
facilitate bicarbonate excretion into bile thereby rendering an alkaline 
environment, which may protect injured bile ducts from toxic bile acids.  In 
addition, it has also been shown to have anti-fibrotic and anti-inflammatory 
effects in ABCB4-/- mice models (105). 
 
Farnesoid X receptor (FXR) agonists 
FXR agonists play a role in bile acid homeostasis by activating the farnesoid 
X receptor.  They up-regulate bile salt export pump thereby facilitating 
excretion of bile acids and may have an additional role in controlling 
inflammation. Obeticholic acid (OCA) is an FXR agonist, which showed 
promising results in phase II and phase III trials in PBC (106) and is now 
licensed to be used as second line treatment for patients with PBC (UDCA 
non-responders) in the UK. OCA has also been studied in PSC in a phase II 
trial and showed dose-dependent reduction in ALP compared to placebo after 
24 weeks of treatment (published as abstract), but longer-term results are 
awaited.   
 
Another FXR agonist that has been studied recently in PSC is NGM282, 
which is a bioengineered analogue of FGF19 (fibroblast growth factor 19) and 
regulates bile acid biosynthesis. In a recent multicenter phase II trial in 
patients with PSC (NGM282 versus placebo) for 12 weeks, the primary end 
point of a change in ALP was not reached. However, there was a significant 
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reduction in bile acid levels and biomarkers of hepatic fibrosis (107). Further 
loner-term studies are needed to determine if NGM282 has a role in treatment 
of PSC or not.  
 
Although theoretically, these are therapeutic options for patients with PSC, 
there have been concerns about the use of such prominent choleretic agents in 
patients with downstream biliary obstruction such as seen in PSC (108).  
Further studies are necessary to establish their efficacy and safety in PSC. 
    
Microbiome modulators 
 Several antibiotics have been studied in PSC but despite improvements in 
liver biochemistry, evidence for long-term clinical benefit is lacking. 
Vancomycin has been consistently shown to improve ALP levels as well as 
the PSC Mayo risk score (discussed on page 46). A phase III trial is currently 
in progress to evaluate the role of oral vancomycin for PSC in IBD patients.  
 
In addition to the novel therapeutic agents discussed above, various 
immunomodulatory (e.g. Vedolizumab and Timolumab) and anti-fibrotic (e.g. 
Simtuzumab) agents have also been evaluated in PSC, but have not shown any 
significant clinical benefit.  
 
Role of endoscopy 
Patients with PSC are at risk of both intra-hepatic and extra-hepatic biliary 
strictures.  Endoscopic therapy is reserved for patients with extra-hepatic 
strictures (distal to the second order bile ducts), especially in the presence of 
persistent cholestasis/hyperbilirubinaemia.  A dominant stricture, defined by 
presence of stenosis ≤ 1.5mm in diameter in the common bile duct (CBD) or ≤ 
1mm in the intra-hepatic duct, develops in up to 50% of patients with PSC and 
should be treated with endoscopic therapy (109).  Patients with a dominant 
stricture should be investigated for the presence of a superimposed 
cholangiocarcinoma (usually with a combination of the tumour marker 
CA19.9, ERCP with brushings +/- FISH).  
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Treatment of biliary strictures is performed endoscopically, while biliary 
reconstruction surgery (in the form of hepatico-jejunostomy) is reserved for 
patients with complex hilar/biliary strictures.  Endoscopic treatment options 
include serial balloon dilatation with or without stent insertion (110).  A multi-
centre randomised controlled trial published in 2018, has shown similar 
clinical benefits with serial dilatation versus stenting, but the latter group had 
more side effects with increased risk of pancreatitis and bacterial cholangitis 
(111).  
 
 
Liver transplantation in PSC 
 
Liver transplantation offers the only chance of cure in PSC.  PSC is the 
leading indication for liver transplantation in some Nordic countries and 
amongst the top five indications in the USA (33).  Outcomes after liver 
transplantation in PSC are encouraging; a recent retrospective analyses of the 
United Network for Organ Sharing (UNOS) database showed 1-year and 5-
year patient survival for cadaveric transplants of 93% and 87.5% respectively 
and even better survival at over 95% after 1-year and 5-years with living 
donor transplants (112).  
 
Role of prognostic models 
Patients with PSC usually run a variable, unpredictable disease course and the 
optimal timing for liver transplantation remains difficult to determine in many.   
Some studies have identified prognostic markers/models to predict outcomes 
in patients with PSC (113, 114).  The most common model used is the revised 
Mayo score (115).  It includes the following clinical parameters to calculate 
the risk score: age, bilirubin, albumin, AST and variceal haemorrhage.  The 
major limitation of the revised Mayo score is that it only estimates a 4-year 
outcome risk and is a less useful discriminant for patients presenting early 
during the course of their disease.   
 
Two new risk scores for PSC have recently been developed and are briefly 
discussed below:  
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Amsterdam-Oxford prognostic model 
The Amsterdam-Oxford prognostic model for PSC is based on seven 
objectively measured and readily available variables: PSC subtype, age at PSC 
diagnosis, albumin, platelets, aspartate aminotransferase, alkaline phosphatase 
and bilirubin (116). The derivation cohort comprised of 692 patients with 
large duct PSC from Netherlands with a median follow up of 110 months. 
Model was validated in an external cohort of 264 patients with PSC from 
Oxford, UK. The test C-statistic for the model developed was 0.68 (0.51 - 
0.85) and allowed accurate prediction of transplant-free survival using 
variables within the first few years of diagnosis.   
 
PSC Risk Estimate Tool (PREsTo) 
Eaton, JE et al., derived this model in a cohort of 509 patients with PSC from 
North America and validated in an independent international cohort of 278 
patients, using a novel machine based learning tool (gradient boosting) to 
predict the risk of hepatic decompensation (ascites, variceal haemorrhage or 
hepatic encephalopathy) (117).  It consists of nine variables: bilirubin, 
albumin, serum ALP, platelets, aspartate aminotransferase (AST), 
haemoglobin, sodium, patient age, and number of years since PSC was 
diagnosed. PREsTo accurately predicted hepatic decompensation with a C-
statistic 0.90 (0.84 – 0.95) and outperformed the Mayo and MELD scores.  
  
However, the current clinical guidelines do not recommend the use of any 
prognostic models to predict clinical outcome, as there is insufficient evidence 
to support the use of such models (19). Further validation of the prognostic 
models described above in independent cohorts is needed before they can be 
used routinely in clinical practice.  
 
Conversely, female sex, the presence of Crohn’s disease (as opposed to UC) 
and small-duct PSC protect against a need for liver transplantation or death 
and may have a role in risk stratification (46). 
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Indications for liver transplantation in PSC 
In the presence of cirrhosis, the indications for considering transplantation are 
similar to those with cirrhosis of other aetiology.  However, additional, 
perhaps softer, indications in PSC include intractable pruritus, fatigue or 
recurrent cholangitis. For those with a dominant stricture and obstructive 
jaundice, which fails to respond to endoscopic intervention, the decision to 
proceed to liver transplantation can be very difficult. 
 
It is also important to screen patient for colorectal dysplasia and cancer and 
attempt to exclude cholangiocarcinoma before transplantation given the poor 
post-transplant survival in these patients with such a high risk of tumour 
recurrence.  Most centres (including those in the UK) exclude patients with 
confirmed CCA from liver transplantation although one group argues that 
outcomes can be satisfactory in a carefully selected minority patient group 
who receive additional neo-adjuvant chemo-radiotherapy (118). 
 
Impact of liver transplantation on the course of IBD 
Patients with PSC and IBD, who have undergone OLT but have an intact 
colon, may be at a higher risk of an IBD flare, despite immunosuppression, 
although this is contentious and some studies demonstrated no change in 
disease activity (119). 
 
However, the cumulative 5-year and 10-year risk of developing colorectal 
dysplasia or cancer in patients with PSC and IBD after liver transplantation is 
significantly elevated at 14% and 17% respectively (120).  All such patients 
should continue to have annual colonoscopy surveillance. 
 
Recurrent PSC 
The diagnosis of recurrent PSC (rPSC) after OLT is very difficult to make.  
There is no gold standard test and patients who develop ischaemic biliary 
strictures whatever the original aetiology have cholangiographic appearances 
identical to those seen in PSC. 
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In 1999, the Mayo clinic proposed criteria for this condition (121): 
 
A) A diagnosis of PSC before liver transplantation. 
B) Cholangiography demonstrating non-anastomotic intra-hepatic and/or extra-
hepatic biliary strictures occurring 90 days after OLT and fibro-obliterative 
lesions with or without ductopenia on liver histology. 
C) The absence of: hepatic artery thrombosis/stenosis, chronic rejection (causes 
pruning of biliary tree), anastomotic strictures alone, ABO incompatibility 
(ABO mismatch) and antibody mediated rejection. 
 
Recurrent PSC develops in approximately 20 to 25% of liver transplant 
recipients at a median duration of 4 to 10 post operative years (119). Several 
risk factors have been associated with development of recurrent PSC 
including: male sex, active IBD (post-liver transplant), the presence of an 
intact colon, acute cellular rejection, HLA DRB1*08 type and extended donor 
criteria grafts (122-125). 
 
No intervention has been found to reduce the risk of recurrent PSC and 
patients are followed carefully in any case for the presence of cholestasis.  
There is evidence suggesting a significantly reduced risk of recurrent PSC in 
patients (with IBD) who have undergone pan-procto-colectomy before 
transplantation, but a prophylactic colectomy cannot be recommended based 
on current evidence, although it is a frequent topic for discussion at transplant 
meetings. 
 
In the absence of effective medical therapy, re-transplantation is the only 
treatment option available for patients with recurrent PSC who develop 
progressive cholestasis unresponsive to endoscopic or surgical intervention.. 
 
 
Role of genetic association studies in complex diseases 
 
A brief explanation of the common terminologies used in genetic association 
studies is in chapter 5 (page 97) and glossary Box 1 (page 160). 
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Genetic association studies help identify disease-causing genes or determine 
genetic risk factors correlated with a disease specific phenotype.  For most of 
the 20th century, linkage analysis and positional cloning remained the 
mainstay of identifying genetic risk factors in diseases and led to the 
association of several disease traits with specific genes by tracing transmission 
in affected families.  However there were significant limitations to this 
approach, mostly due to small family size and a relative paucity of available 
genetic markers, making it difficult to trace inheritance accurately.  When 
applied to complex disease traits such as type II diabetes mellitus, 
hypertension and heart disease, studies using linkage analysis failed to detect a 
single causal gene association, suggesting a more complex polygenic model of 
inheritance in such traits (126).  Similarly in PSC, the lack of families with 
affected sibling pairs precluded linkage-based studies to determine genetic 
susceptibility loci.  
 
To study the genetic risk profile of complex disease traits in the general 
population, genetic association studies were designed, which allowed 
comparison of frequencies of genetic variants occurring among affected and 
unaffected individuals in a simple case-control study design.  This approach 
was initially limited to plausible candidate genes based on their prior 
probability of causing disease.  However, the identification of genes, some of 
which were completely unsuspected on the basis of previous knowledge as 
causing disease in linkage studies, made candidate gene studies difficult to 
interpret reliably. 
 
This led to the emergence of genome-wide association studies (GWAS), 
which analyses thousands of common genetic variants (usually single 
nucleotide polymorphisms (SNPs)) in the human genome, between cohorts of 
patients with the disease phenotype of interest and healthy controls using a 
simple case control association study. The first GWAS was published in 2005 
on age-related macular degeneration (127).  
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At the time of undertaking genetic association studies in the UK PSC cohort, 
GWAS had become a well-established and effective method of identifying 
genetic loci associated with common diseases. As of 1st September 2016, more 
than 24,000 unique SNP-trait associations have been confirmed across 
hundreds of diseases (128). For example, in primary biliary cholangitis (PBC), 
27 non-HLA genetic risk loci have been confirmed to date and have 
implicated key immunoregulatory pathways in PBC pathogenesis (129).   
 
The key concepts, limitations and statistical methods used in GWAS are 
discussed in detail in chapter 5 (page 97).  
 
Genetic susceptibility in PSC 
PSC is considered to be a complex disease with evidence pointing towards a 
role for genetic and environmental risk factors in disease development (130).   
 
Evidence for a genetic risk in PSC pathogenesis derives mainly from: 
A) Increased relative risk in siblings:  
Relative risk in siblings (λs) is a measure of the heritability of a disease and is 
calculated by dividing the disease prevalence in siblings by the disease 
prevalence in the general population.  For monogenic disorders, λs usually 
ranges from 100 to 1000.  The reported λs in PSC is 9 to 39 fold when 
compared to the general population (131). 
 
B) Association with other immune-mediated diseases with strong genetic risk 
(e.g. type 1 diabetes, Coeliac disease and auto-immune thyroid disease).   
 
Genetic susceptibility loci associated with PSC  
Loci associated with risk of developing PSC can be separated in to those seen 
within the HLA complex and those identified by candidate gene studies or 
genome wide association studies (GWAS).  
 
HLA association in PSC 
The HLA complex spans across 7.6 million base pairs of DNA on the short 
arm of chromosome 6 (6p21) and contains 252 expressed protein-coding 
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genes; up to a quarter of these have possible immunological function (132).  
The HLA complex comprises three distinct, but closely linked regions denoted 
as Class I, Class, II and Class III HLA loci.  Class I locus has an extended 
region referred to as Extended Class I, which includes the telomeric limit of 
the histone gene cluster and tRNA.  The HLA region is highly conserved in 
the European population and is characterised by very strong linkage 
disequilibrium (LD) extending across HLA class I and II loci. A brief 
explanation about linkage disequilibrium is in chapter 5 (page 97).  
 
HLA class I molecules (HLA-A, -B and -C) are expressed on all nucleated 
cells, present intracellular antigens to the CD8+ T-lymphocytes and also serve 
as ligands for inhibitory killer immunoglobulin-like receptors (KIRs) on 
natural killer cells (NK) cells and γδ T-lymphocytes.  HLA class II molecules 
on the other hand are expressed on antigen presenting cells (e.g. macrophages, 
dendritic cells and B-lymphocytes) and present extracellular/exogenous 
antigens to CD4+ T-lymphocytes (130). 
 
The first HLA association in PSC was reported in 1982 with HLA-B8 and 
subsequently HLA-DR3 (133, 134).  Several studies have since confirmed an 
HLA association with various haplotypes but the most widely replicated risk 
haplotypes include the “8.1 ancestral haplotype” (A1-B8-DR3-DQ2); 
DRB1*1301-DQA1*0103-DQB1*0603; DRB1*0301-DQA1*0501-
DQB1*0201 and DRB1*1501-DQA1*0102-DQB1*0602 (135, 136).  One of 
the protective haplotypes associated with PSC is the DR4 haplotype - 
DRB1*0401-DQB1*0302, which, when present, has been associated with a 
poor prognosis and possibly cholangiocarcinoma (136, 137).  Other known 
protective HLA haplotypes include:  
DRB4*0103-DRB1*0701-DQA1*0201-DQB1*0303; 
DRB4*0202-DRB1*1101-DQA1*0501-DQB1*0301 
and MICA*002 (137, 138).  Due to the strong linkage disequilibrium across 
this region, it has been very difficult to dissect the association with a specific 
allele/gene within the associated haplotype. 
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This is true for most immune mediated diseases associated with the HLA 
complex.  One way to refine the HLA association is to study the association in 
ethnically different population cohorts such as Africans, which have less 
linkage disequilibrium.  One such study was performed to define shared and 
distinct features with respect to distribution of HLA alleles in two different 
population groups: European Americans (n = 1834), Hispanics and African 
Americans (n = 116) who were listed for liver transplantation in the USA 
(139). The linkage disequilibrium between HLA-B8 and DR-3 in the African-
American population was very low and the association was present for the 
HLA-B*08 but not HLA-DRB1*03, in contrast to the European-American 
population, where the association was present for both.  This suggests that the 
association with the “8.1 ancestral haplotype” may arise primarily from the 
HLA-B*08 i.e. class I effect, but does not exclude associations in class II. 
 
Ideally further studies should be attempted in such populations but given the 
very low prevalence of PSC in this population, such a study would be difficult 
to replicate.  The detailed role and significance of the HLA association in PSC 
is beyond the scope of this thesis and is not discussed further.     
 
Candidate gene studies in PSC (Pre-GWAS era) 
Prior to the widespread availability of GWAS, genetic studies in PSC were 
confined to candidate gene studies.  Several candidate genes (outside the HLA 
complex) have been studied in PSC and were selected on the basis of their 
priory probability as causing disease based on their association with 
inflammatory bowel disease, cholestatic liver disease or other immune 
mediated diseases, which are also prevalent in the PSC population (Table 1.6).  
 
A true candidate gene (see glossary Box 1) shows consistent statistical 
association, has relevant tissue expression and is associated with a functional 
consequence of the identified mutation (140).  Unfortunately, none of the 
studies performed in PSC has been able to identify any susceptibility gene for 
PSC.  Table 1.6 lists the candidate gene studies (non-HLA loci) performed in 
PSC.  There are two important points to note.  First, the sample size of the 
PSC cohort studied was small and the studies may not have been powered 
 54 
adequately to detect association of susceptibility loci with relatively modest 
effect size (OR < 2).  Second, an important negative result from these studies 
was a lack of any association with established IBD risk loci in the PSC cohort, 
especially given the high prevalence of IBD (mainly UC) in all studies.  This 
raises the possibility that the IBD phenotype observed associated with PSC 
might be distinct from that seen in UC and Crohn’s disease.  The advent of 
GWAS has allowed this aspect to be explored in more detail and is discussed 
later in the thesis. 
 
Table 1.6. Candidate gene studies performed in PSC 
Chr Gene Prior disease 
association 
N (PSC) Result Ref 
1q31 IL-10 IBD/RA 96 No association (141) 
2q13 IL-1 IBD/RA 96 No association (141) 
2q24 BSEP PFIC 31 No association (142) 
2q33 CTLA4 T1D, Coeliac 
disease; Grave’s 
disease 
144 No association (143) 
3p21 CCR5 RA/MS 71 No association (144) 
7q CFTR CF 29 No association (145) 
7q21 MDR3 PFIC 30 No association (142) 
11q22 MMP1/MMP3 UC, Crohn's 165 No association (146) 
16q12 CARD15 IBD 365 No association (147) 
 TLR-4 IBD 365 No association  
 CARD-4 IBD 365 No association  
 SLC22A4 IBD 365 No association  
 SLCC22A5 IBD 365 No association  
 DLG5 IBD 365 No association  
 MDR1 IBD 365 No association  
19p13 ICAM-1/MAdCAM-1  104 No association (148) 
21q22 AIRE APS-1 60 No association (149) 
 
APS-1 - autoimmune polyglandular syndrome type-1; CTLA4 - cytotoxic T-lymphocyte-associated protein 
4; CARD15 – capsase activating recruitment domain 15; TLR-4 – toll-like receptor 4; CARD-4 - capsase 
activating recruitment domain 4; SLC22A4 – solute carrier family 22, member 4; SLC22A5 - solute carrier 
family 22, member 5; DLG5 – Drosophila discs large homolog 5; MDR1 – multidrug resistance gene 1.   
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Genome-wide association studies in PSC 
 
Prior to undertaking the genetic association studies in the UK PSC cohort 
(discussed in chapters 6 and 7), two GWAS and an extended analysis of 
GWAS dataset by the same group had been reported in PSC. 
 
Karlsen T et al. published the first GWAS in PSC in 2010 (150).  The 
discovery panel comprised 285 Norwegian patients with PSC and 298 healthy 
controls, genotyped for 443,816 SNPs on the Affymetrix SNP array 5.0.   
 
Three replication panels were used to verify the findings from discovery panel 
and comprised: 
 
a) 137 patients with PSC and 368 healthy controls from Norway and Sweden 
(panel 1). 
b) 229 PSC cases and 735 healthy controls from Belgium and Netherlands 
(panel 2). 
c) 400 PSC cases and 1832 healthy controls from Germany (panel 3). 
 
The strongest associations were detected near HLA-B at chromosome 6p21 
[rs3099844: odds ratio (OR) = 4.8 (3.6 – 6.5); p-value = 2.6 x 10-26 and 
rs2844559: OR = 4.7 (3.5 – 6.4); p-value = 4.2 x 10-26] in the discovery panel. 
 
Outside the HLA complex, none of the SNPs reached genome-wide 
significance (p < 5 x 10-8).  However, rs9524260 at chromosome 13q31 
showed a suggestive association in the discovery panel [OR = 0.67 (0.53 – 
0.85); p-value = 8.1 x 10-4], but did not reach the agreed conventional 
threshold of genome-wide significance (discussed in chapter 5; page 102). 
  
A similar trend towards an association was seen in two of the three 
verification panels (panels 1 and 2) giving a combined association for the 
rs9524260 (A allele) in all 1051 PSC patients and 3233 healthy controls with 
an OR = 0.77 (0.61 – 0.98); p-value = 2.7 x 10-3).  It was suggested that the 
most likely candidate gene at this locus was GPC6 (glypican 6).  Lentiviral 
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silencing of glypican 6, encoded at this locus, led to the up-regulation of pro-
inflammatory markers in a cholangiocyte cell line.  However, as the 
association at this locus did not reach genome-wide significance, its 
pathophysiological role in PSC remains speculative.  
 
As part of the study, 15 established UC susceptibility loci were also replicated 
in the combined discovery and replication panel 1 (i.e. the Scandinavian 
cohort comprising 422 PSC cases and 666 healthy controls).  A suggestive 
association was obtained at chromosomes 2q35 [rs12612347: OR = 1.26 (1.06 
– 1.50); p-value = 8.8 x 10-3] and 3p21 [rs3197999: OR = 1.22 (1.02 – 1.47); 
p-value = 3.3 x 10-2], but this association did not meet threshold for statistical 
significance for multiple testing (chapter 5; page 102).  Circumstantial 
evidence points towards the G-protein-coupled bile acid receptor-1 (GPBAR-
1) and macrophage-stimulating 1 (MST1), respectively, as plausible candidate 
genes at these loci. 
 
Melum et al. reported the second GWAS in PSC in 2011 (151).  The 
discovery panel included 332 Scandinavian and 383 German PSC cases, along 
with 262 Scandinavian and 2700 German controls.  Affymetrix genome-wide 
Human SNP array 6.0 was used as the genotyping platform and a total of 
2,466,182 SNPs were analysed.  The replication panel comprised three 
different cohorts of cases/controls as described below: 
 
a) 259 PSC cases and 729 healthy controls from Scandinavia 
b) 498 PSC cases and 891 healthy controls from Central Europe 
c) 268 PSC cases and 554 healthy controls from United States 
 
The strongest association was detected at 6p21 for SNPs within the HLA 
complex (rs3134792: p-value = 6.8 x 10-49).  To study association outside 
HLA loci, 23 SNPs (pruned from 379 SNPs on the basis of LD) with p-value 
< 10-4 in the discovery panel were taken forward for replication.  
 
Genome-wide significant association was detected for two loci at 2q13 and 
3p21.  The strongest non-HLA association was detected in the discovery panel 
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at 3p21 (p-value = 1.4 x 10-9) and confirmed in a replication panel with a 
combined p-value = 1.1 x 10-16; OR = 1.39 (1.24 - 1.56) for the non-
synonymous (p.Arg689Cys) SNP rs3197999 located in the MST1 gene.  The 
most plausible candidate gene at this locus is macrophage stimulating 1 
(MST1) and has been associated with both UC and Crohn’s disease.  An 
association at 2q13 was also replicated for rs6720394 with genome-wide 
significance and a combined p-value = 4.1 x 10-8; OR = 1.29 (1.10 – 1.51), 
with the most likely candidate gene BCL2L11. 
 
Following on from this study Folseraas et al. performed an extended analysis 
of the results of the GWAS (152).  A total of 59 non-HLA SNPs with nominal 
significance (p < 0.05) in the discovery panel, were selected for replication 
analysis based on their prior association with immune mediated or chronic 
inflammatory diseases. 
 
The strongest association in the replication panel was detected at 1p36 for the 
coding SNP rs3748816 located in the Membrane metallo-endopeptidase-like 1 
(MMEL1) locus and this was the only SNP to achieve genome-wide 
significance with combined p-value = 2.1 x 10-8.  The association signal in this 
region extends into the tumour necrosis factor receptor superfamily member 
14 (TNFRSF14) making it a plausible candidate gene.  
 
In summary: 
four genetic loci (with most plausible candidate genes) were found to be 
associated at genome-wide significance with PSC, prior to undertaking the 
genetic association studies in the UK-PSC cohort: 
 
a) 6p21 (HLA complex) 
b) 2q13 (BCL2L11) 
c) 3p21 (MST1) 
d) 1p36 (MMEL1/TNFRSF14) 
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Chapter 2: UK PSC cohort selection and recruitment. 
 
I identified the principal investigators (PI), obtained study approval at each site and 
led patient recruitment for the UK PSC study. The respective PI identified patients 
with PSC at each hospital.  
  
The UK PSC project 
 
The UK PSC project was established in 2009 as part of a multicentre 
collaboration to collect a large cohort of 2000 or more patients with PSC in 
the UK, to characterise the genetic risk factors that may be associated with this 
condition.  Cambridgeshire 4 National Ethics committee (MREC Number 
08/H0305/45) provided ethical approval for the study (Appendix 1; page 216).  
The consortium comprises principal investigators (PI) at each of the recruiting 
NHS hospital site and is led by a steering committee; the members are listed in 
Appendix 2 (page 219). 
 
I joined the study at the beginning of patient recruitment in January 2010 and 
worked alongside a project administrator from the initial stages to recruit 
patients and collect detailed phenotype data.  The study was adopted as one of 
the UK Comprehensive Local Research Network (CLRN) portfolio studies, 
which enabled recruitment by local research nurses at most of the recruiting 
hospitals to facilitate study approval and patient recruitment.  The study site 
was based at the Academic Department of Medical Genetics, Addenbrooke’s 
Hospital, Cambridge.   
 
Funding for the study was secured from UK and Norwegian PSC Charities 
and included costs for phenotyping and genotyping (genome-wide) of 
recruited patients.  Funding had also been provided to genotype the UK cohort 
using the Immunochip platform as part of the Immunochip Consortium 
(details of the Immunochip study are discussed in chapter 8).  These two 
strategies aimed to provide detailed phenotype and genome-wide association 
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data, including high density SNP genotype data for several autoimmune loci 
(as part of the Immunochip project). 
 
Identification of recruitment sites 
 
All NHS hospital trusts within the UK were eligible for inclusion in the study.  
The research team (Dr Simon Rushbrook [who chaired UK PSC at the time], 
an administrator and myself) identified a principal investigator at each 
potential site to recruit suitable patients for the study.  Study approval was 
obtained at each site by submitting a formal application via the Integrated 
Research Application System (IRAS) to the respective Research and 
Development department.   
 
Inclusion criteria 
 
Inclusion criteria were based on standard diagnostic criteria (1) as detailed in 
chapter 1 (page 19) and included the presence of cholestatic liver function 
tests with characteristic bile duct changes on either endoscopic retrograde 
cholangio-pancreatography (ERCP), magnetic resonance cholangio-
pancreatography (MRCP) and/or liver histology. 
 
Exclusion criteria  
 
Exclusion criteria were presence of any secondary causes of sclerosing 
cholangitis including congenital abnormality of the biliary tree; previous 
biliary tract surgery (excluding cholecystectomy); primary bile duct 
carcinoma; HIV cholangiopathy; primary biliary cholangitis; hepatic 
sarcoidosis and drug induced liver injury. 
 
Recruitment strategy 
 
The PI or the research nurses identified potential patients at each recruiting 
site. This was done by: 
a. searching clinic letters. 
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b. searching existing databases. 
c. searching histology and/or radiology databases. 
d. searching databases in the clinical coding department for patients 
with either the local or ICD-9 code 576.1 (for PSC). 
Patients were also eligible to participate in the study by self-presenting 
through the PSC patient support group website. 
Patients willing to participate sent a reply slip to the study centre confirming 
interest in the study.  A recruitment pack was then sent to each patient with a 
participant questionnaire, consent form and blood test kit.  Patients were 
requested to provide a blood sample for DNA extraction.  EDTA vacutainer 
tubes were sent with the recruitment pack (including a return envelope suitable 
for biological specimens) and patients were advised to have the blood test 
done at their local hospital.  Blood samples were sent back to the research site 
by the patients in pre-paid, self-addressed envelope provided in the 
recruitment pack. 
Please note that patients self-consented at home and returned the questionnaire 
and consent form to the research team at Cambridge.  Upon receipt of the 
consent form, a clinician questionnaire was sent to the respective PI or 
research nurse to verify the diagnosis and obtain data on cholangiography, the 
presence of IBD and transplant status. 
Versions of the participant and clinician questionnaire are attached in 
Appendix 3 (page 222). 
 61 
•PSC PATIENT IDENTIFIED  BY 
CLINICIAN, NURSES 
METHODS OF IDENTIFICATION 
•CLINIC LETTERS ON SEARCHABLE 
SYSTEM
• LOCAL DATABASES
•VIA  CLINICAL CODING 
DEPARTMENT
•CLINICIANS’  MEMORY
•EVIDENCE OF PATIENT BEING 
AWARE OF DIAGNOSIS 
•FROM CLINIC LETTERS FOR 
EVIDENCE OF ACTIVE FOLLOW UP
•EVIDENCE OF PATIENT’S 
ALIVE/DECEASED STATUS AND 
CURRENT ADDRESS
•ALIVE/DECEASED STATUS CHECKED 
ON PAS
•ADDRESS CHECKED ON PAS
•STANDARD INVITATION LETTER 
ON TRUST’S LETTER HEAD 
GENERATED 
•LETTER CHECKED AND SIGNED BY 
PATIENT’S CONSULTANT
•LETTER POSTED TO 
PATIENT WITH REPLY SLIP 
AND FREEPOST ENVELOPE
•NO INTEREST-NO REPLY 
RECEIVED AT CAMBRIDGE. NO 
FURTHER ACTION TAKEN
•RECRUITMENT PACK POSTED TO PATIENT
RECRUITMENT FLOW CHART
PLEASE ADD THE HOSPITAL  LOGO 
ON PAGE 1 &2 OF THE INVITATION LETTER.
Please don't  forget to enclose a prepaid envelope
in each letter.
 
Figure 2.1. Patient recruitment flow chart. 
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Blood DNA extraction and preparation 
Blood samples received (EDTA tubes) were forwarded immediately upon 
receipt for genomic DNA isolation in the molecular genetic laboratory at 
Addenbrooke’s Hospital, Cambridge.  Whole blood samples in EDTA 
vacutainer tubes were stored at -80˚C and thawed overnight or for 3 hours at 
room temperature.  DNA was isolated using the Autopure LS (Large Sample 
Nucleic Acid Purification) procedure on the Gentra Automated System.  This 
system is summarised briefly in the following steps: 
a) Red blood cell (RBC) lysis: Red blood cells are lysed and separated from 
the white blood cells, which form a pellet on centrifuging.  The 
supernatant (of lysed red blood cells) is discarded. 
b) Protein Precipitation: Protein precipitation solution is mixed thoroughly 
with this cell lysate and centrifuged to precipitate proteins and leave DNA 
in solution in the supernatant. 
c) DNA Precipitation and hydration: 100% isopropanol added to the 
supernatant precipitates the DNA, which is pelleted by centrifuging.  The 
DNA pellet is re-suspended in 100μl of DNA Hydration solution (or 
1xTE buffer) for storage. 
d) DNA normalization: DNA samples were diluted by adding variable 
quantity of 1xTE buffer (based on the initial DNA concentration) at room 
temperature to achieve a final concentration of between 50 -300ng/μl for 
downstream genetic experiments.  All DNA samples were stored at -40˚C 
in the Academic Department of Medical Genetics, Addenbrooke’s 
Treatment Centre, Addenbrooke’s Hospital. 
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Chapter 3: Phenotypic description of the UK PSC cohort and factors 
determining liver transplant-free survival. 
 
I collected and analysed data from the participant and clinician questionnaire to obtain 
phenotypic data for all the recruited patients with PSC for this chapter.  
 
Study design 
 
All patients recruited and consented up to 1st December 2013 were included in 
the study.  Each participant completed a participant questionnaire at 
recruitment (Appendix 3; page 222).  Information collated and stored included 
age, gender, medical and surgical co-morbidity including IBD status, a history 
of malignancy, symptoms at presentation, family history of PSC and IBD and 
medical therapy (including the use of and dose of UDCA).  Demographic and 
clinical data for each patient were extracted from the questionnaire and 
analysed. 
 
A clinician questionnaire (Appendix 3) sent to the clinician or research nurse 
at each recruiting site who collated data on findings from the most recent 
cholangiogram and/or liver biopsy, as well as IBD status.  Involvement of first 
order bile ducts (right or left main hepatic duct) and/or common bile duct at 
cholangiography allowed distinction between extrahepatic and intrahepatic 
disease.  The data extracted from the clinician questionnaire were also used as 
a quality control measure to verify the diagnosis and determine the validity of 
patient-reported IBD status. 
 
Statistical analysis 
 
Descriptive statistics were calculated and reported as the number or proportion 
of patients who had completed the questionnaire for the relevant dataset.  
Categorical variables were analysed using Fisher’s exact test.  Continuous 
variables are reported as median and range (minimum, maximum). 
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Site-specific recruitment  
 
At 1st December 2013, 1441 patients had been consented and had completed 
the patient questionnaire.  Of these 1441 patients, 583 patients were recruited 
from transplant centres and 858 patients from non-transplant centres.  
 
Clinician questionnaire 
 
The clinician questionnaire was received for 1230 of those 1441 patients 
(85%).  Cholangiography and/or liver histology compatible with PSC was 
present in 1147 (93%) patients [6/1230 (0.5%) patients had primary biliary 
cholangitis and were excluded from further analysis].  For the remaining 288 
patients, the diagnosis of PSC was made by the recruiting clinician, but the 
clinical questionnaire was either incomplete or not available, so that the 
research team could not verify the diagnosis of PSC.  Thus, 1435 patients were 
included in the final analysis.  Table 3.1 shows the baseline characteristics of 
the cohort. 
 
Table 3.1.  Demographics of the study cohort (n = 1435) 
Parameter Number (range or %) 
Median age at recruitment 
(n = 1435) 
60 years (16 - 89 years) 
Median age at diagnosis 
(n = 1198) 
45 years (8 - 85 years) 
Gender Male: 903 (63%) 
Female: 532 (37%) 
IBD 954 (66.5%) 
UC = 821 
Crohn’s disease = 124 
Indeterminate colitis = 9 
Active smokers 64 (4.5%) 
Non-smokers 884 (62.5%) 
Auto-immune disease 207 (14.5%) 
Small-duct PSC 56 (4%) 
Liver transplant recipients 337 (23.5%) 
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Results 
 
Demographics 
The median age at recruitment was 60 years (range 16 - 89 years).  903/1435 
(63%) were male.  83% (1198/1435) were able to provide the date of 
diagnosis.  For those, the median age at diagnosis was 45 years (range 8 - 85 
years) with a median follow-up of 85 months (interquartile range 48 - 133 
months) (figure 3.1).  64 (4.5%) patients were smokers at recruitment and 
464/1435 (33%) patients were ex-smokers. Thus, the majority (62.5%) had 
never smoked. Smoking status was unknown for 23 patients. 
 
 
 
Figure 3.1. Box plot representing median follow up duration of the cohort 
with interquartile range. 
 
 
Inflammatory bowel disease 
954 of 1435 (66.5%) suffered with IBD; 356 patients did not have any bowel 
disease and IBD status was unknown in 125 (8.5%).  Ulcerative colitis was the 
most common type of IBD, present in 821 (86%); Crohn’s disease in 124 
(13%); and indeterminate IBD in 9 (1%).  741/954 patients were able to 
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provide the date that IBD was first diagnosed and for those, the median age at 
diagnosis of IBD was 27 years (range 6 - 76 years).  638 were able to provide 
the date of onset for both PSC and IBD.  For those, the median age at 
diagnosis of IBD was 27 years (range 5 - 76 years) and of PSC was 42 years 
(range 6 - 79 years).  Clinical manifestations of PSC preceded IBD in only 8% 
(50/638). 
 
Inflammatory bowel disease and smoking 
Smoking status was known for 1286 (98%) patients.  Only 3.6% of patients 
with concomitant IBD reported smoking at recruitment and an additional 29% 
were ex-smokers.  However, the majority (67%) with IBD had never smoked.  
A history of smoking was associated with a reduced risk of IBD (p = 0.0005; 
odds ratio (OR) = 0.63, 95% confidence interval (CI), 0.49 - 0.81) (Figure 
3.2(a)); this effect was more pronounced in patients with ulcerative colitis (p = 
0.0004; OR = 0.57, 95% CI, 0.44 - 0.75) (Figure 3.2(b)).  52% (64/124) of 
patients with Crohn’s disease had never smoked and only 8% (10/124) 
reported smoking at recruitment.  
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Figure 3.2 (a). The relation between smoking and inflammatory bowel 
disease. 
 
 
 
Figure 3.2 (b). The relationship between smoking and ulcerative colitis. 
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Autoimmune diseases 
An increased prevalence of co-existing autoimmune disease was observed.  
207 (14.5%) had one or more autoimmune disease (table 3.2).  Thyroid 
disease was most common and present in 136 (9.5%), coeliac disease in 35 
(2.5 %) and type 1 diabetes mellitus in 26 (1.8%).  These autoimmune 
diseases appear to be more prevalent within the PSC population in comparison 
to the reported prevalence of these conditions in the UK population (table 
3.2). However, a statistical analysis comparing the prevalence rates in age 
matched population cohort and patients with PSC has not been performed.   
 
Table 3.2. Autoimmune diseases identified in the cohort. 
Auto-immune disease Number (%) Prevalence in the UK 
Thyroid disease  136 (9.5%) 3% (153) 
Coeliac disease 35 (2.5%) 1% (154) 
Type 1 Diabetes 26 (1.8%) 0.4% 
Systemic lupus 
erythematosus 
7 (0.5%) 0.1% 
Rheumatoid arthritis 5 - 
Sjogrens syndrome 4 - 
Fibrosing alveolitis 1 - 
Raynaud’s 1 - 
Auto-immune pancreatitis 1 - 
 
 
Autoimmune diseases and the presence of IBD 
Patients with IBD have increased predisposition to autoimmune diseases. 
Given the high prevalence of IBD in PSC population, I evaluated the effect of 
IBD status on the presence of autoimmune diseases.  This was to determine 
whether the increased prevalence of autoimmune disease in the cohort was due 
to co-existing IBD or associated with PSC independent of IBD.  The presence 
or absence of IBD was unrelated to an association between PSC and other 
autoimmune conditions (p-value = 0.13) (Figure 3.3). 
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Figure 3.3. The relation between IBD status and autoimmune disease.  
 
 
Symptoms at presentation  
All symptoms reported by patients are listed in Table 3.3.  At diagnosis 26% 
patients were asymptomatic, 51% had fatigue and/or pruritus at presentation, 
35% were jaundiced and 6% reported ascites and/or gastro-intestinal bleeding. 
 
Table 3.3. Symptoms reported by patients at presentation. 
 Number (%) 
Asymptomatic 376 (26) 
Fatigue 733 (51) 
Pruritus 700 (50) 
Abdominal pain 526 (36.5) 
Jaundice 510 (35.5) 
Ascites or gastro-intestinal bleeding 86 (6) 
Weight loss 15 (1) 
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Malignancy 
A history of hepatobiliary malignancy was reported in 24 (1.5%), with 
cholangiocarcinoma most common (n = 13).  Other hepatobiliary malignancy 
included gall bladder carcinoma (n = 6), hepatocellular carcinoma (n = 4) and 
one case of hepatic leiomyosarcoma. 
 
61 (4%) had a history of colorectal cancer and an additional 13 (1%) had high-
grade colonic dysplasia.  Of 74 patients with colorectal cancer or dysplasia, 
90% had underlying IBD (UC = 64; CD = 3). 
 
A history of malignancy was present in an additional 96 (6.6%) patients 
divided into: skin (n = 39); urological (n = 23); breast (n = 22); haematological 
(n = 8) and gynaecological (n = 4). 16/39 patients with skin cancer were liver 
transplant recipients.  The distribution of the various malignancies is shown in 
Table 3.4. 
The rates of malignancy described above are those observed in patients who 
were recruited in this study and were under regular hospital follow-up. A 
proportion of patients with malignancy may not have been recruited 
introducing a selection bias (discussed on page 78).  
 
Surgical co-morbidity 
A history of total or sub-total colectomy was reported in 256 (18%).  161/256 
patients were able to specify the type of bowel anastomosis following 
colectomy (permanent ileostomy = 107; ileal-anal pouch = 54).  240 (94%) of 
the colectomies were performed in patients with underlying IBD (214 with 
ulcerative colitis and 24 with Crohn's disease and 2 with mixed features).  Of 
the 16 patients without IBD, 4 underwent colectomy for colorectal cancer, but 
the indication was unknown in the remainder.  Cholecystectomy was reported 
in 182 patients (12.5%).  A history of biliary reconstructive surgery was 
reported by 27 (1.8%) patients, all of whom had evidence of either extra-
hepatic or both intra and extra-hepatic disease at cholangiography.  An 
additional 12 patients had undergone liver resection (indication not known) 
and 8 had a history of undergoing a Whipple’s procedure for suspected 
carcinoma of the pancreas.    
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Table 3.4.  Distribution of malignancy in the cohort. 
Malignancy Type of malignancy Number 
Gastro-intestinal* 
 
Colorectal cancer 
High grade dysplasia 
61   
13 
Skin¶ 
Malignant melanoma 
Basal cell carcinoma 
Unknown 
12 
6 
21 
Hepatobiliary 
Cholangiocarcinoma 
Gall bladder cancer 
Hepatocellular carcinoma 
Leiomyosarcoma 
13 
6 
4 
1 
Urological 
Prostate cancer 
Renal cell cancer 
Bladder cancer 
Testicular tumour 
8 
7 
5 
3 
Breast - 22 
Haematological 
Non-Hodgkin’s lymphoma 
Chronic lymphocytic leukaemia 
Post-transplant lymphoproliferative 
disorder 
5 
2 
1 
Gynaecological 
Cervical cancer 
Endometrial cancer 
2 
2 
*IBD present = 67.   ¶ Liver transplant recipients = 16 
 
 
Cholangiography 
Cholangiography consistent with PSC was reported in 866 cases. Details 
regarding cholangiography findings from clinicians were available for 791 
patients (ERCP = 274; MRCP = 517).  Intra-hepatic disease was present in 
405/791 (51%), extra-hepatic in 28 (3.5%) and both intra-hepatic and extra-
hepatic in 281 (35.5%). Cholangiography was normal in 77 (10%), 56 of 
whom had liver histology compatible with PSC (i.e. small-duct PSC).  Liver 
histology was not available for the remaining 21 patients. 
  
Liver histology consistent with PSC was present in additional 225 patients, in 
whom reliable cholangiography data were not available (comprising 117 
diagnostic liver biopsies and 108 liver explants). 
 
 72 
 
UDCA therapy 
Data on the use of UDCA were available in 1294 (90%), while 895 patients 
were also able to provide information on dose.  1022 (79%) patients were 
receiving or had been on UDCA treatment (until liver transplantation) and 272 
(21%) patients were not on medication.  The median dose of UDCA was 1000 
mg daily (range 150 - 4000 mg) and the median dose corrected per kg body 
weight was 12 mg/kg/day (range 2 - 46 mg/kg). 
 
For those with underlying IBD (n = 954), 682 of 866 for whom data were 
available (79%) were treated with UDCA.  After excluding patients with IBD 
who had undergone colectomy, only 530 (75%) of those were treated with 
UDCA; 121 (17%) were not on UDCA and data were unavailable for 63.  The 
proportion of patients who could not take UDCA because of side effects is not 
known. 
 
Liver transplantation 
337 (23.5%) patients were liver transplant recipients and 28 (2%) underwent a 
second transplant.  
 
 
Liver transplantation and time to event analysis 
 
Brief Introduction 
 
A proportion of patients with PSC, develop advanced chronic liver disease and 
ultimately require liver transplantation 12 to 17 years following diagnosis.  
Liver transplantation remains the only definitive treatment for advanced PSC 
(33).  However, it is not possible currently to identify patients at risk of 
developing more advanced disease at an early stage and there have been few 
large prospective studies examining prognosis or a susceptible clinical 
phenotype (113, 155, 156).  Furthermore, most descriptive studies derive from 
single centres or tertiary referral institutions with small sample size and so are 
subject to referral bias.  A recent retrospective study identified an association 
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between the reduction in serum alkaline phosphatase to < 1.5 upper limit of 
normal with improved liver-related outcome (based on liver decompensation, 
transplantation and liver-related deaths) in 139 PSC patients (157).  Our aim 
was to identify those risk factors that might be associated with an increased 
risk of developing end stage liver disease necessitating liver transplantation.  
 
 
Methods and statistical analysis 
 
We performed time-to-event analysis using the Kaplan-Meier method and Cox 
proportional hazards regression analysis.  The following variables were 
analysed: age at diagnosis; gender; symptoms at diagnosis; smoking; presence 
of IBD; ulcerative colitis; coeliac disease; autoimmune disease; UDCA dose 
and cholangiographic changes.  Involvement of first order bile ducts (right or 
left main hepatic duct) and/or common bile duct at cholangiography allowed 
distinction between extra-hepatic and intra-hepatic disease.  In time-to-event 
analysis, the start-point was defined as the date of diagnosis of PSC; the end-
point was liver transplantation and the censor point was the end of the study 
period (01 February 2012).  A complete dataset for all the variables was 
available for 362 patients and the time to event analysis was undertaken for 
this sub-cohort.  Univariate analysis using the Cox proportional hazards 
regression was performed to identify variables associated with transplant-free 
survival.  All variables with a p-value < 0.10 were taken forward for multi-
variable analysis using a Cox-proportional hazard regression model, to 
determine the independent prognostic value of each variable.  Cox 
proportional regression analysis was performed using the package ‘Survival’ 
in R 2.15.2.  Kaplan-Meier survival plots were generated for variables 
associated (p-value < 0.05) with transplant-free survival using Graphpad 
Prism version 4.0.  For survival analysis by UDCA dose, patients were divided 
into two sub-groups based on a dose above or below 15mg/kg/day.   
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Results 
 
20% of patients (72/362) were liver transplant recipients.  Characteristics of 
the cohort are shown in Table 3.5.  Variables associated with a shorter 
transplant-free survival in univariate analysis included: cholangiography (p = 
0.0008; hazard ratio (HR) = 2.28, 95% CI, 1.40 - 3.69) and UDCA dose (mg) 
(p = 0.0007; HR = 0.92, 95% CI, 0.88 - 0.96) (Table 11).  Multivariate 
analysis using a Cox-proportional hazard regression model identified clarify 
intra-hepatic and extra-hepatic disease on cholangiography (p = 0.0005) and 
clarify UDCA dose (p = 0.001) as independent risk factors associated with 
shorter transplant-free survival (Table 3.6). 
 
 
Table 3.5. Characteristics of the sub-cohort and time to event analysis 
(n = 362).  
Variable Number (%) 
Gender Male = 231 (64%). Female = 131 (36%). 
Median age at diagnosis 46 years (10 - 80) 
Liver transplant recipient 72 (20%) 
Cholangiography changes 
 
Intra-hepatic – 205 (56.5%) 
Intra- and extra-hepatic – 157 (43.5%) 
 
Inflammatory bowel disease 
 
n = 264 (73%) 
Ulcerative colitis – 226 (86%) 
Crohn’s disease – 34 (13%) 
Indeterminate – 4 (1%) 
Non-smoker 240 (66%) 
Active or ex-smoker 122 (34%) 
Autoimmune disease 47 (13%) 
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Table 3.6.  Risk factors associated with transplant-free survival (n = 362). 
Variable Univariate          Multivariate 
 p-value HR (95% CI) p-value HR (95% CI) 
Age (years)* 
 
0.28 0.99 (0.97 – 1.00)   
Gender (M/F) 
 
0.25 0.73 (0.43 – 1.24)   
Symptoms 
(Yes/No) 
 
0.12 1.62 (0.87 – 3.02) 
 
 
Non-smoker 0.07 1.68 (0.95 – 2.97) 0.26 1.38 (0.77 – 2.48) 
(Yes/No) 
 
Autoimmune disease 
(present/absent) 
 
 
 
0.35 
 
 
1.39 (0.69 – 2.82) 
  
IBD 
(present/absent) 
0.61 1.15 (0.66 – 1.99)   
 
Ulcerative colitis 
(present/absent) 
 
0.34 
 
1.28 (0.76 – 2.16) 
  
 
Crohn’s disease 
(present/absent) 
 
 
0.08 
 
0.35 (0.11 – 1.13) 
 
0.16 
 
0.43 (0.13 – 1.39) 
UDCA dose  
(mg)¶ 
 
0.0007 0.92 (0.88 – 0.96) 0.001 0.92 (0.88 – 0.97) 
Cholangiography 
(IH+EH/IH) 
0.0008 2.28 (1.40 – 3.69) 0.0005 2.34 (1.44 – 3.8) 
IH+EH – intra-hepatic and extra-hepatic disease; IH – intra-hepatic disease only; HR = hazard ratio; 
CI = confidence interval). (*Median age for this cohort = 46 years (10 – 80 years); ¶ Median dose = 
1000 (150 – 4000 mg).  
 
 
The significance of cholangiography changes and UDCA dose were then 
evaluated in the entire cohort where data were complete, using Kaplan-Meier 
survival analysis.  Data on cholangiography and time to liver transplantation 
or the censor point were available in 587 patients.  Of 250 (42.5%) with both 
intra-hepatic and extra-hepatic disease, 74 (29.5%) patients were transplant 
recipients, in comparison to 63 of 337 (18.5%) with disease confined to intra-
hepatic ducts.  The median survival in the two groups was 17 years and 29 
years respectively (log-rank p = 0.002; HR = 2.1, 95% CI, 1.3 – 3.3) (Figure 
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3.4).  Data on the dose of UDCA and time to transplant or to the censor point 
were available in 775 patients.  Patients were divided into two sub-groups 
based on the prescribed dose of UDCA above or below 15mg/kg/day. 69% (n 
= 533) patients were on < 15mg/kg/day.  20% of patients taking < 
15mg/kg/day of UDCA needed a transplant in comparison to 11% taking ≥ 
15mg/kg/day of UDCA (log-rank p-value = 0.004; HR = 2.16, 95% CI, 1.23 - 
3.25) (Figure 3.5). 
 
 
 
 
 
 
Figure 3.4. Kaplan-Meier transplant-free survival curves for patients with 
both intrahepatic (IH) and extrahepatic disease (EH) and those patients with 
isolated intrahepatic disease. (HR: hazard ratio (95% confidence interval)). 
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Figure 3.5. Kaplan-Meier transplant-free survival curves by UDCA dose (< 
15 mg/kg/day or ≥ 15 mg/kg/day).  
(UDCA: ursodeoxycholic acid; HR: hazard ratio (95% confidence interval)). 
 
 
Discussion 
 
All patients included in the final analyses were recruited according to rigorous 
standard criteria; all were under regular hospital follow-up until the censor 
point or liver transplantation and diagnostic accuracy was confirmed.  This 
represents the largest reported series of patients with PSC that includes 
demographic and phenotypic characteristics.  In agreement with previous 
series, PSC was more common in young, non-smoking males and 66.5% of 
the cohort had IBD, which was most often ulcerative colitis.  The diagnosis of 
IBD preceded the onset of PSC by a median 15 years.  The known protective 
effect of smoking against ulcerative colitis was maintained in the PSC 
population.  In contrast to ulcerative colitis, smoking is a recognised risk 
factor for Crohn's disease (158), but in this cohort defined first by the 
diagnosis of PSC, more than half of the patients with Crohn's disease were 
non-smokers; a protective effect of smoking in Crohn's disease could not be 
established, but the number of such patients in the cohort was small.  Of note, 
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26% patients were asymptomatic with the remainder having mainly non-
specific symptoms or fatigue with or without pruritus at presentation.  The 
non-specific nature of the presenting symptoms makes it difficult to make an 
early diagnosis of PSC especially in general practice.  As a consequence, a 
significant proportion of patients with PSC are identified later in the course of 
their disease, sometimes with features of established chronic liver disease. 
 
The increased prevalence of autoimmune diseases in patients with PSC was 
confirmed.  IBD is also associated with an increased prevalence of other 
immune-mediated diseases. However, patients with ulcerative colitis and PSC 
in this series did not have an increased prevalence of autoimmune disorder 
compared to PSC without ulcerative colitis and the spectrum of autoimmune 
disease identified was more characteristic of the associations described with 
PSC rather than those described in association with ulcerative colitis, 
suggesting that the observed increased prevalence of autoimmune disorder in 
the current series was related to PSC.  It is plausible that PSC shares key 
immunological risk factors and disease pathways with other immune-mediated 
diseases, which are also prevalent in the PSC population.  
 
Colorectal cancer was the malignancy reported most commonly found in 
association with PSC, but was mainly confined to patients with underlying 
IBD, consistent with the increased prevalence of colorectal cancer observed in 
patients with both PSC and ulcerative colitis in this series.  Only 13 patients in 
this series reported a history of cholangiocarcinoma at recruitment.  
Cholangiocarcinoma has an extremely poor prognosis and in a recent study the 
median time from diagnosis of cholangiocarcinoma to death was 6 months 
(159).  All the patients recruited were under active hospital follow-up for PSC.  
It is possible that a sub-set of PSC patients with cholangiocarcinoma that 
presented soon after a diagnosis of PSC could not be captured during 
recruitment for this study because of the poor prognosis and the likelihood that 
such patients would be less likely to be recruited to such studies.  Thus, the 
observed prevalence rate of cholangiocarcinoma in our cohort is unlikely to be 
a true representation of its prevalence in PSC. Likewise, a direct comparison 
of rates of malignancy with a control population was not possible in this study. 
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Colectomy, followed by cholecystectomy, was the surgical procedure 
undertaken most often and confined largely to those with PSC and IBD.  The 
age-standardised prevalence of cholecystectomy in the general UK population 
is 2.6% (females = 3.9%; males = 1.2%) (160), suggesting an increased 
cholecystectomy rate in this male predominant series.  The indications for 
cholecystectomy in this cohort are unknown, but given the increased 
prevalence of gallstones in PSC (73), it is likely to have been the most 
common indication. 
 
Cholangiography (ERCP or MRCP) remains the gold standard for the 
diagnosis of PSC and allows differentiation between intrahepatic and 
extrahepatic disease.  A proportion of patients with PSC develop chronic liver 
disease necessitating liver transplantation eventually.  Few risk factors for 
severe or progressive disease in PSC are known and there are no validated 
prognostic models for PSC.  Patients with small duct PSC have a better 
prognosis than those with larger duct disease and those with an elevated 
bilirubin are more likely to develop advanced liver disease (45, 113). 
 
In this series patients with both intrahepatic and extrahepatic disease had a 
median transplant-free survival of 17 years in comparison to 29 years for those 
in whom disease was restricted to the intrahepatic biliary tree.  The transplant-
free survival in this series was longer than that reported previously and was 
even more marked in those with disease limited to intra-hepatic ducts, 
consistent with recent studies showing a prolonged liver related end-point free 
survival in PSC (7, 15, 157).  Al Mamari et al. also identified an association 
between disease confined to the intra-hepatic ducts and sustained 
improvement in the serum alkaline phosphatase, which in turn was associated 
with an improved liver related outcome (157).  One possible explanation is 
that patients with extensive bile duct strictures have more marked intra-hepatic 
cholestasis, which in itself may exacerbate inflammation and fibrosis.  An 
increased clinical focus on this high-risk group might be beneficial. 
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UDCA is the only available treatment for patients with PSC and has been 
shown to improve both symptoms and liver function tests (100, 161).  One 
pilot study showed improved biochemistry and improved predicted survival at 
4 years (161), but in contrast, several studies have failed to demonstrate 
efficacy of UDCA at either the standard dose or a higher dose (> 
15mg/kg/day) (100).  Current EASL guidelines recommend UDCA in selected 
patients while AASLD guidelines do not recommend UDCA (19, 162).  It has 
been shown that cholestasis reduces UDCA mediated enrichment of bile acid 
pool and higher doses may be required to maintain the same level of 
enrichment (163, 164).  Thus, we divided our patients in to those receiving the 
standard dose (< 15mg/kg/day) or a higher dose (≥ 15mg/kg/day) of UDCA. 
In this large series involving most UK centres and analysed retrospectively, 
there was a dose-dependent benefit of UDCA therapy on transplant-free 
survival at ≥ 15 mg/kg/day.  It must be noted that higher doses of UDCA (28 - 
30 mg/Kg/day) are reported elsewhere to be associated with increased 
mortality, although cause and effect are unproven (99). 
 
This study has several limitations. It was an observational study and data were 
collected retrospectively, while the demographic and phenotypic 
characterisation was extracted from well-designed participant and clinician 
questionnaires.  Further, clinician questionnaires were incomplete in a small 
proportion of patients and data were not available regarding the duration of 
either UDCA therapy or the biochemical response to treatment.  Finally, liver 
biochemistry as a prognostic factor was not assessed and IgG4 levels were 
available in too few patients to allow meaningful analysis.  Thus, the study 
team felt there was a need to collect detailed clinical data, which was 
subsequently undertaken (discussed in chapter 4; page 81).   
 
In conclusion, the phenotypic characteristics of a large, comprehensive cohort 
of UK patients with PSC were established and we identified two clinical 
factors associated with liver transplant-free survival, which may have a role 
for risk stratification in patients suffering with PSC.  
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Chapter 4: Factors associated with clinical outcome and the 
development of a risk scoring system for patients with PSC. 
 
For this chapter, I designed the clinical questionnaire, recruited patients and managed 
the clinical database to capture the additional clinical data.    
The data included in this chapter was analysed by Dr Elizabeth Goode (Clinical 
research fellow, UK PSC study) and Dr AB Clark (Senior lecturer, University of East 
Anglia). 
 
Introduction 
 
Patients with PSC run an unpredictable disease course, with liver 
transplantation as the only definitive treatment option.  Individualised clinical 
risk prediction is lacking, especially during the early course of the disease due 
to various limitations of the existing risk scores as outlined in chapter 1 (page 
46).  
 
The phenotypic characteristics discussed in the previous chapter were obtained 
from participant and clinician questionnaire, but did not include detailed 
biochemical and clinical outcome data. This study was an extension of the 
phenotypic study of PSC patients in the UK and sought to collect more 
complete biochemical and other relevant clinical data from patients recruited 
in the UK PSC study, to help identify clinical risk factors predicting outcome 
and to develop and then validate a clinical risk scoring system.  
 
 
Study Design 
 
Patients recruited to the UK PSC study, ≥ 18 years of age, with PSC incident 
or prevalent between1st August 2008 and 31st March 2015, including those 
who had undergone liver transplantation prior to 31st March 2015, were 
included in the study. 
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Inclusion and Exclusion criteria were as described previously in Chapter 2 
(page 59).  Patients were classified as having extrahepatic disease based on the 
criteria described in chapter 3 (page 63).  
   
 
Data Capture 
 
Data were collected onto pre-specified questionnaires (Appendix 3), through 
review of case notes and included patient demographics, diagnostic 
cholangiography, histology reports, haematology and biochemical blood test 
results including serial liver biochemistry at diagnosis (to), 1-year following 
diagnosis (t1) and 2-years following diagnosis (t2), IBD status, use of UDCA, 
development of liver decompensation and progression to liver transplantation 
or death. Incomplete questionnaires or missing data received, were 
systematically queried with the respective research nurse or clinician at the 
participating site, to ensure accurate and complete capture of data.  
  
Study endpoints 
 
Date of diagnosis (t0) was defined as the date of first cholangiography or liver 
histology confirming a diagnosis of PSC.  The main primary endpoint of the 
study was liver transplantation.  The second primary endpoint was all-cause 
mortality (to encompass all liver related deaths).  Time from diagnosis of PSC 
to study endpoint was calculated.  Patients were censored at their most recent 
follow-up or blood test if they did not reach an endpoint.  
 
Variables evaluated for risk score 
 
The variables were included based upon clinical relevance or prior reported 
association. These included alkaline phosphatase (ALP), haemoglobin (Hb) 
g/l, platelet count (Plts) x 109/l, serum albumin (Alb) g/l and bilirubin (Bili) μ
mol/l.  
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Data analysis 
 
Descriptive statistics were calculated and reported as numbers or percentages. 
Variables with > 40% missing data were excluded from further analysis. This 
cut-off was chosen arbitrarily to allow inclusion of certain clinically relevant 
parameters (e.g. ALT). Time-to-event analysis was conducted using Cox’s 
proportional hazards model, ensuring at least 10 events per risk factor 
included in the model.  Events were truncated at 10 years follow-up to 
facilitate accurate prediction of risk.  Categorical variables were only 
considered if the categories had > 5% of the cohort in each category.  
 
Univariate analysis was performed in the raw dataset to show association 
between risk factors and outcome.  Where data were missing, multivariable 
imputation was performed using iteratively chained equations.  Results of ten 
imputed data sets were combined using Rubin’s equation and used to estimate 
the multivariate model.  Method of backward elimination was used to select 
variables for the final risk score, with removal of risk factors not significant at 
the 10% level.  Continuous variable were assessed for non-linear association 
using cubic splines.  Variables demonstrating a linear association were 
included in a standard continuous fashion and those showing a non-linear 
association were categorised using cubic splines and clinical judgment to 
allow for ease of interpretation.  
 
Association with alkaline phosphatase (ALP) 
 
Association between ALP at t1 and t2 with outcome was analysed to determine 
the optimal threshold for predicting 10-year hazard of outcome.  ALP was 
divided into categorical variables from </≥0.5 to 4xULN, with increments of 
0.1.  Each ALP cut-off was plotted against the hazard of reaching an endpoint. 
The optimal threshold for ALP was determined using Harrell’s C statistic.  
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Derivation of UK PSC risk scores 
 
We derived three separate risk scores, to determine the model with the best 
discrimination. The first was a score using t0 data to predict 10-year risk of 
outcome, the second a short-term risk score using t0 data to predict two-year 
risk of outcome (RSST) and the third, a long-term risk score using t0 and t2 data 
to predict 10-year risk of outcome (RSLT).  The RSLT included only those 
patients who did not reach a primary endpoint within 2 years of diagnosis. 
Harrell’s C statistic was used to compare discrimination of each risk score. 
Calibration curves for RSST and RSLT were generated by creating deciles of 
data and comparing the model’s predicted survival rates with the observed 
rates in the cohort, estimated by Kaplan-Meier (KM) curve.  
 
Independent validation of UK PSC risk scores 
 
An independent data set from two external PSC patient cohorts, not included 
in the original analysis was used to validate the UK PSC risk scores.  The first 
was a national validation cohort, n = 352, from two UK hospitals (John 
Radcliffe Hospital, Oxford and Queen Elizabeth Hospital, Birmingham).  The 
second validation cohort was from Norway (n = 99).  Validation of the scoring 
system was performed by fitting a Cox-model to the validation cohort using 
the scoring system derived from the derivation cohort.  Further visual 
validation was performed by displaying Kaplan-Meier (KM) survival curves 
for four separate risk groups in both cohorts.  Risk groups were defined by 
dividing the derivation cohort into four equal sized groups with increasing 
RSLT and the validation cohort divided into four groups according to the same 
RSLT categories.  
 
Comparison of the UK PSC score with existing scores 
 
Two existing risk scores were compared with the UK PSC risk score in both 
derivation and validation cohorts: revised Mayo risk score and AST:platelet 
ratio index (APRI) score using Harrell’s C statistic.  
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Statistical analysis 
 
All analyses were performed using Stata software (version 14.0/SE; StataCorp 
LP, College Station, Tx). 
  
Results 
 
Cohort characteristics 
 
1749 patients were recruited to the UK PSC cohort; 1252 questionnaires 
distributed and 1131 returned. 130 were excluded following quality control, 
leaving 1001 patients for analysis.  57% of the patients were recruited from 
non-transplant centres.  Table 4.1 shows the cohort characteristics.  
 
 
Table 4.1. Demographics of the UK PSC (derivation) cohort and national and 
international validation cohorts. 
Parameter Variable UK cohort 
(n = 1001)  
% 
Validation cohorts 
National 
(n = 352) % 
International 
(n = 99) % 
Demographics Male 
Median age at diagnosis (yrs) 
Median age at transplant (yrs) 
Median follow-up (yrs) 
63.8 
46.8 
47 
14.8  
 
62.4 
45 
47 
6 
75.7 
35 
39 
8 
Disease 
distribution 
Extra-hepatic biliary disease 
present (%) 
44.1 47.8 33.3 
IBD IBD 
UC 
CD 
IC 
72.5 
80.4 
14.2 
5.4 
71.0 
73.6 
10.7 
3.2 
86.0 
77.6 
15.3 
7.1 
Events Total events 
Transplants 
Deaths (all-cause) 
35.7 
27.8 
7.9 
39.2 
13.9 
25.3 
32.3 
11.1 
21.2 
IBD – Inflammatory bowel disease; UC – ulcerative colitis; CD – Crohn’s disease; IC – indeterminate 
colitis 
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Study endpoints 
 
35.7% of patients reached a primary endpoint over a cumulative follow-up 
period of 7,904 years.  27.8% of the cohort underwent OLT at a median age of 
47 years.  7.9% of the cohort died without a transplant; 47.8% of all deaths 
were PSC-related.  The overall proportion of the cohort that was event-free at 
2, 5 and 10 years was 92%, 82% and 64% respectively.  39% of men reached 
an outcome, compared to 29% of females (p-value = 0.002).  43% of those 
with extra-hepatic biliary disease reached an outcome compared to 23% of 
those without (p-value = 0.001).  Patients with extra-hepatic biliary disease 
had a reduced median transplant-free survival compared to those without 
extra-hepatic disease (11.7 versus 23 years).  UDCA use in the first 2 years 
following diagnosis was not associated with outcome. 
 
Serum alkaline phosphatase is associated with PSC outcome 
 
ALP data at t1 and t2 was available for 72% and 70% of the cohort 
respectively.  At both t1 and t2, raised ALP was associated with an increased 
10-year hazard of reaching an outcome (p-value < 0.001) (figure 4.1a and 
4.1b).  There was a log-linear association between serum ALP and outcome. 
At t1 the optimal threshold for predicting 10-year outcome was ALP ≥ 2.4 x 
ULN (HR = 3.05, C = 0.63) (supplementary figure 4.1a).  Median transplant-
free survival at t1 for those with ALP ≥ 2.4 x ULN was 63 versus 108 months 
for those with ALP < 2.4 x ULN (p-value < 0.0001 (log-rank test)) (figure 
4.1c).  At t2, the optimal threshold for predicting 10-year outcome was ALP ≥ 
2.2 x ULN (HR = 3.05, C = 0.66) (supplementary figure 4.1b).  Median 
survival for those with a t2 ALP ≥ 2.2 x ULN was 44 versus > 96 months for 
those with a t2 ALP < 2.2 x ULN (p-value < 0.0001 (log-rank test)) (figure 
4.1d).  
 
Disease distribution is associated with outcome 
 
Cholangiographic data at t0 were available in 87.2% of the cohort. The 
presence of extrahepatic biliary disease was associated with an adverse 
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outcome (HR = 1.45 (95% CI = 1.09 – 1.92); p-value = 0.010).  However, > 
50% of patients in both groups (intrahepatic and extrahepatic) were event free 
at 10 years and thus median survival was not reached.   
 
 
Derivation of a UK PSC risk score 
 
UK PSC risk score was designed using clinical variables available at diagnosis 
(t0) to predict 10-year risk of outcome.  Following multivariate analysis, seven 
variables were included in the score: age at t0, serum bilirubin, ALP, albumin, 
haemoglobin, platelet count and presence of extra-hepatic biliary disease at t0 
(supplementary table 4.1).  The C statistic was 0.78 with shrinkage of 0.94. 
The event rate within the cohort in the first two years of PSC diagnosis was 
high (8%).  Therefore, to determine if variables predicting short-term and 
long-term risk were different, two different risk scores were developed as 
follows: 
 
a) Short-term risk score (RSST): clinical variables at t0 were analysed to 
predict risk of outcome within 2 years following diagnosis.  The best 
fitting Cox model included four variables – bilirubin, albumin, 
haemoglobin and platelet count (table 4.2).  Based on these coefficients, a 
prognostic model was developed to predict risk of death or liver 
transplantation by year 2 (C = 0.81, shrinkage = 0.92) (supplementary Box 
4.1).  
 
b) Long-term risk score (RSLT): clinical variables at t2 were analysed to 
predict 10-year risk of outcome.  The best fitting Cox model included 
seven variables: age at t0, presence of extra-hepatic biliary disease at t0, 
serum bilirubin at t2, ALP at t2, albumin at t2, platelet count at t2 and 
variceal haemorrhage at t2 (C = 0.80, shrinkage = 0.96) (table 4.3 and 
supplementary Box 4.1). 
 
Both RSST and RSLT demonstrated improved predictive ability over the 
original risk score model. Calibration of RSST and RSLT using predicted versus 
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observed survival rates estimated by the Kaplan-Meier curve demonstrated 
good correlation. 
 
 
Table 4.2. Univariate analysis of factors at diagnosis associated with 2-year risk of 
transplant or death (using un-imputed data and multivariate analysis using 10 
imputed data sets). 
 Univariate Analysis Multivariate Analysis 
Factor   HR (95% CI) p-value H   HR (95% CI) p-value 
Female 0.88 (0.54,1.42)   0.596     
Age at diagnosis 1.01 (1.00,1.03)   0.126   
Extra-hepatic disease 1.30 (0.77,2.21)   0.332   
IBD presence 1.09 (0.49,2.44)   0.832   
   UC      
   CD     
   IC     
Autoimmune disease 0.90 (0.46,1.75)   0.757   
Smoker 1.22 (0.74,2.02)   0.426   
Bilirubin (μmol/l)     
   35 -49 4.03 (1.36,11.98)   0.012 2.11 (0.74,5.96) 0.159 
   50+ 14.12 (7.89,25.3) <0.001 5.02 (2.76,9.13) 0.000 
ALP (ratio of ULN)     
  1.5 - <2.5 1.25 (0.49,3.17)   0.634   
  2.5+ 2.64 (1.35,5.17)   0.005   
ALT (IU/l) 1.02 (0.98,1.05)   0.331   
Albumin (g/l) 0.87 (0.84,0.90) <0.001 0.94 (0.90,0.99) 0.011 
Haemoglobin (g/l) 0.79 (0.71,0.89) <0.001 0.99 (0.97,1.00) 0.095 
Platelets group (×109/l)     
  150 - 199 0.23 (0.08,0.72)   0.011 0.62 (0.26,1.48) 0.283   
  200 - 399 0.22 (0.11,0.45) <0.001 0.50 (0.25,0.98) 0.045   
  400+ 0.32 (0.13,0.78)   0.012 0.38 (0.15,0.98) 0.046   
Eosinophils (×109/l) 1.10 (0.89,1.36)   0.368   
Sodium (mmol/l) 0.89 (0.82,0.98)   0.015   
Creatinine >120 (µmol/l) 4.21 (1.66,10.68)   0.002   
IgG (g/l) 1.08 (0.93,1.25)   0.313   
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Table 4.3. Univariate analysis of factors at 2 years associated with 10-year risk of 
transplant or death (using un-imputed data and multivariate analysis using 10 
imputed data sets). 
 Univariate Analysis Multivariate Analysis 
Factor       HR (95% CI)   p-value HR (95% CI)      p-value 
Female 0.81 (0.60,1.10) 0.181   
Age at diagnosis 1.01 (1.00,1.03) 0.005 1.03 (1.01,1.04) <0.001 
Extra-hepatic disease 1.95 (1.42,2.69) <0.001 1.70 (1.15,2.48) 0.008 
IBD 0.91 (0.59,1.38) 0.646   
Autoimmune disease 1.27 (0.88,1.83) 0.200   
Smoker 0.96 (0.70,1.32) 0.790   
Bilirubin (μmol/l)     
   35 -49 6.77 (3.87,11.85) <0.001 3.31 (1.65,6.62) 0.001 
   50+ 7.92 (5.62,11.18) <0.001 3.96 (2.37,6.62) <0.001 
ALP (ratio of ULN)     
  1.5 - 2.4 1.75 (0.98,3.15) 0.061 1.50 (1.09,2.30) 0.015 
  2.5+ 1.40 (1.04,1.88) 0.025 1.57 (1.12,2.52) 0.011 
ALT (IU/l) 1.05 (1.03,1.08) <0.001   
Albumin (g/l) 0.88 (0.85,0.90) <0.001 0.93 (0.90,0.96) <0.001 
Haemoglobin (g/l) 0.75 (0.69,0.81) <0.001   
Platelets group (×109/l)     
  150 - 199 0.35 (0.20,0.60) <0.001 0.58 (0.31,1.10) 0.092 
  200 - 399 0.29 (0.20,0.43) <0.001 0.60 (0.40,0.91) 0.016 
  400+ 0.32 (0.17,0.60) <0.001 0.46 (0.23,0.92) 0.028 
Eosinophils (×109/l) 0.81 (0.52,1.29) 0.380   
Sodium (mmol/l) 0.90 (0.96,0.93) <0.001   
Creatinine >120 
(µmol/l) 
0.66 (0.21,2.07) 0.474   
IgG (g/l) 1.01 (0.92,1.12) 0.774   
UDCA use 0.96 (0.72,1.28) 0.795   
Variceal bleed by yr 2 5.97 (2.93,12.16) <0.001 2.76 (1.14,6.66) 0.024 
 
 
 
Defining risk groups based on long-term risk score (RSLT) 
 
In order to define low and high-risk disease groups according to RSLT, we 
divided the cohort into four equal quartiles.  Event-free survival, plotted on a 
Kaplan-Meier survival curve (figure 4.2a) demonstrated an observed event 
rate of 6.0%, 8.4%, 19.1% and 55.8% in the four respective risk groups. 
Curves for the four risk groups were generally well separated, although the 
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model was less able to distinguish between the two lowest risk groups. RSLT 
defining the four risk groups is shown in table 4.4.  
 
Table 4.4. Event rates in four groups defined according to long-term risk score in 
the derivation and validation cohorts.  
  Derivation cohort Validation cohort 
Risk 
group 
Score (RSLT) No. of 
individuals 
Observed 
event rate (%) 
No. of 
individuals 
Observed 
event rate (%) 
1 RSLT < -2.019 216 13 (6.0%) 105 3 (2.9%) 
2 -2.019 < RSLT < -1.463 215 18 (8.4%) 77 8 (10.4%) 
3 -1.463 < RSLT < -0.814 215 41 (19.1%) 60 12 (20.0%) 
4 -0.814 < RSLT < 2.737 215 120 (55.8%) 94 45 (47.9%) 
 
 
Validation of the UK PSC risk scores 
 
The predictive ability of both risk scores was analysed in a separate UK 
international cohort.  In the respective national and international validation 
cohorts (table 1), 62.4% and 75.7% of the cohort were male, diagnosed at a 
median age of 47 and 39 years, with 71% and 86% diagnosed with 
concomitant IBD.  The most notable differences between the two cohorts were 
the shorter median follow-up (6 and 8 years in the national and international 
cohorts respectively versus 14.8 years), higher death rate (25.3% and 21.2% 
versus 7.9%) and lower transplant rate (13.9% and 11.1% versus 27.8%).  
 
Both the RSST and RSLT were associated with outcome in the national 
validation cohort (p-value < 0.001).  In the international validation cohort, the 
lack of events within the first two years meant only RSLT could be validated, 
which was associated with long-term outcome (p-value < 0.001).  
 
Further visual validation of the RSLT was performed by comparing KM 
survival curves for the validation cohort according to the same four previously 
defined risk groups as the derivation cohort (figure 4.2b).  Event rates were 
similar to the derivation cohort at 2.9%, 10.4%, 20.0% and 47.9% (table 4.4). 
Both set of four curves were quite well separated, confirming that the model 
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had discrimination in both cohorts, however the model was less able to 
distinguish between the two intermediate risk groups in the validation cohort.  
 
Comparison of UK PSC risk score with existing scores 
 
We compared the predictive accuracy of the revised Mayo and APRI scores to 
the RSST and RSLT in the derivation dataset, both of which use AST levels to 
calculate the risk scores. ALT rather than AST is measured in most 
biochemistry laboratories in the UK. 
  
Based upon a subset of 170 patients from the validation cohort, for which both 
AST and ALT measurement were available for t0 and t2, there was strong 
correlation (r = 0.94, p-value < 0.0001) and strong concordance (c = 0.92, p-
value < 0.0001) between the two variables.  Therefore, ALT was used instead 
of AST for calculation of the Mayo and APRI scores in the derivation cohort.  
 
In predicting 2-year outcome, the RSST out-performed the APRI and revised 
Mayo scores with C statistics of 0.81, 0.63 and 0.75 respectively.  In 
predicting 10-year outcome the RSLT demonstrated an incremental 
improvement over the APRI and Mayo scores with statistics of 0.80, 0.59 and 
0.79 respectively.  Similar observations were noted in the validation cohort as 
well. 
 
 
Discussion 
 
The UK PSC cohort is a large ethnically homogeneous cohort of patients 
recruited from both transplant and non-transplant centres across the UK, thus 
representing the full spectrum of PSC disease severity. This study has identified 
clinically relevant variables associated with disease outcome.  
 
Akin to PBC, we have confirmed the importance of ALP as a prognostic 
indicator in PSC.  ALP level < 2.4 x ULN and < 2.2 x ULN at 1 and 2 years 
following PSC diagnosis, is associated with improved transplant-free survival. 
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Significance of ALP level at the time of PSC diagnosis remains unclear, as it 
was not associated with short-term outcome.  This may partly be due to the 
fluctuations in ALP seen at time of diagnosis (e.g. due to untreated cholangitis).  
 
In addition, I have provided further confirmation of an association between 
extrahepatic biliary disease and reduced transplant-free survival, which we 
found on the initial analysis (as discussed in chapter 3).  This highlights the 
importance of accurate assessment of disease extent on cholangiography (by 
radiologists) at the time of PSC diagnosis to allow early disease risk 
stratification.  There is no clear evidence based guidance on appropriate 
surveillance strategy in PSC.  Based on the findings from this study, it might be 
possible to identify patients, who present with or develop poor prognostic 
indicators and thus be monitored closely with regular clinic review and interval 
follow-up scans. 
   
A high event rate (8%) was observed within the first two years following 
diagnosis, suggesting there is a subset of patients who present late in their 
disease course, or who have a rapidly progressive disease.  Hence, separate risk 
scores were developed for short-term (RSST) and long-term (RSLT) risk 
prediction.  The key differences between the two are the laboratory parameters 
included for calculating the score. RSST includes parameters of intrinsic liver 
function (bilirubin, albumin, haemoglobin and platelet count), which are 
probably more relevant in predicting immediate outcome. 
 
Conversely, RSLT includes laboratory parameters (bilirubin, albumin, platelet 
count, ALP) in addition to variceal haemorrhage and cholangiographic disease 
distribution.  This would allow clinicians to recalculate risk at 2 years following 
diagnosis for greater prognostic accuracy. 
In addition, the new PSC risk score out-performed the existing revised Mayo 
score, with the latter only allowing a 4-year risk prediction of all-cause 
mortality but not liver transplantation.  In comparison, the UK PSC risk score 
predicts short-term (2 year) and long-term (10 year) risk of liver transplantation 
in addition to all-cause mortality.  
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Based on this study and using the RSLT risk score, it is possible to define a low-
risk disease group (patients with RSLT score < -2.02 had < 10% chance of an 
event by 10 years follow-up) and a high-risk group (patients with RSLT score -
0.81 < RSLT < 2.74 had ~ 50% chance of an event by 10 years) (table 4.4).  
 
The main limitation of this study is the retrospective nature of case 
ascertainment and data capture.  It is thus inherently biased towards those 
patients who were transplanted and recruited in to the study in comparison to 
patients who died or developed cholangiocarcinoma (median survival 4 – 6 
months). 
 
In addition, there was a proportion of patients with missing data.  Rates of 
missing data were higher for patients diagnosed many years previously and as it 
was predominantly related to the year of diagnosis, the data were considered to 
be ‘missing at random’, which is defined as any systematic difference between 
the missing values and the observed values that can be explained by differences 
in the observed data (165).  Thus, imputation was used to improve the validity 
of the results.  
 
In conclusion, this study was based on a detailed clinical evaluation of a large 
representative cohort of patients with PSC and has identified clinical parameters 
that predict their outcome.  Further studies are needed in even larger cohorts to 
validate the findings from this study with greater confidence, in particular the 
predictive accuracy of the UK PSC risk score. 
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Figure 4.1 (a). Association between alkaline phosphatase (as ratio of ULN) at year-1 
and hazard of reaching a clinical endpoint within 10 years, with 95% CI. 
 
0
2
4
6
8
1
0
0 2 4 6 8 10
Year  2  ALP  ratio  (ULN)
upper/low hazard
 
Figure 4.1 (b). Association between alkaline phosphatase (as ratio of ULN) at year-2 
and hazard of reaching a clinical endpoint within 10 years, with 95% CI. 
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Figure 4.1 (c). Kaplan Meier survival curve for transplant-free survival in patients 
with ALP ≤ 2.4 x ULN (blue line) versus ALP > 2.4 x ULN (red line) at 1-year 
following diagnosis (0 = 12 months post diagnosis).  
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Figure 4.1 (d). Kaplan Meier survival curve for transplant-free survival in patients 
with ALP ≤ 2.2 x ULN (blue line) versus ALP > 2.2 x ULN (red line) at 2-years 
following diagnosis (0 = 24 months post diagnosis). 
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Figure 4.2 (a) Derivation cohort Kaplan Meier survival curves for 4 risk groups.  
(b) Validation cohort Kaplan Meier survival curves for 4 risk groups. 
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Chapter 5: Genetic association studies – key concepts. 
 
This chapter gives a brief introduction to the key terminologies used in subsequent 
chapters, the concepts underlying study design and statistical analysis, in population 
based case-control genetic association studies, including its limitations.  
 
Introduction 
 
The main aim of case-control genetic association studies is to identify genetic 
risk factors associated with various diseases, especially complex disease traits 
where genetic factors may contribute towards disease development or 
pathogenesis.  The field of bioinformatics is rapidly evolving and offers a 
variety of technology, study designs and analytical tools to aid genetic studies. 
 
The two most popular study designs for case-control genetic association 
studies are: 
 
a) Candidate gene study: Candidate gene studies are hypothesis-driven, and 
focus on a particular gene or genetic region, due to compelling evidence or 
a priory probability of association with the disease.  
b) Genome wide association study (GWAS): GWAS are hypotheses free 
and seek to identify novel genes or genetic regions, associated with the 
disease.  
 
The most common genetic variation studied is the single nucleotide polymorphism 
(SNP).  
 
Single Nucleotide Polymorphism 
 
A SNP is a variation at single base-pair position in a DNA sequence occurring 
at an appreciable frequency (typically greater than 1%) in the population.  A 
SNP has two alleles (genotype) and its frequency is denoted by the frequency 
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of the less common allele in the general population i.e. minor allele frequency 
(MAF).  
 
In genetic association studies, a large number of SNPs are genotyped in 
individuals by using commercially available chip based microarray platforms 
(e.g. Illumina or Affymetrix).  Comparing the genotype frequency at each 
SNP between cases and healthy controls, allows identification of genetic 
regions that differ between the two cohorts, thereby implicating genes in these 
regions in disease pathogenesis.  Hence, SNPs are considered to be markers of 
the genetic region in the genome. 
  
A SNP is usually present in the non-coding region of the genome but can be 
present in the coding region as well. Commonly occurring SNPs have the 
ability to highlight potential candidate genes within the associated genetic 
region, which may have role in disease pathogenesis.    
 
Common disease Common variant hypothesis (CDCV) 
 
Monogenic disorders (e.g. cystic fibrosis) are usually caused by genetic 
variants occurring within a single gene.  By studying the genetic make-up and 
segregation in families affected by specific diseases using linkage analysis, it 
was possible to map heritable trait genes to their chromosome locations. 
Linkage typically tested highly polymorphic markers or SNPs in pedigrees 
segregating a trait to identify chromosome regions likely to harbor genes for 
the trait. Sequencing was then used to find the causal variant that was typically 
rare but had large effect size and high penetrance (166) (167).  However, when 
linkage was applied to more commonly occurring diseases, it failed to identify 
chromosomal regions associated with such diseases.  
 
The CDCV hypothesis was proposed following the identification of relatively 
common genetic variants (defined as MAF > 0.01) associated with common 
diseases; for example, the apolipoprotein E (APOE) gene for Alzheimer’s 
disease (168). 
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The hypothesis states that, commonly occurring disorders are likely to be 
influenced by genetic variants that occur commonly within the same 
population.  An important implication of this hypothesis is in relation to the 
penetrance (glossary Box 1; page 160) or the effect size of the common 
variant identified.  It is believed that, a common genetic variant will invariably 
have a small effect size.  If a common variant exerts a very strong effect, then 
the phenotype (disease) will also be equally common in the general population 
(169).  Hence, for commonly occurring diseases in the population, it is likely 
that many common variants, each with small effect size, exert a combined 
effect, thereby contributing to a proportion of the disease risk in the population 
(i.e. heritability – glossary Box 1; page 160).  
 
It is likely that there is a combination of genotypic, environmental and 
epigenetic interactions in disease causation and such diseases are referred to as 
complex diseases (e.g. diabetes mellitus and cardiovascular diseases).  This 
led to the emergence of population based, case-control genetic association 
studies especially for complex disease traits.  
 
The International Human Haplotype Map project 
 
The International HapMap project was established in 2002 to identify 
commonly occurring genetic variations (MAF ≥ 0.05) across the genome with 
a view to developing a haplotype map of the human genome, HapMap, to 
describe the common patterns of human DNA sequence variation (i.e. 
haplotypes) (170).  Four populations were selected for inclusion in the 
HapMap: 30 adult-and-both-parents Yoruba trios from Ibadan, Nigeria (YRI), 
30 trios of Utah residents of northern and western European ancestry (CEU), 
44 unrelated Japanese individuals from Tokyo, Japan (JPT) and 45 unrelated 
Han Chinese individuals from Beijing, China (CHB).  Approximately, 10 
million SNPs were genotyped as part of this project in 3 different phases 
across different populations, which act as the reference point.  The complete 
dataset obtained in Phase I was published on 27 October 2005.  The analysis 
of the Phase II dataset was published in October 2007.  In Phase III of the 
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project, a total of 11 global ancestry groups were assembled and their dataset 
was released in 2009. 
 
Haplotype and concept of Tag SNPs 
 
Sets of SNPs in close proximity on the same chromosome segregate together 
in blocks.  The pattern of SNPs within a block is referred to as the Haplotype, 
which represents that genetic region.  A few SNPs within each block are 
sufficient to identify the haplotype blocks by virtue of linkage disequilibrium 
between different markers. These SNPs are referred to as Tag SNPs. 
Information on common haplotypes allowed identification of a minimum set 
of Tag SNPs that would allow capture of majority of the genetic variation 
across the genome.  This concept allows reduction in the total number of SNPs 
needed to be genotyped from 10 million to approximately 500,000 SNPs.  
Only the tag SNPs are genotyped to cover the entire genome.  This was a 
crucial development, which facilitated the planning of genome-wide 
association studies in a cost effective manner.  
 
All the resources were made freely available to the public for use in genetic 
association studies.  International HapMap data were used in the UK PSC 
genetic association studies discussed in Chapters 6 and 7.   
   
As of June 2016, the HapMap resource site has been decommissioned.  It has 
been surpassed by the 1,000 genomes project, which was set up in 2008, to 
develop a comprehensive catalogue of genetic variants (SNPs) with a 
frequency of ≥ 0.01.  That is now established as the research standard for 
population genetics and genomics for all future genetic studies. 
 
Linkage Disequilibrium 
 
In a given population, which is undergoing random mating, repeated random 
recombination events over several generations will break apart contiguous 
segments of a chromosome.  Eventually, over a period of time, it will lead to 
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random distribution of alleles (i.e. independent of each other) throughout the 
genetic region – this is referred to as ‘linkage equilibrium’. 
 
Linkage disequilibrium refers to the combination of an allele with an allele of 
another SNP, more often than would be expected by chance (i.e. non-random 
association).  Two loci are in linkage disequilibrium, if the frequency of 
association of their respective alleles is higher or lower than what would be 
expected if they were associated randomly.   
 
Linkage disequilibrium is measured statistically by calculating the difference 
between the observed frequency of the combination of two alleles and the 
frequency expected if the two markers were independent.  The measure of 
linkage disequilibrium is often denoted by the variance D`, or by the squared 
correlation between the presence and absence of alleles at different loci, 
denoted by ‘r2’.  D` is a measure of population genetics, related to the 
recombination events between markers. A D` of 1 between two markers 
indicates complete LD. 
 
The values of r2 range from 0 to 1, with 0 suggesting no linkage 
disequilibrium and 1 complete linkage disequilibrium (169).  In genetic 
studies, r2 > 0.80 suggests strong genetic correlation between two loci and is 
often used as the cut-off to determine marker/SNP correlation.  
 
The concept of linkage disequilibrium is vital in planning genetic association 
studies.  In the presence of high linkage disequilibrium between two loci, 
genotyping one loci will ascertain the alleles (genotype) at both loci.  
 
Power calculation in genetic association studies 
 
The success of a genetic association study is dependent upon the strength of 
statistical power of the study.  It measures the probability of rejecting a false 
null hypothesis.  Various factors influence the statistical power of the study to 
detect associations and it is crucial that these factors are taken into 
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consideration while planning genetic association studies. The following 
factors play an important role in determining the power of a GWAS: 
 
 
a) Disease phenotype and prevalence 
b) Sample size (cases and controls) 
c) Number of SNPs genotyped and their frequency  
d) Linkage disequilibrium  
e) Effect size of the associated variants 
f) Inheritance models used for analysis (e.g. additive, dominant or 
multiplicative)  
 
Estimating the statistical power of a study is a useful tool, which allows 
selection of the appropriate sample size.  Adequate statistical power is 
generally estimated to have 80% probability of detecting an association.  It is 
inversely correlated with Beta (type II error): the higher the power of a study, 
the lower the risk of a false negative result. 
 
Due to the low prevalence of PSC, a small sample size is a major limiting 
factor for adequate statistical power in genetic association studies.  The 
concept of varying degrees of statistical power of an allelic test in a case 
control association study according to: (A) minor allele frequency (MAF), (B) 
disease prevalence, (C) linkage disequilibrium (LD), and (D) case-to-control 
ratio, is illustrated very well by Hong, E.P. et al. using genetic power 
calculator (171) (supplementary figure 5.1).  
 
As a general guide, for low prevalent complex disease traits, a sample size of 
2000 cases and 2000 controls will give a power of 80% to detect a common 
genetic variant (MAF > 0.05) with a modest effect size (OR > 1.3).  
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Significance threshold in GWAS 
 
Conventionally, a test is statistically significant if the p-value is below a preset 
threshold (α) < 0.05.  This is applicable to a single statistical test.  However, 
in GWAS, several independent tests are conducted depending upon the 
number of SNPs genotyped.  When several independent statistical tests are 
performed, such as in GWAS (i.e. 500,000 to 1 million), the probability of 
false positive test results (type 1 error; glossary Box 1; page 160) is much 
higher unless correction is made for multiple testing. 
 
The most common method used to correct for multiple testing is to apply 
Bonferroni’s correction threshold, which is calculated by dividing the 
significance threshold (0.05) by the total number of independent tests 
performed (500,000 – 1 million SNPs in GWAS).  Thus, the accepted 
threshold for genome-wide significance is p-value < 5 x 10-8.  
 
This stringent threshold should not be applied to candidate gene studies and 
replication studies, where there is already a priori a probability of an 
association.  Instead, for validation, the conventional p-value of < 0.05 should 
be used to confirm statistical significance.   
 
Genotyping  
 
Development of chip based microarray technology with capacity to genotype 
several hundred thousand SNPs simultaneously, has made GWAS possible. At 
the time of undertaking genetic association studies in the UK-PSC cohort, the 
two main commercially available genotyping platforms were: Illumina (San 
Diego, CA) and Affymetrix (Santa Clara, CA).  The genotyping chips used in 
GWAS were designed to capture common genetic variants (SNPs with MAF > 
0.05) and the genotyping platforms preferentially included SNPs in high LD 
(r2 > 0.8) with other variants in the genetic region to maximize the coverage 
and reduce the cost by genotyping fewer SNPs.  
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Quality control in genetic association studies 
 
In this section, I have briefly outlined the key data quality control (QC) steps 
carried out in genetic association studies, focusing on GWAS.  QC steps 
performed in the UK PSC genetic association studies are discussed 
individually in chapters 6 and 7.  
 
The main purpose of stringent quality control steps is to identify and remove 
DNA samples and SNPs/markers that may introduce bias and/or errors, 
resulting in a high number of false positive and/or false negative results.  
 
It is usual practice to implement the QC steps in individuals (cases and 
controls) first, prior to ‘marker/SNP’ QC.  This minimises the risk of markers 
being removed (in error), due to a set of poorly genotyped individuals. 
 
The ‘individual’ and ‘marker’ QC steps usually undertaken in genetic case-
control association studies are outlined below.  
  
‘Individual’ quality control 
 
There are four key steps involved in ‘individual’ QC which are performed 
sequentially as outlined below: 
 
a) Identification of discordant sex information 
The genotype data from the X-chromosome is used to check for 
discordance with the ascertained sex information.  It is particularly 
relevant if sex-stratified analysis is planned, but may also help detect DNA 
plating errors.  As males only have one copy of the X-chromosome, they 
can only be homozygote for SNPs genotyped on this chromosome 
(homozygosity rate ~ 1).  On the other hand, females have a much lower 
homozygosity rate (< 0.2).  The genotype-calling algorithm (glossary Box 
1; page 160) calculates the homozygosity rate across all X-chromosome 
SNPs in all individuals and compares it with the expected rate.  Individuals 
with discordant sex information should be excluded from further analysis.  
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b) Calculating the missing genotype and heterozygosity rate 
The missing genotype rate and sample heterozygosity rate are both 
measures of the DNA quality of the individuals.  It measures the 
proportion of SNPs with missing genotype data for that individual. 
Individuals who are missing genotypes above a pre-determined threshold 
(usually 3 to 5%) are removed from further analysis. 
 
Likewise, the proportion of individuals with an excessive or reduced 
number of heterozygote genotypes (heterozygosity rate) could suggest 
sample contamination.  Mean heterozygosity rate (H) is calculated by 
using the formula: 
 
H = (N – O)/N 
(N is the total number of non-missing genotypes, and O is the number of 
homozygous genotypes for a given individual). 
 
Distribution of the mean heterozygosity rate is inspected to identify 
individuals with extreme heterozygosity rates (more than ± 3 standard 
deviations from the mean) and should be excluded from further analysis. 
 
c) Identification of duplicate or related individuals 
In population based studies, it is important to identify duplicate samples 
and individuals who are closely related, as it can result in false 
overrepresentation of genotypes and inflation of allele frequencies in the 
studied population.  Information about duplicate samples is obtained by 
calculating the proportion of alleles shared at genotyped SNPs (excluding 
sex chromosome) between individuals and referred to as Identity by state 
(IBS). 
  
The degree of relatedness can be measured by calculating identity by 
descent (IBD), using genome wide IBS data.  The IBS approaches 1 for 
duplicate samples or monozygotic twins; 0.5 for 1st degree relatives and 
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0.25 for 2nd degree relatives.  Individuals who are closely related (i.e. 1st or 
2nd degree) are typically removed from further analysis.   
 
d) Population stratification  
Prior to undertaking a genetic association study, it is vital that cases and 
controls arise from the same population, to minimise the risk of 
confounding due to population stratification (glossary Box 1; page 160). 
  
Population structure variations in the study subjects can lead to 
confounding in genetic association studies.  Despite strict inclusion 
criteria, individuals from a different ethnic and population background 
may occasionally be inadvertently included in the study.  This may result 
in differences between allele frequencies in the population studied, not 
because of association with disease risk, but because certain alleles may be 
over or under represented in a different population.  For example, if a 
disease is studied in a European population to identify genetic risk factors, 
then it would not be ideal to have individuals from Asia or Africa in the 
same group, as their genetic make-up would be different to that of 
Europeans.  Population stratification can introduce significant bias in 
GWAS and must be addressed prior to association analysis. 
  
One of the statistical methods to identify individuals of divergent ancestry 
is principal component analysis, which is discussed below.  
 
      Principal component analysis (PCA) 
 
In simple terms, PCA measures the genotype correlation between 
individuals and SNPs in reference to populations of known ancestry (using 
the HapMap reference data).  
 
Principal component modeling is done first, using the available HapMap 
genotype data and allows clustering of the population into different 
ancestral groups based on their genetic make-up.  The model is then 
applied to individuals in the study to calculate their respective principal 
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component scores based on genotype data and group them closest to their 
reference ancestry groups from HapMap samples.  Usually, the first 
principal component score would allow detection of most of the variation 
in the study group, followed by second, third and fourth component scores. 
In well-defined population study groups the first two principal components 
are usually sufficient to identify ancestral outliers, who should then be 
removed from further analysis.  
 
‘Marker/SNP’ quality control 
 
The following steps are typically performed to identify SNP genotyping error:  
 
a) Calculating the ‘genotype call rate’ 
This is the proportion of individuals per SNP with non-missing data.  Poorly 
genotyped SNPs could introduce bias and should be removed from the study. 
SNPs with a call rate less than 95 to 97% are typically removed.   
  
b) Hardy-Weinberg equilibrium  (HWE) 
HWE assumes that the allele and genotype frequencies in successive 
generations remain constant in a large population in the absence of mutation, 
natural selection or migration.  Significant deviation from the HWE could 
indicate genotyping or genotype calling error.  It is important to note that, 
SNPs associated with a disease may deviate significantly from HWE, due to 
their underlying disease association and removing such SNPs would fail to 
identify true disease association. 
 
Thus, HWE thresholds should only be applied to control samples to detect 
genotyping or calling error.  The significance threshold applied for HWE is 
variable and in the UK PSC GWAS, we used a stringent threshold of p-value 
< 1 x 10-6.     
 
c) Minor allele frequency (MAF) 
SNPs with very low MAF should be removed to reduce false positive results. 
The threshold applied to remove SNPs varies, depending upon the size of the 
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study.  In the UK-PSC genetic association study, SNPs with MAF < 0.05 (5%) 
were removed from further analysis.  
 
Despite the above steps, genotyping errors may still be present.  The genotype cluster 
plots for all SNPs showing an association, should be visually inspected to ensure that 
genotypes have been called correctly. 
 
 
Imputation 
 
Imputation is a statistical tool, which allows prediction of the genotype of a SNP that 
was not directly genotyped in the study.  It uses information from the genotyped SNPs 
and haplotype patterns from a reference panel (e.g. HapMap or 1000 genomes) to 
predict the unobserved genotypes in a dataset (172).  Imputation increases the power 
of GWAS to detect associations and allows meta-analysis of genome wide association 
scans in samples that were originally genotyped using a different platform. 
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Chapter 6: Replication and fine mapping of genetic risk loci in PSC. 
 
This chapter focuses on a replication and a candidate gene study that was undertaken 
in 2012 in the UK PSC cohort. The aim of this study was to validate the loci 
identified in previous GWAS using the UK PSC cohort. 
 
I designed this study and identified the SNPs for replication. After obtaining extracted 
DNA samples from the laboratory, I diluted and normalised the DNA samples to the 
appropriate concentration before sending it for genotyping, which was performed at 
the Institute of Clinical Molecular Biology (ICMB), Kiel, Germany.  
I performed the statistical analysis for this study under the supervision of Dr George 
Mells, MRC research fellow, Addenbrooke’s Hospital, Cambridge.  
 
Introduction 
 
At the time of undertaking this study, two genome-wide association studies 
(GWAS) had identified susceptibility loci at 2q13, 2q35, 3p21, and 13q31 
with the most likely candidate genes proposed as BCL2-like 11 (BCL2L11), 
G-protein- coupled bile acid receptor 1 (GPBAR1), macrophage stimulating 1 
(MST1) and glypican 6 (GPC6) respectively (150, 151).  Details of these two 
GWAS were covered in chapter 1 (page 54).   
 
In addition to the genome-wide significant associations, several SNPs at the 
interleukin-2 receptor-α (IL2RA) locus showed a suggestive association in the 
discovery panel of the study by Melum et al., but were not replicated, 
probably due to effect size heterogeneity in the replication panels (151). 
Intriguingly, the 4q27 locus harboring the ligand interleukin-2 (IL-2) of 
IL2RA has also been implicated in a candidate gene study in PSC (173). 
 
Genetic risk variants at 4q27 and 10p15 are shared across multiple immune-
mediated diseases and harbor plausible candidate genes IL2/IL21 and IL2RA 
respectively (174). They are of interest because of the role of IL-2 signaling in 
immune tolerance. Furthermore, Il-2ra-/- mice spontaneously develop 
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intestinal and biliary inflammation (175), making IL-2/IL2RA a highly 
plausible signaling pathway in PSC pathogenesis. 
 
The aim of this study was to: 
a) Replicate and validate the association at four non-HLA loci previously 
reported to be associated with PSC at 2q13, 2q35, 3p21, and 13q31.  
 
b) Further characterize and refine the associations at 4q27 (IL-2/IL-21) and 
10p15 (IL2RA) in a large UK cohort of PSC cases and healthy UK 
controls.  
 
Methods 
 
Cohort ascertainment 
At the time of the study, a total of 1030 PSC cases (with DNA samples) were 
recruited, including all transplant centres in the UK. All patients with PSC 
were diagnosed using standard diagnostic criteria as described in chapter 2 
(page 58), and were mostly Caucasian.  The characteristics of the cohort are 
shown in Table 6.1.  
 
The control population comprised 5162 individuals from the 1958 British 
Birth Cohort and National Blood Service samples genotyped as part of the 
Wellcome Trust Case Control Consortium 2 (WTCCC2) project. 
 
Table 6.1. Characteristics of patients included in the replication study 
(n = 130). 
Ethnic origin 100% Caucasian (97.5% British) 
Median age at 
recruitment 
58 (range, 16 - 86) years 
Gender Males = 650, Females = 380  
(M:F = 1.7 : 1) 
Inflammatory bowel 
disease 
Total = 658 (64%); UC = 570 (86%), 
CD = 83 (13%), IC = 5 (1%) 
Liver transplant recipients 252 (24%) 
UC – Ulcerative colitis; CD – Crohn’s disease; IC – Indeterminate colitis 
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Selection of markers and SNPs 
a) Four SNPs previously associated with PSC identified from two GWAS 
were included.  These were rs6720394 (2q13; BCL2L11), rs12612347 
(2q35; GPBAR1), rs3197999 (3p21; MST1) and rs9524260 (13q31; 
GPC6).  
 
b) To study the interleukin 2 receptor alpha (IL2RA) locus, an 80Kbp region 
was selected on chromosome 10p15 between 6080Kbp - 6160 Kbp 
spanning IL2RA.  SNP data were downloaded for the CEU population 
from HapMap (170) Data Rel 24/phase II Nov 08, on NCBI B36 assembly, 
dbSNP b126 and Haploview v4.2 (176) was used for selecting tagging 
SNPs.  The HapMap data was filtered based on the following quality 
control (QC) thresholds: minimum genotype rate = 80%; maximum 
Mendelian errors = 1; minimum minor allele frequency (MAF) ≥ 0.05 and 
Hardy-Weinberg Equilibrium (HWE) test P-value > 0.001. 77 markers met 
QC criteria.  The SNP list was refined to 48 tag SNPs using a pairwise 
tagging approach (r2 threshold ≥ 0.8), force including eight key SNPs 
because of their reported association with immune-mediated diseases.  
 
c) To study the IL-2/IL-21 locus, a 564Kbp region was selected on 
chromosome 4q27 between 123236Kbp - 123800 Kbp that included the 
KIAA1109, ADAD1, IL-2 and IL-21 genes.  A total of 252 markers were 
selected for generating the Tag SNP list with a pairwise tagging approach 
(r2 threshold ≥ 0.8).  Five SNPs were force included based on their 
reported association. As this region shows very high linkage 
disequilibrium (LD), 39 tag SNPs adequately covered this region.  
 
A list of IL-2 (five SNPs) and IL2RA (eight SNPs) SNPs, which were force 
included and their respective prior disease associations, is shown in Table 6.2. 
Please note that the summary discovery panel statistics from a recent GWAS 
(151) were also used as a reference to select the SNPs to be force included for 
genotyping. Altogether, 91 SNPs were taken forward for design of genotyping 
assays.  
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Table 6.2 IL-2/IL-21 and IL2RA SNPs force included because of  their 
published association with immune-mediated diseases.  
SNP Locus Previous association (Reference) 
rs2104286 IL2RA MS (177), T1D (178) 
rs12722489 IL2RA MS (179) 
rs4147359 IL2RA T1D (180), PSC (151) 
rs10905718 IL2RA PSC (151) 
rs4749955 IL2RA T1D (178) 
rs12251307 IL2RA T1D (178, 180) 
rs706778 IL2RA PSC (151), RA (181) 
rs11594656  IL2RA MS (177), T1D (180), RA (181) 
rs6822844 IL2/IL21 CoD (182), MS (177), CD (183), RA 
(181), T1D (184), UC (185), PS (186) 
rs11938795 IL2/IL21 CD (183) 
rs13151961 IL2/IL21 UC (185), CoD (182), PS (186) 
rs13119723 IL2/IL21 RA (181), UC (185) 
rs6840978 IL2/IL21 CoD (182), UC (185), PS (186) 
MS – multiple sclerosis; T1D – type 1 diabetes mellitus; PSC – primary sclerosing 
cholangitis; RA – rheumatoid arthritis; CoD – coeliac disease; CD – Crohn’s disease; 
UC – ulcerative colitis; PS – psoriasis.  
 
 
DNA and plate preparation 
DNA extraction and plating was undertaken as described in chapter 2 (page 
62).  
 
Genotyping 
 
Genotyping in cases 
The Sequenom iPlex Gold™ genotyping platform was used for genotyping. 
SNP assay design failed for 25/91 SNPs and these were discarded. However, 
all thirteen key SNPs listed in Table 13 passed assay design.  Thus, 66 SNPs 
were taken forward for genotyping in 1030 cases.  Genotyping was performed 
at the Institute of Clinical Molecular Biology (ICMB), Kiel, Germany with the 
Sequenom platform, using an automated laboratory setup and all process data 
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were written to and administered by a database-driven laboratory information 
management system (LIMS). 
 
One SNP (rs3197999) failed genotyping with very low call-rate on Sequenom. 
This SNP alone was subsequently re-genotyped using TaqMan technology at 
ICMB, Kiel according to the manufacturer's recommendations.  Results from 
the genotyping assay were analysed using the SDS 2.3 software. 
 
Genotyping in controls 
We did not genotype the control population. Instead, control genotype data 
(fully quality controlled for heterozygosity, gender, ethnicity and relatedness) 
were obtained for 5162 individuals from the WTCCC2, that had previously 
been genotyped using the Illumina Human1M-Duo array (Illumina, San 
Diego, California). Control genotype data were available for 47/66 SNPs. 
Imputed data were generated for the remaining 19 SNP controls. 
 
Imputation of SNPs in the control population 
Imputation for 19 SNPs in the control population was carried out by Prof 
Heather Cordell, Professor of Statistical Genetics, Institute of Genetic 
Medicine, Newcastle University, Newcastle upon Tyne, UK, where genotype 
data were not available.  The steps involved in generating the imputed data are 
summarised below: 
 
Imputed data were generated for controls (on the basis of genotyped SNPs 
from the Illumina Human1M-Duo array) using the MACH software (187). 
Phased CEU haplotypes from HapMap Phase II were used as the reference 
sample (170).  Prior to imputation, SNPs with genotype call rate < 95%, minor 
allele frequency < 1% or HWE (P–value < 10-4) were removed. Any A/T or 
C/G SNPs (for which strand flips would not necessarily be automatically 
detected) were also removed. Following imputation, only those genotypes that 
had been imputed with a posterior probability of > 99%, according to the 
MACH output were retained. Two SNPs, rs4833248 (4q27) and rs1996077 
(4q27), showed unacceptably low overall rates of genotype assignment when 
using this 99% threshold and were excluded from the study. 
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Quality control 
 
Stringent individual and SNP QC thresholds were applied to both cases and 
controls as describe below.  
 
QC in Cases 
38 cases were excluded due to low genotyping rate (< 90%); the genotyping 
rate in the remaining cases was > 99%. None of the SNPs showed significant 
deviation from HWE (P-values > 10-4). One SNP rs3197999 (3p21; MST1) 
had a genotype rate of < 95%. This key SNP was found to be associated with 
PSC in a previous GWAS (151). For this SNP genotyping was repeated using 
TaqMan technology with a genotyping success rate > 98%. 
 
QC in Controls 
QC thresholds were applied to 47 genotyped SNPs in 5162 controls before 
combining the dataset with imputed genotype data for the remaining 17 SNPs. 
The total genotyping rate in controls was > 99% and all the markers had 
acceptable genotyping rate (> 95%). None of the markers deviated 
significantly from the Hardy-Weinberg equilibrium (P-value > 10-4). One SNP 
rs2390352 (4q27) had MAF < 0.05 and was removed from further analysis. 
 
After QC, 63 SNPs were analysed in 992 cases and 5162 controls. Details of 
all the SNPs, which passed QC and were analysed and the method of 
genotyping (genotyped or imputed) in control population are given in Table 
6.3. 
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Table 6.3 Genotyping method used in controls for SNPs included in the analysis. 
Chr 
Locus 
SNP Position Alleles Genotyping method in controls 
2 BCL2L11 rs6720394 111,705,843 G/T Genotyped 
2 GPBAR1 rs12612347 218,765,583 G/A Imputed 
3 MST1 rs3197999 49,696,536 A/G Genotyped 
13 GPC6 rs9524260 93,311,791 A/G Genotyped 
4 IL-2/IL-21 rs12511287 123,797,981 A/T Imputed 
4 IL-2/IL-21 rs6822844 123,728,871 T/G Genotyped 
4 IL-2/IL-21 rs13151961 123,334,952 G/A Genotyped 
4 IL-2/IL-21 rs13125087 123,238,043 T/A Imputed 
4 IL-2/IL-21 rs11938795 123,292,459 C/T Genotyped 
4 IL-2/IL-21 rs6840978 123,774,157 T/C Genotyped 
4 IL-2/IL-21 rs6827444 123,352,628 G/C Imputed 
4 IL-2/IL-21 rs13143866 123,760,208 A/G Genotyped 
4 IL-2/IL-21 rs7693745 123,455,033 G/A Imputed 
4 IL-2/IL-21 rs2137497 123,777,704 T/G Genotyped 
4 IL-2/IL-21 rs12642902 123,727,951 A/G Genotyped 
4 IL-2/IL-21 rs11722421 123,491,118 C/G Imputed 
4 IL-2/IL-21 rs6849146 123,545,541 C/T Genotyped 
4 IL-2/IL-21 rs975404 123,740,742 C/T Imputed 
4 IL-2/IL-21 rs17454584 123,572,882 G/A Genotyped 
4 IL-2/IL-21 rs1512971 123,744,785 T/C Imputed 
4 IL-2/IL-21 rs6534355 123,781,100 T/C Imputed 
4 IL-2/IL-21 rs4295278 123,766,991 C/T Genotyped 
4 IL-2/IL-21 rs4833810 123,237,840 T/C Imputed 
4 IL-2/IL-21 rs4833834 123,685,801 G/A Genotyped 
4 IL-2/IL-21 rs6534338 123,246,319 T/C Genotyped 
4 IL-2/IL-21 rs13110000 123,797,510 C/T Genotyped 
4 IL-2/IL-21 rs7678445 123,502,222 T/G Genotyped 
4 IL-2/IL-21 rs13119723 123,437,763 G/A Genotyped 
4 IL-2/IL-21 rs11931332 123,236,177 C/T Imputed 
4 IL-2/IL-21 rs6848868 123,369,736 C/T Genotyped 
4 IL-2/IL-21 rs6419221 123,783,569 T/C Genotyped 
4 IL-2/IL-21 rs1022234 123,782,528 G/A Genotyped 
10 IL2RA rs4147359 6,148,445 A/G Genotyped 
10 IL2RA rs706778 6,138,955 T/C Imputed 
10 IL2RA rs7090530 6,150,881 C/A Genotyped 
10 IL2RA rs10905718 6,154,862 G/A Imputed 
10 IL2RA rs10905669 6,132,099 T/C Genotyped 
10 IL2RA rs11594656 6,162,015 A/T Genotyped 
10 IL2RA rs10905716 6,154,016 T/C Imputed 
10 IL2RA rs706779 6,138,830 T/C Genotyped 
10 IL2RA rs7090512 6,150,835 C/T Genotyped 
10 IL2RA rs706781 6,126,391 C/T Imputed 
10 IL2RA rs4749924 6,122,402 C/A Genotyped 
10 IL2RA rs11256456 6,120,718 C/T Genotyped 
10 IL2RA rs2104286 6,139,051 C/T Genotyped 
10 IL2RA rs2476491 6,135,416 T/A Genotyped 
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10 IL2RA rs11256497 6,127,800 A/G Genotyped 
10 IL2RA rs12722563 6,109,567 A/G Genotyped 
10 IL2RA rs2256774 6,137,171 C/T Genotyped 
10 IL2RA rs12251307 6,163,501 T/C Genotyped 
10 IL2RA rs12359875 6,091,113 T/C Imputed 
10 IL2RA rs6602392 6,118,085 A/C Genotyped 
10 IL2RA rs791587 6,128,705 A/G Genotyped 
10 IL2RA rs9663421 6,095,610 T/C Genotyped 
10 IL2RA rs11598648 6,124,031 A/G Imputed 
10 IL2RA rs11256457 6,120,800 G/C Genotyped 
10 IL2RA rs2076846 6,103,259 G/A Genotyped 
10 IL2RA rs4749955 6,158,972 C/T Genotyped 
10 IL2RA rs12722596 6,096,300 C/T Genotyped 
10 IL2RA rs12722588 6,100,439 T/C Genotyped 
10 IL2RA rs7093069 6,103,325 T/C Genotyped 
10 IL2RA rs12722489 6,142,018 T/C Genotyped 
10 IL2RA rs12244380 6,093,380 G/A Genotyped 
Position refers to NCBI’s build 36. Chr – chromosome.  
 
 
 
Statistical analysis  
 
Case control association analysis 
Allelic association analysis for all the SNPs was performed using logistic 
regression in PLINK v. 1.07 (188). I only included control genotypes that had 
been imputed with > 99% probability to reduce the risk of false positive 
results. To correct for multiple testing for the 63 SNPs analysed, I determined 
a Bonferroni corrected threshold for a significant P-value at < 7.9 x 10-4 
(0.05/63).  
 
Meta-analysis 
For selected SNPs, previously published summary statistics were used to 
perform meta-analysis using the Metagen (inverse variance method) package 
in the R statistical software package (R v 2.13.1). Most significant SNPs 
reported in the two previous GWAS were included: rs6720394 (BCL2L11); 
rs12612347 (GPBAR1); rs3197999 (MST1) and rs9524260 (GPC6). In 
addition, most significantly associated SNPs at 4q27 (IL2/IL21) and 10p15 
(IL2RA) loci (whose summary statistics from previous studies were available) 
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were included in the meta-analysis: rs6822844 (IL2/IL21), rs12511287 
(IL2/IL21), rs4147359 (IL2RA), rs706778 (IL2RA) and rs7090530 (IL2RA).  
 
To account for differences between the population groups, I used a random 
effects model even though a test for heterogeneity was not statistically 
significant for any of the associated SNPs.  
 
Conditional analysis 
Conditional analysis is usually performed at an associated locus, to identify if 
there is effect of associated SNPs is independent of each other or not. I 
performed a logistic regression analysis conditioned on the most associated 
SNPs at 4q27 and 10p15 loci in PLINK v. 1.07, to determine the strength and 
validity of association of the SNPs in relation to each other. 
 
Phenotype based sub-group analyses 
I performed a sub-group analysis based on: 
 
a) Auto-immune disease status  
I hypothesized that the presence of co-existing immune-mediated diseases in 
the cohort could influence the association analysis results in particular because 
of the reported association of SNPs with immune loci. Thus, I identified and 
excluded 122 cases suffering with one or more autoimmune diseases from the 
original cohort: n = 908 (1030 - 122) and then applied quality control (QC) 
thresholds to these 908 cases.  33 cases were further removed for low 
genotyping rate (< 90%), leaving 875 cases. None of the 63 markers studied 
had low genotyping rate (< 95%) or deviated significantly from HWE (P > 10-
4).   
Thus, 63 SNPs were analysed in 875 cases and 5162 controls using logistic 
regression in PLINK v 1.07. 
 
b) IBD status 
For the IBD sub-group analysis I used fully quality-controlled dataset (n = 992 
cases) and identified the cases based on their IBD status and then performed a 
logistic regression analysis in PLINK comparing: 
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- PSC cases with IBD (PSC + IBD = 625) with 5162 controls  
-  PSC cases without IBD (PSC - IBD = 367) with 5162 controls.  
 
Results 
 
Allelic association analysis 
After quality control, 992 PSC cases were compared with 5162 controls at 63 
SNPs. Association results for all the studied SNPs are shown in supplementary 
table 6.1. 
 
a) Results of SNPs associated in the previous GWAS 
Only one of the four previously reported non-HLA loci SNPs was replicated. 
This was at 3p21 (rs3197999); p-value = 1.9 x 10-6; ORA vs G = 1.28, 95% 
confidence interval [CI] (1.16 - 1.42). 
 
SNPs at 2q13 (BCL2L11); 2q35 (GPBAR1) and 13q31 (GPC6) did not reach 
threshold for statistical significance (i.e. p-value < 7.9 x 10-4) (Table 6.4). 
 
Table 6.4. Association results for SNPs previously associated in GWAS. 
Ch
r 
Locus SNP Position Alleles 
MAF 
(cases/controls) 
P-value 
(UK cohort) 
OR (95% CI) 
(UK cohort) 
2 BCL2L11 rs6720394 111,705,843 G/T 0.13/0.12 0.40 1.07 (0.92 - 1.23) 
2 GPBAR1 rs12612347 218,765,583 G/A 0.48/0.50 0.21 0.94 (0.85 - 1.04) 
3 MST1 rs3197999 49,696,536 A/G 0.33/0.28 1.9E-06 1.28 (1.16 - 1.42) 
13 GPC6 rs9524260 93,311,791 A/G 0.40/0.40 0.77 0.99 (0.89 - 1.09) 
Association results for four SNPs in the UK cohort (992 PSC cases and 5162 controls) that have previously been associated in GWAS 
are shown. Logistic regression analysis was performed in PLINK v1.07. Position refers to NCBI’s build 36. Bonferroni corrected P-
value threshold for significance was determined to be < 7.9 x 10-4. All the reported odds ratios are with reference to minor allele vs. 
major allele. Chr – chromosome, MAF – Minor allele frequency, OR – Odds ratio, CI – Confidence interval.  
 
 
b) Association at 4q27 
At 4q27 locus, a significant association was observed for rs12511287 (P-value 
= 3.0 x 10-4, ORA vs T = 1.21, 95% CI (1.09 - 1.35)) (Table 6.4). The second 
most associated SNP at this locus (rs6822844) was associated at nominal 
significance but was insufficiently robust for multiple corrections  (P-value = 
1.9 x 10-3, ORT vs G = 0.81, 95% CI (0.70 - 0.92)).  
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In addition, eight other SNPs at this locus were nominally associated (Table 
6.5). A regional association plot for all the SNPs analysed at 4q27 locus is 
shown in Figure 6.1 (page 128). 
 
Table 6.5. Association results for SNPs analysed at 4q27 locus.   
Chr 
Locus 
SNP Position Allele 
MAF 
(cases/controls) 
P-value 
(UK cohort) 
OR (95% CI) 
(UK cohort) 
4 IL-2/IL-21 rs12511287 123,797,981 A/T 0.31/0.27 3.0E-04 1.21 (1.09 - 1.35) 
4 IL-2/IL-21 rs6822844 123,728,871 T/G 0.15/0.17 1.9E-03 0.81 (0.70 - 0.92) 
4 IL-2/IL-21 rs13151961 123,334,952 G/A 0.15/0.17 3.2E-03 0.82 (0.71 - 0.93) 
4 IL-2/IL-21 rs13125087 123,238,043 T/A 0.16/0.19 3.9E-03 0.82 (0.72 - 0.94) 
4 IL-2/IL-21 rs11938795 123,292,459 C/T 0.23/0.26 5.9E-03 0.85 (0.76 - 0.95) 
4 IL-2/IL-21 rs6840978 123,774,157 T/C 0.18/0.21 8.5E-03 0.85 (0.75 - 0.96) 
4 IL-2/IL-21 rs6827444 123,352,628 G/C 0.22/0.19 0.02 1.15 (1.02 - 1.30) 
4 IL-2/IL-21 rs13143866 123,760,208 A/G 0.26/0.28 0.028 0.89 (0.79 - 0.99) 
4 IL-2/IL-21 rs7693745 123,455,033 G/A 0.29/0.26 0.034 1.12 (1.01 - 1.25) 
4 IL-2/IL-21 rs2137497 123,777,704 T/G 0.43/0.40 0.040 1.11 (1.01 - 1.22) 
4 IL-2/IL-21 rs12642902 123,727,951 A/G 0.32/0.34 0.066 0.91 (0.82 - 1.01) 
4 IL-2/IL-21 rs11722421 123,491,118 C/G 0.35/0.33 0.20 1.07 (0.97 - 1.18) 
4 IL-2/IL-21 rs6849146 123,545,541 C/T 0.39/0.38 0.21 1.06 (0.97 - 1.17) 
4 IL-2/IL-21 rs975404 123,740,742 C/T 0.35/0.36 0.28 0.94 (0.85 - 1.05) 
4 IL-2/IL-21 rs17454584 123,572,882 G/A 0.23/0.22 0.34 1.06 (0.94 - 1.19) 
4 IL-2/IL-21 rs1512971 123,744,785 T/C 0.28/0.27 0.36 1.05 (0.94 - 1.17) 
4 IL-2/IL-21 rs6534355 123,781,100 T/C 0.24/0.24 0.37 1.05 (0.94 - 1.18) 
4 IL-2/IL-21 rs4295278 123,766,991 C/T 0.06/0.05 0.38 1.10 (0.89 - 1.34) 
4 IL-2/IL-21 rs4833810 123,237,840 T/C 0.39/0.38 0.45 1.04 (0.94 - 1.15) 
4 IL-2/IL-21 rs4833834 123,685,801 G/A 0.09/0.10 0.45 0.94 (0.79 - 1.11) 
4 IL-2/IL-21 rs6534338 123,246,319 T/C 0.30/0.29 0.52 1.04 (0.93 - 1.15) 
4 IL-2/IL-21 rs13110000 123,797,510 C/T 0.44/0.43 0.52 1.03 (0.94 - 1.14) 
4 IL-2/IL-21 rs7678445 123,502,222 T/G 0.08/0.07 0.53 1.06 (0.89 - 1.27) 
4 IL-2/IL-21 rs13119723 123,437,763 G/A 0.15/0.15 0.65 0.97 (0.85 - 1.11) 
4 IL-2/IL-21 rs11931332 123,236,177 C/T 0.34/0.34 0.78 1.01 (0.92 - 1.12) 
4 IL-2/IL-21 rs6848868 123,369,736 C/T 0.08/0.08 0.81 0.98 (0.82 - 1.16) 
4 IL-2/IL-21 rs6419221 123,783,569 T/C 0.37/0.37 0.87 0.99 (0.90 - 1.10) 
4 IL-2/IL-21 rs1022234 123,782,528 G/A 0.31/0.32 0.91 0.99 (0.90 - 1.10) 
Association results for all the SNPs analysed in the UK cohort (992 PSC cases and 5162 controls) at 4q27 locus are 
shown. Logistic regression analysis was performed in PLINK v1.07. Position refers to NCBI’s build 36. Bonferroni 
corrected P-value threshold for significance was determined to be < 7.9 x 10-4. SNPs with nominal association (P-value < 
0.05) are shown in bold. All the reported odds ratios are with reference to minor allele vs. major allele.     
Chr – chromosome, MAF – Minor allele frequency, OR – Odds ratio, CI – Confidence interval.  
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c) Association at 10p15 
At the 10p15 locus, significant associations were observed after correction for 
multiple testing (P-value < 7.9 x 10-4), for three SNPs: rs4147359, P-value = 
2.6 x 10-4, ORA vs G = 1.20, 95% CI (1.09 - 1.33); rs706778, P-value = 4.3 x 
10-4, ORT vs C = 1.19, 95% CI (1.08 - 1.31); and rs7090530, P-value = 7.0 x 10
-
4, ORC vs A = 0.84, 95% CI (0.76 - 0.93).  
 
A nominal association (P-value < 0.05) was seen for an additional 10 SNPs at 
this locus (Table 6.6). A regional association plot for all the SNPs analysed at 
10p15 locus is shown in Figure 6.1 (page 128). 
 
 
Table 6.6. Association results for SNPs analysed at 10p15 locus. 
Chr Locus SNP Position Allele 
MAF 
(cases/controls) 
P-value 
(UK cohort) 
OR (95% CI) 
(UK cohort) 
10 IL2RA rs4147359 6,148,445 A/G 0.39/0.34 2.6E-04 1.20 (1.09 - 1.33) 
10 IL2RA rs706778 6,138,955 T/C 0.44/0.40 4.3E-04 1.19 (1.08 - 1.31) 
10 IL2RA rs7090530 6,150,881 C/A 0.36/0.40 7.0E-04 0.84 (0.76 - 0.93) 
10 IL2RA rs10905718 6,154,862 G/A 0.35/0.31 1.0E-03 1.18 (1.07 - 1.31) 
10 IL2RA rs10905669 6,132,099 T/C 0.27/0.23 1.6E-03 1.20 (1.07 - 1.33) 
10 IL2RA rs11594656 6,162,015 A/T 0.21/0.24 2.8E-03 0.84 (0.74 - 0.94) 
10 IL2RA rs10905716 6,154,016 T/C 0.19/0.22 4.2E-03 0.84 (0.74 - 0.95) 
10 IL2RA rs706779 6,138,830 T/C 0.44/0.47 8.8E-03 0.88 (0.80 - 0.97) 
10 IL2RA rs7090512 6,150,835 C/T 0.27/0.30 0.011 0.87 (0.78 - 0.97) 
10 IL2RA rs706781 6,126,391 C/T 0.28/0.26 0.021 1.14 (1.02 - 1.27) 
10 IL2RA rs4749924 6,122,402 C/A 0.30/0.33 0.025 0.89 (0.80 - 0.99) 
10 IL2RA rs11256456 6,120,718 C/T 0.23/0.21 0.032 1.14 (1.01 - 1.28) 
10 IL2RA rs2104286 6,139,051 C/T 0.26/0.28 0.044 0.89 (0.80 - 1.00) 
10 IL2RA rs2476491 6,135,416 T/A 0.27/0.29 0.053 0.90 (0.81 - 1.00) 
10 IL2RA rs11256497 6,127,800 A/G 0.35/0.37 0.072 0.91 (0.82 - 1.01) 
10 IL2RA rs12722563 6,109,567 A/G 0.10/0.12 0.085 0.87 (0.75 - 1.02) 
10 IL2RA rs2256774 6,137,171 C/T 0.32/0.34 0.11 0.92 (0.83 - 1.02) 
10 IL2RA rs12251307 6,163,501 T/C 0.11/0.12 0.11 0.88 (0.76 - 1.03) 
10 IL2RA rs12359875 6,091,113 T/C 0.23/0.25 0.14 0.92 (0.82 - 1.03) 
10 IL2RA rs6602392 6,118,085 A/C 0.10/0.09 0.18 1.12 (0.95 - 1.31) 
10 IL2RA rs791587 6,128,705 A/G 0.45/0.46 0.21 0.94 (0.85 - 1.04) 
10 IL2RA rs9663421 6,095,610 T/C 0.27/0.28 0.22 0.93 (0.84 - 1.04) 
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10 IL2RA rs11598648 6,124,031 A/G 0.44/0.43 0.22 1.06 (0.96 - 1.17) 
10 IL2RA rs11256457 6,120,800 G/C 0.38/0.40 0.25 0.94 (0.86 - 1.04) 
10 IL2RA rs2076846 6,103,259 G/A 0.37/0.36 0.40 1.04 (0.94 - 1.15) 
10 IL2RA rs4749955 6,158,972 C/T 0.44/0.45 0.44 0.96 (0.87 - 1.06) 
10 IL2RA rs12722596 6,096,300 C/T 0.10/0.10 0.55 1.05 (0.90 - 1.23) 
10 IL2RA rs12722588 6,100,439 T/C 0.19/0.19 0.68 1.03 (0.91 - 1.16) 
10 IL2RA rs7093069 6,103,325 T/C 0.19/0.19 0.68 1.03 (0.91 - 1.16) 
10 IL2RA rs12722489 6,142,018 T/C 0.16/0.16 0.72 0.98 (0.86 - 1.11) 
10 IL2RA rs12244380 6,093,380 G/A 0.43/0.43 0.81 1.01 (0.92 - 1.12) 
Association results for all the SNPs analysed in the UK cohort (992 PSC cases and 5162 controls) at 10p15 locus are shown.  Logistic 
regression analysis was performed in PLINK v1.07. Position refers to NCBI’s build 36. Bonferroni corrected P-value threshold for 
significance was determined to be < 7.9 x 10-4. SNPs with nominal association (P-value < 0.05) are shown in bold.  All the reported odds 
ratios are with reference to minor allele vs. major allele. Chr – chromosome, MAF – Minor allele frequency, OR – Odds ratio, CI – 
Confidence interval. 
 
 
 
Meta-analysis 
 
Results from the UK cohort were combined with summary statistics from 
three other published genetic association studies (150, 151, 173) for four SNPs 
(at non-HLA loci) associated previously with PSC and selected SNPs at 4q27 
and 10p15 loci where data were available.  
 
Results of the combined analysis for SNPs included in the meta-analysis are 
shown in Table 6.7. Genome-wide significance (P-value < 5 x 10-8) was 
observed for rs3197999 at 3p21 (Pcombined = 3.8 x 10
-12, ORA vs G = 1.38, 95% 
CI (1.26 - 1.51)) and for rs4147359 at 10p15 (Pcombined = 1.5 x 10
-8, ORA vs G = 
1.25, 95% CI (1.16 - 1.36)). The other previously reported non-HLA SNPs at 
2q13; 2q35 and 13q31 were not associated in the UK cohort or combined 
analysis (Table 6.7).  
 
At the 4q27 locus, the association at rs6822844 did not reach the significance 
threshold (robust for multiple corrections) in the UK cohort. However, in a 
recent study of 1,186 northern European PSC patients, it was found to be 
associated with PSC. So I performed a combined analysis using published 
summary statistics from the study by Janse et al. and the UK cohort, which 
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strengthened the association at rs6822844 (P-valuecombined = 6.9 x 10
-6; ORT vs 
G = 0.77, 95% CI (0.69 – 0.86)) (Table 6.7).  
 
 
Table 6.7. Results for SNPs included in the meta-analysis.  
C
hr 
SNP Locus Alleles 
(minor/
major) 
MAF 
(case/ 
control) 
P-value 
(UK 
cohort) 
OR (95% CI) 
(UK cohort) 
               Meta-Analysis  
             (random effects)   
         OR  
  (combined) 
   P-value 
(combined) 
2 rs6720394* BCL2L11 G/T 0.13/0.12 0.40 1.07 (0.92 – 1.23) 1.28 (1.03-1.60) 0.024 
2 rs12612347§ GPBAR1 G/A 0.48/0.50 0.21 0.94 (0.85 – 1.04) 0.88 (0.74-1.04) 0.12 
3 rs3197999¶ MST1 A/G 0.33/0.28 1.9 x 10-6 1.28 (1.16 – 1.42) 1.38 (1.26-1.51) 3.8 x 10-12 
4 rs6822844λ IL2/IL21 T/G 0.15/0.17 1.9 x 10-3 0.81 (0.70 – 0.92) 0.77 (0.69-0.86) 6.9 x 10-6 
10 rs4147359¶ IL2RA A/G 0.39/0.34 2.6 x 10-4 1.20 (1.09 – 1.33) 1.25 (1.16-1.36) 1.5 x 10-8 
10 rs706778¶ IL2RA T/C 0.44/0.40 4.3 x 10-4 1.19 (1.08 – 1.31) 1.24 (1.14-1.35) 3.4 x 10-7 
13 rs9524260§ GPC6 A/G 0.40/0.40 0.77 0.99 (0.89 – 1.09) 0.82 (0.68-0.98) 0.034 
Association results are shown for SNPs associated after correction for multiple testing (Bonferroni corrected threshold for significance P-value < 
7.9 x 10-4).  Meta-analysis for selected SNPs¶ was performed by combining summary statistics from a recent PSC GWAS (151), using the Metagen 
(inverse variance method) package in R statistical software package.  A random effects model was used for meta-analysis even though a test for 
heterogeneity was not statistically significant for any of the associated SNPs. All the reported odds ratios are with reference to minor allele vs. 
major allele. Chr – Chromosome, MAF – minor allele frequency, OR – odds ratio, CI – confidence interval. 
 
 
Conditional analysis 
 
a) At 4q27 locus 
I performed logistic regression analyses at 4q27 locus, conditioned on the two 
most associated SNPs rs12511287 and rs6822844, which were not in linkage 
disequilibrium with each other (pairwise r2 = 0). When conditioned on 
rs12511287 (most associated SNP at 4q27), the strength of association of all 
the remaining SNPs remained unchanged when compared to the original 
results (figure 6.2 A; page 129). However, conditioning on rs6822844 
weakened the effect of all other SNPs except for rs12511287, suggesting an 
independent effect of these two SNPs at this locus (figure 6.2 B; page 129).  
 
b) At 10p15 locus 
A logistic regression analysis conditioned on the three most associated SNPs 
(rs4147359; rs706778; and rs7090530) at 10p15 locus was performed. 
Pairwise linkage disequilibrium between these three SNPs is shown in Table 
6.8. For each of the conditional analysis performed, the strength of association 
weakened for all other SNPs, suggesting the association to be dependent on 
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each other. Results (P-value) of the conditional analysis are shown in Table 
6.9. An association plot for each of the conditional analyses is shown in Figure 
6.3 (A - C) (page 130).  
 
 
Table 6.8. Pairwise LD for SNPs at 10p15 locus included in the 
conditional analysis. 
SNP1 SNP2 r2 
rs4147359 rs706778 0.68 
rs706778 rs7090530 0.42 
rs7090530 rs4147359 0.34 
 
 
 
Table 6.9. Association analysis results conditioned on the three most associated 
SNPs at 10p15 locus. 
Chr SNP P-value 
(UK cohort) 
P-value 
(conditioned on 
rs4147359) 
P-value 
(conditioned on 
rs706778) 
P-value 
(conditioned on 
rs7090530) 
10 rs4147359 2.60E-04 N/A 0.09254 0.04597 
10 rs706778 4.30E-04 0.6068 N/A 0.09858 
10 rs7090530 7.00E-04 0.1246 0.1216 N/A 
10 rs10905718 1.00E-03 0.7835 0.4598 0.1009 
10 rs10905669 1.60E-03 0.4527 0.2738 0.06342 
10 rs11594656 2.80E-03 0.09713 0.09589 0.3156 
10 rs10905716 4.20E-03 0.04862 0.02835 0.5427 
10 rs706779 8.80E-03 0.3666 0.9962 0.647 
10 rs7090512 0.011 0.3716 0.3292 0.8246 
10 rs706781 0.021 0.767 0.394 0.1071 
10 rs4749924 0.025 0.1769 0.1085 0.2634 
10 rs11256456 0.032 0.8255 0.5931 0.1983 
10 rs2104286 0.044 0.5799 0.7143 0.04148 
10 rs2476491 0.053 0.4958 0.6038 0.8746 
10 rs11256497 0.072 0.3225 0.546 0.8598 
10 rs12722563 0.085 0.3031 0.3874 0.6156 
10 rs12251307 0.11 0.4167 0.3379 0.5672 
10 rs2256774 0.11 0.5235 0.77 0.8992 
10 rs12359875 0.14 0.7532 0.7859 0.9697 
10 rs6602392 0.18 0.2379 0.242 0.2152 
10 rs791587 0.21 0.6126 0.4668 0.9935 
10 rs11598648 0.22 0.7524 0.9171 0.2835 
10 rs9663421 0.22 0.7164 0.7707 0.8993 
10 rs11256457 0.25 0.3905 0.273 0.7457 
10 rs2076846 0.4 0.5463 0.8806 0.4255 
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10 rs4749955 0.44 0.2125 0.5727 0.3115 
10 rs12722596 0.55 0.6957 0.8599 0.3992 
10 rs12722588 0.68 0.09227 0.03735 0.6468 
10 rs7093069 0.68 0.09172 0.03758 0.6472 
10 rs12722489 0.72 0.3499 0.3675 0.1245 
10 rs12244380 0.81 0.4509 0.3691 0.9039 
Results of conditional analysis at 10p15 locus are shown. The three most associated SNPs in the UK 
cohort at this locus are highlighted in bold.  When conditioned on one another, these SNPs lose their 
significance suggesting an association that is dependent on each another at this locus.  
 
 
Phenotype based sub-group analyses 
 
I performed a phenotype based, sub-group analysis within the cohort for the 
following sub-groups of patients based on:  
 
a) Autoimmune disease phenotype  
63 SNPs were analysed in 875 cases and 5162 controls using logistic 
regression in PLINK v 1.07. A significant association (P-value < 7.9 x 10-4) 
was observed for rs3197999 at 3p21 (MST1), P-value (AID excluded) =  1.2 x 10
-6, 
ORA vs G = 1.31, 95% CI (1.17 – 1.46); and rs12511287 at 4q27 (IL2/IL21), P-
value(AID excluded) = 4.7 x 10
-4, ORA vs T = 1.22, 95% CI (1.09 – 136). None of 
the SNPs at 10p15 (IL2RA) locus reached the threshold for significance.  
 
Results for all SNPs that reached nominal significance (P-value (AID excluded) < 
0.05) in this sub-group analysis are shown in Supplementary Table 6.2. 
 
b) IBD phenotype 
I performed a logistic regression analysis in PLINK comparing PSC cases 
with (PSC + IBD = 625) or without (PSC - IBD = 367) IBD against 5162 
controls. A significant association (P-value < 7.9 x 10-4) was observed only 
for rs3197999 at 3p21 (MST1) in PSC patients with IBD, P-value (PSC with IBD) = 
1.2 x 10-5, ORA vs T = 1.32 (1.16 – 1.49); P-value (PSC without IBD) = 7.2 x 10-3, 
ORA vs T = 1.24 (1.06 – 1.45). Results for all SNPs that reached nominal 
significance (P-value (PSC with IBD) or (PSC without IBD)  < 0.05) in this sub-group 
analysis are shown in Supplementary Table 6.3. 
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Discussion 
 
This study identifies for the first time an association between PSC and SNPs at 
a 10p15 locus with genome wide significance and confirms an association at 
3p21 and 4q27. The most plausible candidate genes at these loci are IL2RA, 
MST1 and IL-2/IL-21 respectively.  
 
The MST1 SNP, rs3197999, encodes a non-synonymous change p.Arg689Cys 
in MST1 and is also associated with IBD, suggesting shared genetic risk 
factors between PSC and IBD (189). MST1 is highly expressed in the liver and 
encodes macrophage-stimulating protein (MSP). It plays a role in cell 
proliferation, leucocyte adhesion and chemotaxis, and has a critical role in 
attenuating the inflammatory response by inhibition of lipopolysaccharide-
induced inflammatory mediators (190).    
 
At the 10p15 locus, association signal peaks at rs4147359, which is located in 
the intergenic region between IL2RA and RNA binding motif protein-17 
(RBM17).  This SNP has been associated previously with type-1 diabetes 
(180). Other type-1 diabetes risk alleles at this locus have been associated with 
reduced serum concentrations of soluble IL-2RA (180), making IL2RA a 
plausible candidate gene, as well as suggesting a possible mechanism for the 
genetic association. Of note, spontaneous mutation of IL2RA in humans causes 
systemic autoimmunity and multi-organ inflammation (191).  
 
At 4q27 locus, the most associated SNP (rs12511287) is located upstream of 
the IL-21 gene. The second most associated SNP at this locus, rs6822844, 
located in a noncoding region upstream of IL2 and downstream of IL21, has 
previously been associated with other autoimmune diseases and is considered 
as a general autoimmune risk locus (192). I have for the first time shown two 
independent association signals at this locus marked by rs12511287 and 
rs6822844 in PSC.  
 
IL-2 is a likely candidate gene at 4q27 (173), especially given the strong PSC 
association with its receptor (IL2RA). IL-2 is a cytokine produced 
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predominantly by activated T cells and exhibits its actions both in an autocrine 
and paracrine fashion by binding to the IL-2 receptor (IL-2R). It plays a 
crucial role in modulating immune responses by promoting proliferation, 
differentiation, and function of activated T cells as well as maintaining the 
homeostasis and functioning of CD4+CD25+ Foxp3+ T regulatory (Treg) cells 
(193). A defect in Treg cell production is believed to be the main reason for 
autoimmunity associated with IL-2/IL-2R deficiency as seen in murine models 
and humans (191, 194).  
 
Another gene encoded at 4q27 locus, which also appears to be a plausible 
candidate gene at this locus is IL-21. IL-21 plays an important role in 
immunoglobulin production and T-cell function, has pro-apoptotic actions on 
B-cells and drives the terminal differentiation of B-cells to plasma cells (195). 
IL-21 protein expression is increased in colonic tumours and it has been 
shown in animal models that IL21-/- knockout mice are resistant to colon 
cancer (196). IL-21 may thus have a role in amplifying the gut inflammatory 
milieu in patients with ulcerative colitis, thereby promoting the growth of 
colitis-associated cancer. PSC further increases the risk of colorectal cancer in 
IBD patients but the mechanism is unknown (197). It is possible that PSC 
patients with IBD may have dysregulated IL-21 function, making it an 
interesting candidate gene at this locus.  
 
Genetic variants at 4q27 (IL-2/IL-21) and 10p15 (IL2RA) are associated with 
other autoimmune diseases, such as coeliac disease, rheumatoid arthritis, type 
1 diabetes mellitus, multiple sclerosis and psoriasis (174, 198, 199).  
 
There is widespread sharing of genetic risk loci (including variants at 4q27 
(IL2/IL21) and 10p15 (IL2RA)) between these diseases (174), making them 
non-organ specific autoimmune disease susceptibility loci. PSC is associated 
with an increased prevalence of other autoimmune diseases and its association 
with genetic variants at 4q27 and 10p15 loci could imply not only a shared 
genetic risk with other autoimmune diseases but also allow us to identify the 
shared immunological pathways favouring disease development.  
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The present results refine the known genetic architecture of PSC by 
confirming MST1, IL2RA and IL-2/IL-21 locus associations, suggesting a role 
of both innate and adaptive immune responses in PSC pathogenesis. Despite 
successfully replicating and confirming the associations at these loci, I was not 
able to refine the association signal to a specific causal variant. It is important 
to emphasise that genetic association studies (GWAS or candidate gene 
studies) have limited utility in identifying true causal genetic variants 
associated with complex diseases such as PSC. They do allow identification of 
the most likely biological pathways that may be involved in disease 
pathogenesis and serve as good starting points to design robust functional 
studies based on the implicated pathways (200). PSC is believed to be a multi-
factorial disease and genetic polymorphisms not yet discovered are likely to be 
important along with potential environmental and epigenetic risk factors. 
Functional studies at each of the associated locus are now required to identify 
the true causative gene or genes to facilitate rapid translation to the discovery 
of novel therapeutics.  
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Figure 6.1 Regional association plots at 10p15 (IL2RA) and 4q27 (IL-2/IL-21). The plots show association results at 10p15 (IL2RA) (Panel A) and 4q27 (IL-2/IL-21) 
(Panel B) for all the SNPs analyszed in the study. Results are shown as –log of the p-values plotted against the marker position (NCBI B36). All the SNPs are denoted by a 
square with red colour gradient as the measure of LD in relation to the SNP with the lowest p-value (denoted by a diamond) in each panel. The blue lines denote the rate of 
recombination along the chromosomal region based on data from the HapMap project. The plots were created using SNAP (201). LD = linkage disequilibrium. 
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Figure 6.2. Regional association plots for all the SNPs at 4q27 (IL2/IL21) conditioned on rs12511287 (A) and rs6822844 (B). The plots show association results from a 
conditional analysis of the two most associated SNPs at 4q27 locus. Panel A: When conditioned on rs12511287 (most associated SNP at 4q27), the strength of association of 
all the remaining SNPs remains unchanged as compared to the original results. Panel B: Conditional analysis on rs6822844 weakens the effect of all other SNPs except for 
rs12511287 suggesting an independent effect of these two SNPs at this locus. All the SNPs are denoted by a square with red colour gradient as the measure of LD with the 
lead SNP (denoted by a diamond) in each panel. The blue lines denote the rate of recombination along the chromosomal region based on data from the HapMap project. The 
blue peak just upstream of IL-21 gene denotes the point of recombination peak at this locus. The plots were created using SNAP.  
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           (A)           (B) 
          (C) 
        
 
Figure 6.3 (A - C). The plots show association analysis results for all 
the SNPs at 10p15 locus conditioned on the three most associated 
SNPs: rs706778 (A); rs4147359 (B) and rs7090530 (C). For each of 
the conditional analyses performed, the strength of association 
weakened for all the remaining SNPs, suggesting the association to be 
dependent on each other. All the genes at this locus are shown on the x-
axis with chromosome position (NCBI B36). All the SNPs are denoted 
by a square with red colour gradient as the measure of LD with the lead 
SNP (denoted by a diamond) in each panel. The blue lines denote the 
rate of recombination along the chromosomal region based on data from 
the HapMap project. The plots were created using SNAP. 
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Chapter 7: Genome wide association study in the UK PSC cohort. 
 
A genome wide association study (GWAS) was performed in a well-characterised 
cohort of UK PSC patients in 2011. At the time of undertaking this study, it was the 
largest GWAS in PSC patients.  
 
I collected and plated all the DNA samples, which were genotyped at the Wellcome 
Trust Sanger Institute. I performed the statistical analysis for this study, under the 
supervision of Dr George Mells (Research fellow, Academic department of medical 
genetics, Cambridge) and Dr Carl Anderson (Genetic and Genomic Epidemiology 
Unit, Wellcome Trust Sanger Institute, Cambridge).   
 
 
Aims and objectives 
 
The main aim of this study was to find genetic markers associated with PSC 
and to identify potential susceptibility loci that could be implicated in PSC 
pathogenesis.   
 
 
Methods 
 
Case ascertainment and description 
A total of 1020 PSC cases were included in the discovery panel and cases 
were recruited from the UK including all transplant centres. All PSC cases 
were diagnosed using standard diagnostic criteria as described in chapter 2 
(page 59), and were mostly of Caucasian ethnicity. The characteristics of the 
cohort are shown in Table 7.1. 
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Controls 
The control population in the discovery panel comprised 2930 individuals 
from the 1958 British Birth Cohort (BBC) and 2737 individuals from the 
National Blood Service (NBS) cohort. Their DNA samples were genotyped as 
part of the Wellcome Trust Case Control Consortium 2 (WTCCC2) project. A 
total of 5667 controls were available for the discovery panel. 
 
DNA preparation 
DNA preparation and plating steps were as described in chapter 2 (page 62).  
 
Genotyping platform 
PSC cases were genotyped using the Illumina HumanOmni2.5-8 BeadChip 
(Illumina, San Diego, CA, USA) and called using the GenCall algorithm 
implemented in GenomeStudio. Genotyping was done at the Wellcome Trust 
Sanger Institute (Hinxton, UK). 
  
We did not genotype the control population. Instead, control genotype data 
were obtained for 5667 individuals from the WTCCC2, who had previously 
been genotyped using the Illumina Human1M-Duo array (Illumina, San 
Diego, California). 
 
 
Table 7.1. Characteristics of patients included in the GWAS (n = 
1020).  
Ethnic origin 100% Caucasian (97.5% British) 
Median age at recruitment 58 (range, 16 – 86) years 
Gender Males = 646, Females = 374  
(M:F = 1.7:1) 
Inflammatory bowel 
disease 
Total = 652 (64%); UC = 568 (87%), 
CD = 80 (12%), IC = 4 (1%) 
 
Liver transplant recipients 252 (24.5%) 
UC – Ulcerative colitis; CD – Crohn’s disease; IC – Indeterminate colitis 
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Statistical analysis  
 
Quality control 
 
Cases and Controls: 
Stringent quality control steps were applied to the cases and controls in the 
discovery panel to identify and remove individuals with: 
 
a) Discordant sex information 
b) Genotype failure rate ≥ 0.03 
c) Heterozygosity rate (mean ± 3 standard deviations (s.d.)) 
d) Identity by descent > 10% (i.e. related), or 
e) Divergent or non-European ancestry (using principal component analysis 
(PCA)).  
 
Ancestry clustering was done using HapMap 3 reference samples, into three 
population groups (Figure 7.1a): 
 
a) CEU (European) - Utah residents with Northern and Western European 
ancestry from the CEPH collection 
b) CHB + JPT (Asian) - Han Chinese in Beijing, China + Japanese in Tokyo, 
Japan 
c) YRI (African) - Yoruba in Ibadan, Nigeria 
 
Marker (SNPs): 
SNPs with a call rate < 97%, HWE p-value < 1 × 10−6 and MAF < 0.05 were 
removed.  
 
Association analysis 
 
Case-control association tests were conducted using 1-degree-of-freedom 
Cochran-Armitage trend tests implemented in PLINK v1.07. Cluster plots for 
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all SNPs with p-value < 1 × 10−4 were examined to check the accuracy of 
genotype calling.  
 
Replication 
 
Replication cohort 
This comprised a cohort of well-characterised 332 Scandinavian and 383 
German patients with PSC who had been genotyped on Affymetrix Genome-
Wide Human SNP Array 6.0 (Affymetrix) for a previous GWAS study (151).  
 
Replication analysis 
As part of the replication analysis, we did not genotype the most associated 
SNPs (outside of the HLA region) from the discovery panel in an independent 
validation cohort. Instead, we used summary statistics from a GWAS study 
done in an independent European (Scandinavian and German) PSC cohort, 
and performed an in-silico replication analysis to identify SNPs associated 
with PSC. Details regarding the in-silico replication analysis are described 
below. 
 
Selection of SNPs for in-silico replication analysis 
All SNPs with p-value < 1 x 10-4 were identified and susceptibility locus 
defined for each associated region by finding a 0.1 cM interval on either 
side of the most associated SNP. Melum et al. provided summary statistics 
for these SNPs, for in-silico replication and meta-analysis.  
 
Allele/strand matching of SNPs between UK and replication data 
The GWAS data from UK PSC and replication cohorts were merged using 
PLINK. When merging two datasets, it is important that the two sets of SNPs 
are concordant in terms of positive or negative strand. We flipped the strands 
for SNPs with a mismatch and recoded the allele information (in PLINK) to 
have full concordance between the discovery panel and replication datasets.  
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Meta-analysis 
Meta-analysis was performed using GWAS data and summary statistics from 
the replication cohort using Metagen (inverse variance method) package in the 
R statistical software package (R v 2.13.1). To account for differences 
between the population groups, we used a random effects model even though a 
test for heterogeneity was not statistically significant for any of the associated 
SNPs. In the combined meta-analysis, genome wide significance threshold (p-
value < 5 x 10-8) was used to confirm disease association.  
 
We did not perform any sub-group analysis comparing IBD risk loci because 
of small number of patients in each sub-group cohort, which would reduce the 
power of such type of study to detect true association.  
 
 
Results 
 
QC results 
Individual QC 
After QC steps, 79/1020 cases were removed. 143/2930 controls were 
removed from the BBC controls and 111/2737 controls were removed from 
the NBS controls (total number of controls removed = 254 out of 5667). The 
discovery panel thus comprised 941 PSC cases and 5413 healthy controls.  
Table 7.2 lists individuals removed for each of the QC steps in cases and 
controls. 
 
Figure 7.1 (a) (page 142) shows the ancestry clustering of PSC cases based on 
the genome wide data and HapMap 3 reference samples. Figure 7.1 (b) (page 
142) shows the thresholds applied to remove PSC cases, based on the first and 
second principal component scores.  
Supplementary figures 7.1 (a) and (b), show the thresholds applied to remove 
BBC and NBS controls, based on the first and second principal component 
scores respectively.  
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Marker (SNP) QC 
After applying QC thresholds in each of the case and control cohorts, 
465,662 SNPs were taken forward for analysis.  
 
Supplementary figures 7.2 (a - c) show the histograms of missing genotype 
data across all PSC cases and controls (BBC and NBS cohorts) that passed 
individual quality control.  
 
 
Discovery panel results 
 
Following QC, 465,662 SNPs were analysed in 941 PSC cases and 5413 
controls. The strongest genome-wide significant association was seen at the 
HLA loci. Figure 7.2 (page 143) shows the Manhattan plot of GWAS results 
in the discovery panel.  
 
Outside of the known HLA association, 26 loci (across 16 chromosomes) were 
identified, where one or more markers showed at least suggestive (p-value ≤ 1 
x 10-4) association in the discovery panel (supplementary table 7.1 shows the 
list of all SNPs with suggestive association). Regional association plots were 
Table 7.2. Individuals failing quality control thresholds.  
Sample Quality control criteria Total* 
 Gender Genotype 
failure 
rate 
Heterozygosity 
rate 
Relatedness 
(IBD) 
Non-
European  
 
PSC 
cases 
1 3 17 17 67 79 
BBC 
controls 
5 83 118 1 92 143 
NBS 
controls 
12 58 69 2 72 111 
IBD – identity by descent; BBC – British birth cohort; NBS – national blood service. 
*Some individuals failed quality control for more than one criteria.  
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plotted using SNAP (201) for each of the 26 suggestive loci, to examine the 
distribution of association across all the SNPs at each locus and identify any 
spurious associations (supplementary figures 7.3(a – z)).  
 
 
Replication results 
 
A total of 96 SNPs meeting criteria for suggestive association (p-value < 1 x 
10-4), were considered for in-silico replication analysis (supplementary table 
7.2). As the genotyping platforms used in the discovery panel (Illumina 
HumanOmni2.5-8 BeadChip) and replication cohort (Affymetrix) were 
different, genotype data were available for 86/96 SNPs identified for in-silico 
replication. Table 7.3 shows the list of all SNPs for which summary statistics 
from the replication cohort were available and analysed in the meta-analysis.  
 
 
Meta-analysis results 
 
The meta-analysis of summary statistics from the UK-PSC data and summary 
statistics provided by Melum, et al. (151) identified genome wide significant 
association (p < 5 x 10-8) at three loci: 3p21, 10p15 and 12q24 in the 
combined analysis (Table 7.4). The direction of effect of the minor allele was 
same in both the cohorts. Test for heterogeneity at these loci using the 
Cochrane's Q statistic (in PLINK) was not significant (i.e. p-value > 0.05).  
 
Table 7.4 shows the PSC risk loci that reached genome-wide significance in 
the combined meta-analysis. Supplementary table 7.3 shows the combined 
analysis results for all the 86 SNPs that were analysed in the meta-analysis.  
 
Melum, et al. reported the association at 3p21, with MST1 as the most likely 
candidate gene (151). At 10p15, IL2RA is the most likely candidate gene, 
which I have reported in chapter 6 (page 109). There are two plausible 
candidate genes at 12q24: SH2B3 and ATXN2 and are discussed below.   
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Table 7.3. List of all SNPs (n = 86) taken forward for in-silico replication analysis. 
CHR SNP Position 
(GRCh37.5); build 
19 
CHR SNP Position 
(GRCh37.5); build 
19 
1 rs11121203 8648240 10 rs7090530 6110875 
1 rs1953827 8679848 10 rs10905669 6092093 
1 rs4908760 8526142 10 rs7072793 6106266 
1 rs7553298 8770883 10 rs3763700 6181709 
1 rs10492965 8598127 10 rs12412095 6113523 
1 rs10492966 8598005 10 rs2387015 6215257 
1 rs11121182 8522553 10 rs3814195 6213960 
1 rs7520572 8871690 10 rs11255072 5806248 
2 rs16823732 145204758 11 rs836141 34537316 
2 rs12105918 145208193 11 rs11221265 128236936 
2 rs10192562 145184316 11 rs7928323 38841059 
2 rs13389578 145216048 11 rs2068461 38831942 
2 rs11883829 145519623 11 rs11034972 38860022 
2 rs13032840 145506108 11 rs10837055 38845174 
3 rs13070798 48705934 11 rs7936255 38998451 
3 rs9836462 48712791 11 rs7116065 38979245 
3 rs12107418 48689787 11 rs2912573 38950513 
3 rs11719291 48735706 12 rs10774625 111910219 
3 rs13063312 48661985 12 rs1265566 111716376 
3 rs13324142 48669447 12 rs11065987 112072424 
3 rs2276852 48666923 12 rs17696736 112486818 
4 rs13132933 123010587 12 rs11066320 112906415 
4 rs6822844 123509421 12 rs11066301 112871372 
4 rs13151961 123115502 12 rs770460 78132040 
4 rs11938795 123073009 14 rs17119456 84485390 
4 rs11734090 123228113 14 rs1257641 99480395 
4 rs7684187 123341159 14 rs1015277 84438074 
4 rs10027390 123368516 14 rs17119553 84509670 
4 rs345367 86754638 14 rs1824343 98920773 
4 rs4693142 87252259 16 rs8060332 2892770 
4 rs7689808 87254477 16 rs3810801 2892370 
4 rs434193 86253489 16 rs8047221 2897372 
5 rs419119 6021846 18 rs7229974 28890717 
5 rs1567520 118159871 18 rs9952617 28881801 
5 rs17132677 118175674 18 rs2114270 28885116 
5 rs17648108 177831556 20 rs1885082 17593984 
5 rs6874399 118225616 20 rs4814628 17593315 
5 rs2029036 118275869 20 rs13734 17594729 
5 rs12109252 118267633 20 rs2064726 50715685 
8 rs2617094 4456167 21 rs1893592 43855067 
8 rs17070773 4463359 21 rs378108 40469520 
9 rs7027092 95812707 21 rs2836878 40465534 
10 rs3118470 6101713 21 rs2836881 40466299 
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Table 7.4. Results for SNPs showing suggestive association in the UK-PSC cohort and genome-wide     
                  significance in the meta-analysis.  
Chr SNP 
Candidate 
gene 
Alleles 
(minor/
major) 
MAF 
(case/ 
control) 
P-value 
(UK 
cohort) 
OR (95% 
CI) 
(UK cohort) 
 
P-value 
(replication 
cohort) 
 
 
OR (95% 
CI) 
(replication 
cohort) 
 
Meta-analysis 
(random effects) 
         OR  
  (combined) 
   P-value 
(combined) 
3 rs13070798 MST1 C/T 0.14/0.10 1.21 x 10-6 
1.39 
(1.21 - 1.59) 
 
1.9 x 10-3 
 
1.32 
(1.10 – 1.57) 
 
1.36 
(1.22 – 1.51) 
1.07 x 10-8 
3 rs9836462 MST1 G/A 0.14/0.10 3.63 x 10-6 
1.36 
(1.19 -1.56) 
1.8 x 10-3 
       1.33 
(1.11 – 1.58) 
1.35 
(1.21 – 1.50) 
2.73 x 10-8 
10 rs3118470 IL2RA C/T 0.36/0.31 1.65 x 10-5 
1.23  
(1.12 - 1.35) 
2.01 x 10-5 
 
1.33 
(1.16 – 1.51) 
 
1.26 
(1.17 – 1.36) 
2.27 x 10-9 
12 rs10774625 
SH2B3/ 
ATXN2 
G/A 0.43/0.49 1.22 x 10-7 
0.78  
(0.71 - 0.85) 
1.2 x 10-3 
 
0.81 
(0.71 – 0.92) 
 
0.79 
(0.73 – 0.85) 
6.79 x 10-10 
12 rs1265566 
SH2B3/ 
ATXN2 
C/T 0.26/0.31 6.06 x 10-6 
0.79  
(0.71 – 0.87) 
2.0 x 10-3 
 
0.79 
(0.69 – 0.92) 
 
0.79 
(0.73 – 0.86) 
4.46 x 10-8 
Meta-analysis was performed by combining summary statistics from a recent PSC GWAS (151), using PLINK.  A random effects model was used for 
meta-analysis even though a test for heterogeneity was not statistically significant for any of the associated SNPs.  All the reported odds ratios are with 
reference to minor allele vs. major allele.  Chr – Chromosome, MAF – minor allele frequency, OR – odds ratio, CI – confidence interval. 
 
 
 
Discussion 
 
This genome wide association study confirms the reported genome-wide 
association at 3p21 (MST1) and the association at 10p15 (IL2RA). In addition, 
this study has identified a novel association at 12q24 in a relatively modest 
size cohort of PSC patients. 
  
Melum et al. (151) and Folseraas et al. (152) have reported genome-wide 
association at 2q13 (BCL2L11) and 1p36 (MMEL1, TNFRSF14) respectively. 
However, we did not find significant associations at these loci in our study.   
 
I have discussed the plausible candidate genes at 3p21 (MST1) and 10p15 
(IL2RA) and their functional role in chapter 6 (page 125).  
 
The association at 12q24 is novel and confirmed in a homogeneous cohort of 
UK PSC patients. There are two plausible candidate genes at this locus: 
SH2B3 and ATXN2.  
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SH2B3 is a protein-coding gene for a member of the SH2B adaptor family of 
proteins involved in a range of signaling activities by growth factor and 
cytokine receptors. The encoded protein is a key negative regulator of 
cytokine signaling pathways, T cell activation, tumour necrosis factor and 
Janus kinase 2 and 3 (JAK2/3) signaling and plays a critical role in 
hematopoiesis. Interestingly, an association at 12q24 (SH2B3) is also seen in 
primary biliary cholangitis (PBC) (202) and autoimmune hepatitis (AIH) 
(203).  
 
In addition, mutations in this gene are linked strongly to myeloproliferative 
disorders, autoimmune diseases such as coeliac disease and insulin-dependent 
diabetes mellitus and inflammatory syndromes, where both immune and 
vascular cells display a role (204).  
 
The functional effect of SH2B3 (rs3184504) genotype on inflammatory 
cytokine response, in relation to stimulation by lipopolysaccharide (LPS) and 
muramyl dipeptide (MDP - which is a specific ligand of the pattern-
recognition receptor NOD2) - has recently been studied in patients with 
coeliac disease (205). The cells isolated from individuals homozygous for the 
SH2B3 risk allele, showed a significantly increased cytokine production, 
thereby implicating an inhibitory effect of the SH2B3 protein on the MDP-
NOD2-RIP signalling pathway, so that SH2B3 may be an important 
autoimmune locus, especially in immune-mediated liver diseases. 
 
ATXN2 is involved in regulating mRNA translation through its interactions 
with the poly(A)-binding protein. It is involved in the formation of stress 
granules and P-bodies, which also plays a role in RNA regulation (206).  
Loss-of-function mutations in this gene may be associated with susceptibility 
to type I diabetes, obesity and hypertension. 
 
The genetic risk loci found thus far in PSC, could suggest involvement of an 
immune mediated process in pathogenesis of PSC. However, unlike GWAS in 
other diseases (e.g. primary biliary cholangitis) (207), it has not yet been 
possible to identify any clear biological pathways that can be implicated in 
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PSC causation. Further immunological studies are needed to elucidate gain or 
loss of function of the implicated candidate genes in patients with PSC, 
matched with healthy and disease controls (e.g. PBC or AIH). Until then, the 
role of such candidate genes remains speculative.  
 
The main limitation of this study was the relatively small discovery and 
replication sample size. Due to the low incidence and prevalence of PSC, there 
is a need for large-scale genome-wide association studies to be undertaken in 
collaboration with other international cohorts to identify additional 
susceptibility loci. This could shed light on yet unknown disease causing 
pathways in PSC, which could be targeted for functional studies and therapy.   
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Figure 7.1(a). Ancestry clustering based on genome-wide association data in all PSC 
cases (blue circles).  HapMap 3 reference samples: CEU (red), CHB+JPT 
(green/yellow) and YRI (brown). 
 
 
Figure 7.1(b). PSC cases (blue circles) with first principal component score (V2) < 
0.16 (vertical line) and second principal component score (V3) < 0.072 (horizontal 
line) were removed. 
 
 143 
 
 
Figure 7.2. Manhattan plot of simple χ2 allelic test of association p-values in the 
discovery panel. The plot shows –log10 p-values for each SNP against each 
chromosomal location (blue and green dots). Green points indicate SNPs with p-
values ≤ 1 x 10-5.  
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Chapter 8: Discussion. 
 
The data presented in the previous chapters have already been discussed at the 
end of each chapter.  
 
The main focus of this chapter is to discuss the: 
 
1) International collaborative efforts to identify additional risk loci in PSC  
2) Summary of genetic risk in PSC 
3) Role of genetic risk factors in predicting disease outcome 
4) Limitations of genetic association studies  
 
 
1) International collaboration to identify additional susceptibility loci in PSC 
 
One of the strategies to increase the power of detecting additional 
susceptibility loci in genome wide association studies is to have a large sample 
size of cases and controls. Commonly occurring diseases such as 
inflammatory bowel disease (IBD) and type 1 diabetes mellitus, have been 
able to recruit > 10,000 cases for such studies.  
 
Due to the low prevalence of PSC, it has not been possible to undertake large-
scale genetic association studies in PSC. During the period of my MD thesis 
this has driven international groups to collaborate and undertake studies, 
combining data from the PSC cohorts across Europe and U.S.A.  
 
The phenotype and genotype data from the UK PSC cohort is an invaluable 
resource for such collaborative and other downstream studies.  It represents 
the largest homogeneous cohort of PSC patients from a single nation; two 
studies undertaken in collaboration with other European ancestry PSC cohorts 
from Europe and USA have identified 13 novel loci at genome-wide 
significance (208, 209). These studies are discussed briefly below. 
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Please note that the lead authors of respective studies undertook the primary 
analyses described in studies below.  UK PSC and I contributed by recruiting 
PSC patients from the UK, providing genetic and phenotypic data and were 
involved in writing the final drafts.    
 
A) Immunochip study 
 
Immunochip is a custom-made Illumina Infinium genotyping chip, containing 
196,524 polymorphisms (718 small insertion deletions, 195,806 SNPs) spread 
across 186 known immune-mediated disease loci (210).  It was designed to 
map the genetic overlap and variance between various immune-mediated 
diseases and fine-map the established genetic risk loci.  
 
Liu et al. compared 3,789 European ancestry PSC cases (including 1,033 UK 
PSC cases) to 25,079 healthy population controls across 130,422 SNPs, which 
were genotyped using the Immunochip (208). 72% of PSC patients had 
concomitant IBD (UC = 58%; CD = 11%; Indeterminate = 3%). Twelve (non-
HLA) genome-wide significant loci were identified, of which nine were novel 
associations (Table 8.1). The most significantly associated SNP at seven of the 
nine loci, was the same SNP or in strong linkage disequilibrium (r2 > 0.80) 
with the original association reports for another immune-mediated disease.  
 
Identifying candidate genes at associated loci 
Various methods can be used to prioritise candidate genes in GWAS, such as 
functional annotation of risk loci using data from the ENCODE project, 
construction of networks based on functional similarity measures known as 
protein-protein interactions (DAPPLE) and published literature (GRAIL) as 
well as expression quantitative loci (eQTL) analysis. The functional role of the 
plausible candidate genes identified in PSC is highlighted in Box 2 (page 161) 
and discussed further in the section: ‘summary of genetic risk in PSC’ (page 
150). 
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Table 8.1. Association results for twelve non-HLA genome-wide significant 
associations for PSC in the Immunochip study.  
Chr SNP Candidate 
gene 
Risk 
allele 
P-value 
(UK cohort) 
OR (95% CI) 
(UK cohort) 
1p36 rs3748816 MMEL1, 
TNFRSF14 
A 7.41E-12 1.21 (1.14 – 1.27) 
2q33 rs7426056 CD28 A 1.89E-20 1.30 (1.23 – 1.37) 
3p21 rs3197999 MST1 A 2.45E-26 1.33 (1.26 – 1.40) 
4q27 rs13140464 IL2/IL21 C 8.87E-13 1.30 (1.21 – 1.40) 
6q15 rs56258221 BACH2 G 8.36E-12 1.23 (1.16 – 1.31) 
10p15 rs4147359 IL2RA A 8.19E-17 1.24 (1.18 – 1.30) 
11q23 rs7937682 SIK2 G 3.17E-09 1.17 (1.11 – 1.24) 
12q13 rs11168249 HDAC7 G 5.49E-09 1.15 (1.10 – 1.21) 
12q24 rs3184504 SH2B3, 
ATXN2 
A 5.91E-11 1.18 (1.12 – 1.24) 
18q22 rs1788097 CD226 A 3.06E-08 1.15 (1.10 – 1.21) 
19q13 rs60652743 PRKD2, 
STRN4 
A 6.51E-10 1.25 (1.16 – 1.34) 
21q22 rs2836883 PSMG1 G 3.19E-17 1.28 (1.21 – 1.36) 
Chr – Chromosome; OR – odds ratio; CI – 95% confidence interval; Nine novel SNPs 
associated with PSC in the Immunochip study are highlighted in bold.  
 
 
 
The majority of the patients in this cohort had concomitant IBD (72%). 
However, despite that, only six of the twelve PSC risk loci were found to be 
associated with IBD in the International IBD Genetics Consortium (IIBDGC) 
Immunochip analysis (211). Upon comparing the genetic architecture of PSC 
and IBD risk loci using the Immunochip study data, no particular functional 
sub cluster of PSC genes was associated with IBD and vice versa. This 
suggested that the genetic susceptibility to PSC is not defined entirely by the 
risk factors related to IBD and that the new immune mediated risk loci may 
have an important role in PSC pathophysiology.  
 
 
B) GWAS in PSC and quantification of genetic relationship with IBD 
 
PSC is strongly associated with IBD (mainly UC), but the cause of this 
phenotypic association has not been clearly identified. Data from the 
Immunochip study did not show any significant genetic overlap between PSC-
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IBD, at least at risk loci, which are associated with other immune mediated 
diseases.    
 
Ji et al. (209) performed the largest GWAS in PSC to date and also studied the 
genome-wide genetic correlation between PSC and IBD (UC and CD). The 
discovery panel comprised of 2,871 PSC cases (1,227 UK-PSC cases) and 
12,019 population controls. IBD was present in 65% of cases (UC = 53%; CD 
= 9% and IC = 3%). 
  
7,891,602 SNPs were tested in the discovery panel and forty SNPs were taken 
forward for replication study in an independent cohort of 1,925 PSC cases and 
7,936 population controls. In the replication panel, the prevalence of IBD was 
51% (UC = 39%; CD = 9% and IC = 3%). IBD status was not known in 14% 
and 27% of discovery and replication panels respectively.    
 
Association was confirmed at fifteen of the previously known loci in PSC and 
four novel loci were identified at 3p13, 11q13, 16p13 and 21q22, with the 
most likely candidate genes as FOXP1, CCDC88B, CLEC16A and UBASH3A 
respectively (table 8.2). The associated SNPs at 11q13, 16p13 and 21q22, 
were found to be in high linkage disequilibrium with variants associated with 
other immune-mediated diseases, suggesting a shared immune genetic risk 
with PSC. This could potentially explain the increased prevalence of some 
forms of immune-mediated disease in PSC.  However, there has been no prior 
reported association at 3p13 (FOXP1) for any other immune mediated disease.  
 
The most associated SNPs at each locus were evaluated for their functional 
role using eQTL databases and Genome Wide Annotation of Variants 
(GWAVA) online tool (212). The most associated SNP at 21q22 (rs1893592) 
was the most strongly associated eQTL of UBASH3A gene, which is involved 
in regulation of T-cell signaling. The C allele was found to be associated with 
a reduced risk of PSC (frequency in controls = 27.8%). 
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Table 8.2. GWAS summary statistics of previous and new loci (highlighted in bold) associated with PSC (adapted from Ji et al. (209)). 
SNP Risk 
Allele 
Chr Gene GWAS Replication GWAS + Replication 
RAF OR P-value RAF OR P-value RAF OR P-value 
rs3748816 A 1p36 MMEL1 0.67 1.18 3.54E-07 0.66 1.23 2.27E-07 0.66 1.20 5.17E-13 
rs72837826 T 2q13 BCL2L11 0.11 1.35 1.26E-09 0.12 1.20 1.30E-03 0.12 1.29 2.36E-11 
rs7426056 A 2q33 CD28 0.25 1.21 3.26E-08 0.24 1.31 4.26E-10 0.25 1.25 2.12E-16 
rs3749171 T 2q37 GPR35 0.18 1.16 3.44E-04 NA NA NA 0.18 1.16 3.47E-04 
rs80060485 C 3p13 FOXP1 0.07 1.41 8.54E-09 0.07 1.49 4.67E-08 0.07 1.44 2.62E-15 
rs3197999 A 3p21 MST1 0.29 1.30 2.60E-13 0.31 1.37 1.59E-14 0.30 1.33 5.11E-26 
rs13140464 G 4q27 IL2-IL21 0.84 1.28 5.17E-09 0.84 1.27 4.53E-06 0.84 1.28 1.19E-13 
rs56258221 C 6q15 BACH2 0.19 1.23 6.21E-07 0.18 1.18 4.80E-04 0.18 1.21 1.41E-09 
rs4147359 A 10p15 IL2RA 0.36 1.24 4.06E-13 0.37 1.18 2.04E-05 0.36 1.22 7.54E-17 
rs663743 G 11q13 CCDC88B 0.67 1.18 8.42E-08 0.66 1.22 4.44E-07 0.66 1.20 2.24E-13 
rs7937682 C 11q23 SIK2 0.28 1.13 1.85E-04 0.27 1.16 6.66E-04 0.28 1.14 4.77E-07 
rs11168249 C 12q13 HDAC7 NA NA NA 0.48 1.12 3.36E-03 0.48 1.12 3.33E-03 
rs3184504 T 12q24 SH2B3 0.50 1.20 5.05E-10 0.48 1.15 1.20E-04 0.50 1.18 4.27E-13 
rs725613 T 16p13 CLEC16A 0.65 1.22 5.50E-10 0.66 1.17 9.52E-05 0.65 1.20 3.59E-13 
rs1452787 A 18q21 TCF4 NA NA NA 0.72 1.02 6.88E-01 0.72 1.02 6.87E-01 
rs1788097 T 18q22 CD226 0.49 1.19 9.73E-07 0.49 1.20 1.41E-06 0.49 1.19 6.58E-12 
rs60652743 A 19q13 FUT2, PRKD2, 
STRN4 
0.84 1.30 1.01E-07 0.84 1.27 3.91E-06 0.84 1.28 1.99E-12 
rs2836883 G 21q22 PSMG1 0.74 1.35 5.40E-14 0.73 1.12 7.77E-03 0.74 1.23 4.21E-13 
rs1893592 A 21q22 UBASH3A 0.73 1.22 1.90E-07 0.72 1.22 2.42E-06 0.73 1.22 2.19E-12 
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Genetic relationship with IBD 
 
The genetic relationship between PSC and IBD was studied across eighteen 
established PSC risk loci, to identify loci with evidence of shared or 
independent causal variants between the two phenotypes. Summary statistics 
from previous IBD association studies (from the IBD genetics consortium) 
were obtained for 17,647 UC cases, 20,550 CD cases and 48,485 controls of 
European ancestry (213). 
   
Of the eighteen PSC risk loci, four (BCL211, FOXP1, SIK2 and UBASH3A) 
have not previously been found to be associated at genome-wide significance 
with IBD.  Of the remaining fourteen loci found previously to be associated 
with IBD, the lead SNPs at four loci (IL2RA, CCDC88B, CLEC16A and 
PRKD2) in the PSC and IBD studies, were found to be in low linkage 
disequilibrium (r2 < 0.2), suggesting an independent association at these loci 
between the two diseases. 
  
This would imply that even though there may be association at the same 
region of the genome for diseases occurring together, the causal variant might 
be different. Six of the fourteen loci associated with PSC and IBD displayed 
strong evidence of shared causal variant with UC, CD or both (MST1, IL21, 
HDAC7, SH2B3, CD226 and PSMG1).  
 
The observed genetic correlation in this study between PSC and IBD is small 
and does not explain the extent of comorbidity between the two diseases, 
implicating other environmental factors and/or rare genetic variants not 
captured by this GWAS. The genetic dissimilarity also supports the notion that 
PSC-IBD might be an entity distinct from UC.  
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2) Summary of the genetic risk in PSC and role of identified candidate genes 
 
Other than the known HLA associations, genetic association studies in PSC 
have now confirmed 22 susceptibility loci with genome-wide significance. 
Table 8.3 shows the timeline of all the non-HLA susceptibility loci associated 
with PSC. 
 
 
 
 
 
 
 
 
Table 8.3. Timeline of all non-HLA susceptibility loci associated with PSC. 
Year Chr Lead SNP Candidate gene UK PSC data 
included 
Ref 
2011 2q13 rs6720394 BCL2L11 No (151) 
 3p21 rs3197999 MST1 No  
2012 10p15 rs4147359 IL2RA Yes (214) 
2012 1p36 rs3748816 MMEL1, TNFRSF14 No (152) 
2013 2q33 rs7426056 CD28, CTLA4 Yes (208) 
 4q27 rs13140464 IL2, IL21   
 6q15 rs56258221 BACH2   
 11q23 rs7937682 SIK2   
 12q13 rs11168249 HDAC7   
 12q24 rs3184504 SH2B3, ATXN2   
 18q22 rs1788097 CD226   
 19q13 rs60652743 FUT2, PRKD2, STRN4   
 21q22 rs2836883 PSMG1   
2013 2q37 rs3749171 GPR35 No (215) 
 18q21 rs1452787 TCF4   
2016 2q36 rs7556897 CCL20 No (216) 
 4q24 rs3774937 NFKB1   
 12q23 rs12369214 RFX4, RIC8B   
2017 3p13 rs80060485 FOXP1 Yes (209) 
 11q13 rs663743 CCDC88B   
 16p13 Rs725613 CLEC16A, SOCS1   
 21q22 rs1893592 UBASH3A   
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Associations between PSC and the HLA complex were covered in the chapter 
1 (page 51). The significance and pathophysiological implications of non-
HLA susceptibility loci are discussed in the section below.  
 
 
Non-HLA susceptibility loci in PSC 
There are a total of 29 plausible candidate genes across the 22 loci found to be 
associated with PSC with genome-wide significance. Putative functions of 
these candidate genes are shown in Box 2 (page 161). A significant proportion 
of PSC susceptibility loci are shared with other autoimmune diseases, 
particularly at 4q27 (Il2/IL21), 6p15 (BACH2), 10p15 (IL2RA) and 12q24 
(SH2B3). The pleiotropic nature of some of these loci could imply shared 
biological pathways in the development of immune-mediated diseases. It is 
important to note that often there is more than one plausible candidate gene at 
each associated loci and it is not possible to identify the exact causal variant at 
each locus due to the presence of high linkage disequilibrium across the 
genome. 
 
Loci/Genes involved in immunological pathway 
Most of the plausible candidate genes identified in PSC play a role in both 
innate and adaptive immune responses, supporting the hypothesis that PSC is   
an immune mediated disease.  
 
Cftr-/- mice develop biliary inflammation via the LPS–TLR4–NFκB axis, an 
innate immune pathway. PRDX5, TGR5 and PSMG1 might have a role in 
humans in regulating bile duct inflammatory changes in response to LPS along 
this pathway (217).  
  
There is suggestive evidence of involvement of the IL-2 signalling pathway in 
PSC. IL2RA (CD25) forms part of the IL2 receptor and is constitutively 
expressed by the regulatory T cells (Treg). Impairment of Treg function is 
associated with autoimmunity and it is possible, that it could also cause 
immune dysregulation in PSC.  
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In a recent study, Sebode et al. (218) investigated the frequency of Treg cells in 
patients with PSC and the association between their numbers with gene 
polymorphisms. Interestingly, the number of Treg cells in peripheral blood as 
well as in the liver, was decreased in PSC (in comparison to PBC). 
Furthermore, the reduced peripheral Treg numbers were significantly 
associated with homozygosity for the major allele of the SNP ‘rs10905718’ in 
the IL2RA gene. This study lends further support to implicate impaired Treg 
function as a possible cause for immune dysregulation in PSC.  
 
The association at 19q23, where FUT2 is a potential candidate gene, is 
interesting. FUT2 encodes the enzyme galactoside 2-alpha-L-
fucosyltransferase 2, which regulates the type 1 oligosaccharide chains and is 
involved in antigen expression in the ABO blood group. In addition, it has a 
role in modifying the composition of the gut microbiome by affecting 
carbohydrate metabolism in the gut and has been be associated with Crohn’s 
disease. This makes FUT2 a potentially relevant candidate gene in PSC.   
 
The association at 12q24 (SH2B3) is also seen in PBC and AIH, suggesting its 
predominant role in liver related immune functions and has been discussed in 
detail in the previous chapter (page 140). Association at TNFRSF14 in PSC 
could imply a role for TNF signalling pathways in PSC, but further functional 
studies are needed. 
 
The overwhelming association of the immune risk genes with PSC, as well as 
the high rate of PSC recurrence following a liver transplant, supports the role 
of peri-biliary immune dysregulation as one of the likely initial events in PSC 
development. It is plausible that certain environmental factors presented via 
the gut, act as the initial trigger for this immune activation, but these are yet to 
be identified. In addition to the potential role of innate and adaptive immune 
responses, PSC risk genes also have been found to have a role in apoptosis 
(BCL2L11, UBASH3A), autophagy (CLEC16A) and metabolic function 
(ATXN2).  
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The functional role of genetic risk factors identified in the genetic association 
studies in PSC, is at best speculative. However, it forms the basis to undertake 
functional work at each associated risk loci, to determine gain or loss of 
putative gene function, identify biological pathways and develop targeted 
therapeutic interventions.   
 
 
3) Role of genetic risk factors in predicting disease outcome 
 
The association between genetic risk variants and disease severity in complex 
disease, including PSC has not been well studied. Using the Immunochip 
genotype data, Alberts et al. (219) studied the role of genetic variants with risk 
of progression and complications in PSC.  
 
The phenotypic data collected included: sex, date of birth, PSC subtype (small 
or large duct), date of PSC diagnosis, intrahepatic and/or extrahepatic disease, 
dominant strictures, concomitant IBD and type of IBD, date of IBD diagnosis 
and smoking status. Follow-up data were also collected for: date and cause of 
death, date and indication of liver transplantation, occurrence and date of 
diagnosis of cholangiocarcinoma, colorectal cancer and gallbladder 
carcinoma. After quality control, a total of 130,422 SNPs were analysed in 
3,402 PSC cases (UK PSC cases = 1,033).  Clinical characteristics of the 
cohort including sub-phenotypes are shown in table 8.4.  
 
Genome-wide multivariable Cox proportional hazards regression analysis was 
performed to estimate the effect of genetic variants on time-to-event analysis. 
The time-to-event liver transplant-free survival was defined as the time 
between PSC diagnosis and the composite endpoint of either liver 
transplantation or PSC-related death. 
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Table 8.4. Clinical characteristics of the PSC cohort (n = 3402).   
Variable Groups Number (%) 
Age at PSC diagnosis 
(median) 
 38.6 years old  
(28.0–50.1) 
Sex Male 2185 (64.7) 
 Female 1193 (35.3) 
Main diagnosis PSC 3159 (94.6) 
 Small duct PSC 75 (2.2) 
 PSC with AIH overlap 107 (3.2) 
Liver transplantation Yes 874 (26.3) 
 No 2444 (73.7) 
 Missing 84 (2.5) 
IBD No IBD 816 (25.5) 
 Ulcerative colitis 1940 (60.5) 
 Crohn's disease 357 (11.1) 
 IBD-U 93 (2.9) 
Cholangiocarcinoma Yes 188 (5.6) 
 No 3147 (94.4) 
Colorectal carcinoma Yes 127 (4.3) 
 No 2822 (95.7) 
Gall bladder carcinoma Yes 30 (1.0) 
 No 2977 (99.0) 
Death Non-PSC related 47 (1.5) 
 Liver failure 66 (2.1) 
 Cholangiosepsis 18 (0.6) 
 Gallbladder carcinoma 12 (0.4) 
 Cholangiocarcinoma 85 (2.6) 
 Hepatocellular carcinoma 6 (0.2) 
 Colorectal carcinoma in case 
of coexisting IBD 
3 (0.1) 
 Alive 2977 (92.6) 
 
 
In the sub-group genetic association analysis, no genome wide significant 
genetic associations were identified for the following binary PSC sub-
phenotypes – small-duct PSC, cholangiocarcinoma or gall bladder carcinoma. 
However, upon comparing 107 patients with PSC and autoimmune hepatitis 
(PSC/AIH) with 3159 patients with PSC but without AIH overlap, a strong 
genetic association in the HLA-DQB1 gene was identified for rs3891175 (p-
value = 4.6×10-11, OR = 2.41).  
 
Interestingly, in the time to event analysis, genome-wide significant 
association was identified for rs853974 (p-value = 6.07 x 10-9), which is 
located on chromosome 6. The homozygous AA genotype had a 2.14 (95% CI 
1.66 to 2.76) increased hazard, indicating a 2.14 larger relative risk for need 
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for liver transplantation or for PSC-related death compared with GG 
homozygous genotype.  
 
The most likely candidate gene at this locus is the R-Spondin 3 (RSPO3) gene, 
and RNA sequencing on healthy and cholestatic cholangiocytes (from normal 
C57BL/6 mice), showed an increased RSPO3 expression in the cholangiocytes 
(healthy > cholestatic), compared to any other organs.    
 
Interestingly, neither the Immunochip study, nor the GWAS, has identified 
association at this locus in PSC. It is possible that this locus may have a 
predominant role in disease progression rather than disease susceptibility or 
interacts with other associated genes (epistasis), to exert functional effect.  
 
As a proof-of-concept, this study shows that it is possible to determine genetic 
variants associated with disease progression. The main utility of such a study 
would be to identify biological pathways that may play a role in disease 
progression, and develop targeted therapy. This would ultimately pave way for 
stratified medicine, in which individuals can be prioritised into high-risk 
groups based on their respective phenotype and genotype, to determine most 
appropriate therapeutic intervention.  
 
 
4) Limitations of genetic association studies 
 
The genetic risk factors identified in complex diseases typically account for < 
10% of disease susceptibility, often referred to as the missing heritability. In 
addition, only a handful of the common variants have been validated to have a 
functional role in disease biology. As a result, the common disease common 
variant (CDCV) hypothesis, which forms the basis for genome wide 
association studies, has come under increased scrutiny. 
 
There is now emphasis on the role played by rare variants (MAF 0.002 - 0.01) 
with large effect-size (rare allele model), which are not identified by 
conventional genotyping platforms and GWAS. Studies to identify rare 
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variants require a considerably large sample size (more than 15,000 - 25,000 
cases), making such studies difficult or even unfeasible in the context of PSC.  
 
There may be a role for the environmental (e.g. gut microbiome) and 
epigenetic (glossary Box 1; page 160) risk factors in disease causation, which 
are not captured by conventional GWAS. These should now be studied in 
greater detail, alongside studies involving finer resolution of the genome (e.g. 
using partial or whole genome sequencing).  
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Chapter 9: Summary and Conclusion. 
 
 
Summary of the UK PSC studies  
The UK PSC cohort has recruited more than 2000 patients, from district general 
hospitals, university hospitals and transplant centres. It represents a unique 
cohort of ethnically homogeneous patients with PSC in the UK and the largest 
independent single nation cohort in the world. 
 
In the first phase of the study, I recruited patients to the UK PSC cohort and 
collected samples to develop a PSC DNA biobank. This was followed by 
detailed phenotypic characterisation of the UK PSC cohort, which firmly 
established the cohort as a true representation of patients with PSC, with 
demographic and phenotype features similar to those reported in previous 
studies. Only 6 patients out of 1230, who had an underlying diagnosis of PBC 
instead, were recruited incorrectly, giving further confidence in our robust 
patient recruitment process. 
 
One of the key findings to emerge from the phenotype study, and not reported 
previously, was the association between the extent of bile duct involvement and 
patient related outcome of liver transplant or death. Patients with both 
intrahepatic and extrahepatic bile duct involvement with PSC, have a 
significantly reduced transplant-free survival in comparison to those with only 
intrahepatic disease.  
 
This cohort is not a true representation of the malignant risk in PSC, especially 
cholangiocarcinoma (CCA), as these patients have an extremely poor median 
survival of approximately 6 months, and thus will not be captured by such a 
study. In addition, the data collected were retrospective in nature and full 
laboratory data were not collected at the time of recruitment.  
 
The laboratory and missing clinical data at initial diagnosis and follow-up, was 
subsequently collected by one of my collaborators and another UK PSC 
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research fellow (Dr Elizabeth Goode), which allowed a more detailed 
assessment of risk factors associated with clinical outcome (liver transplantation 
or death) in PSC, and development of the UK PSC risk score (awaiting peer 
review): http://www.uk-psc.com/resources/the-uk-psc-risk-scores/. When NHS 
Digital comes on stream these data will be collated with ease.  
 
A recent multi-centre study by Weismuller et al. (46) evluated basic 
demographic and clinical parameters in more than 7000 patients with PSC and 
found younger age, female sex and IBD phenotype (Crohn’s disease) to be 
associated with improved transplant-free survival or death. Information on the 
extent of bile duct involvement was not available for participants, so that 
cholangiographic changes could not be included.  
 
In the UK PSC study, we did not oberve any difference in outocme according to 
sex or subtype of IBD. It is possible that our cohort of 1,452 patients was 
underpowered to detect any such effect.  
 
However, we have shown that it is now possible to estimate short term and long 
term risk for patients presenting at different stages of the disease.  In addition, 
there is evidence now to suggest that younger, female patients without IBD (or 
with Crohn’s disease) and with intrahepatic disease have a very favourable long 
term outcome in an otherwise debilitating disease. This allows patients to be 
risk-stratified earlier in the course of their disease in clinical practice and will 
reduce the risk of recruitment bias in clinical trials, by categorising patients 
appropriately based on the disease severity. 
 
In the second phase of the study, I performed a replication/candidate gene study 
and a genome wide association study in a modest cohort of  1,030 and 1,020 
patients with PSC respectively. We identified two novel associations at 10p15 
and 12q24 at genome-wide significance, with the most likely candidate genes as 
Il2RA and SH2B3/ATXN2. The plausible candidate genes at both loci play an 
important role in adaptive immune pathways and support the notion that 
immune dysregulation in and around bile ducts may have role in PSC 
pathophysiology.  
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The international collaborative studies in PSC have led to two large scale 
genetic association studies, with UK PSC consortium contributing the largest 
number of patients. These studies have confirmed the associations described 
above and identified a total of 22 PSC risk loci (table 8.3) and in addition, 
mapped the genetic correlation beween PSC and IBD risk loci (208, 209).  
Furthermore, genetic association has been confirmed for a locus on 
chromosome 6 (RSPO3) with the risk of liver transplantation or death.   
 
 
Conclusion 
In this thesis, I have outlined the development of the UK-PSC cohort, to which 
I recruited over 1,400 patients from the UK. I have described the phenotypic 
characteristics of the UK PSC cohort and identified the association between 
the extent of cholangiography changes and clinical outcome. I also performed 
two genetic association studies, and identified genome wide significant 
association at two novel immune risk loci.   
 
Future directions 
Set up in 2008 as a Clinical research network (CLRN) portfolio study, the UK 
PSC study has now recruited more than 2000 patients. The UK PSC cohort has 
been expanded recently to include children in the study. 
  
The main priorities of the study are to now undertake more detailed sub-
phenotyping of patient groups, evaluate the impact of PSC on patients quality 
of life and identify biomarkers associated with disease severity and 
cholangiocarcinoma, which is a significant cause of mortality in PSC.    
 
One of the major challenges and unmet need in PSC is the complete lack of 
effective medical therapy that can alter disease progression. The long-term 
vision of the UK PSC study would be to develop a national PSC bio repository 
and undertake translational work to identify genes or biological pathways that 
can be targeted for therapy, as well as determine the role of ‘yet unknown’ 
environmental variables in disease causation.  
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Box 1. Glossary of terms.  
Call rate (genotype) The proportion of genotypes per marker with non-missing data. 
Candidate gene Any gene that has a priori possibility to cause a disease, either due 
to its location in a particular chromosome region suspected of being 
involved in the disease or its protein product. 
Confounding A type of bias in statistical analysis causing spurious or distorted 
findings, due to the existence of factors that are associated with 
disease risk as well as the exposure of interest. 
Epigenetics Modifications that occur in a chromosome without alterations to the 
underlying DNA structure, and contribute to phenotypic changes 
(e.g. DNA methylation and Histone modification).  
Genetic variance The contribution of genotypic differences among individuals to 
phenotypic variation. 
Genotype-by-
environment interactions 
(G×E interactions). Refers to the situation in which the effect of the 
genotype is conditional on the environment, which may include 
abiotic (temperature), biotic (viral exposure) and 
cultural/behavioural influences. 
Genotype-by-genotype 
interactions 
(G×G interactions). Otherwise known as epistasis, this refers to the 
situation in which the effect of one genotype is conditional on 
genotypes at one or more other unlinked loci. 
Genotype relative risk 
(GRR) 
The ratios of the risk of disease between individuals with and 
without the genotype. A ratio of 1.1 equates to a 10% increase in 
risk. 
Heritability The proportion of the phenotypic variance in a population that is 
due to genotypic differences among individuals. 
Penetrance Describes the proportion of individuals with a mutation or risk 
variant that have the disease. 
Pleiotropy Association of one gene with two or more seemingly unrelated 
phenotypes.  
Population stratification A situation of confounding in genetic studies, where cases and 
controls are not selected from the same population (i.e. different 
ethnic origin), and in which the subpopulations differ in relation to 
the allele frequencies of the genetic variants under study and the 
prevalence of disease. 
Power The probability of a study to obtain a significant result if this result 
is true in the underlying population from which the study subjects 
were sampled. 
Type 1 error The probability of rejecting the null hypothesis of no effect of 
exposure on disease when in fact the null hypothesis is true. For 
genetic association studies, type I errors reflect false positive 
findings of associations between allele/genotype and disease. 
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Box 2. Overview of putative candidate gene function at PSC associated risk loci (217, 220). 
Candidate gene Putative gene function 
BCL2L11 BCL2L11 encodes BCL2-Like 11 (BIM), which is an apoptotic activator critical 
for apoptosis in B and T cells, macrophages and granulocytes 
MST1 The MST1 encoded  protein MSP has an inhibitory function towards macrophages 
during inflammation 
IL2RA IL2RA encodes the alpha chain of the IL-2 receptor (consisted of α, β and γ 
chains), which is responsible for capturing IL-2 cytokine and mediating its 
signalling effects. PSC-associated variants within IL2RA lead to reduced 
expression of IL2RA, which have implications for induction of immune tolerance. 
Il2ra−/− mice spontaneously develop intestinal and biliary inflammation.  
MMEL1  
 
TNFRSF14 
MMEL1 is a member of the membrane metallo-endopeptidase family. Little is 
known about its function.  
The TNFRSF14 protein is expressed on CD4 and CD8 T lymphocytes, B cells, 
monocytes, neutrophils, dendritic cells and mucosal epithelium. It acts as a 
molecular switch modulating T cell activation via binding to its ligand LIGHT 
[73], but can also propagate inhibitory signals through the immunoglobulin 
superfamily member BTLA (B and T lymphocyte attenuator). This dual role of 
TNFRSF14 is thought to regulate immune tolerance 
CD28 
 
CTLA4 
CD28 is expressed on T lymphocytes and provides co-stimulatory signals that are 
essential for T cell activation, survival and proliferation.  
CTLA-4, also known as CD152, is a major negative regulator of T-cell activation 
by binding to CD80 and CD86 in competition with CD28.  
IL2 
 
 
IL21 
IL-2 is the most investigated interleukin with a broad role in regulation of the 
immune system. IT is essential for T-cell proliferation and regulatory T (Treg) cell 
homeostasis.  
IL-21 is an inflammatory cytokine mainly expressed by activated type 1 and type 
17 T helper cells, and overproduction leads to tissue damage and destruction.  
BACH2 BACH2 encodes a transcription factor, which regulates B cell differentiation. 
Downregulation of BACH2 has been demonstrated to attenuate activation of genes 
involved in antiviral innate immune response after nucleic-acid triggering.  
SIK2 SIK2 is a serine/threonine protein kinase belonging to the AMP-activated protein 
kinase (AMPK) family. It regulates IL-10 in macrophages and Nur77 in 
leukocytes.  
HDAC7 HDAC7 is a class IIa deacetylase, which has essential roles in the vasculature 
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development and cytotoxic T lymphocyte function.  
SH2B3 
 
 
 
 
ATXN2 
SH2B3 is a key regulator of cytokine signalling, and genetic variation within 
SH2B3 has been demonstrated to affect the production of pro-inflammatory 
cytokines in response to stimulation with bacterial cell wall peptidoglycans, 
pointing to a role for SH2B3 in innate immunity and in the protection against 
bacterial infection.  
ATXN2 is a stress-regulated protein expressed in specific neuron populations and 
hepatocytes, and might have a role in obesity and insulin resistance.  
CD226 CD226 is a co-stimulatory adhesion molecule constitutively expressed on immune 
and endothelial cells. It can enhance cytotoxic function of natural killer cells and T 
cells. 
PRKD2 
 
STRN4 
PRKD2 belongs to the protein kinase D (PKD) family, which are involved in the 
regulation of cell proliferation and cytokine production.  
STRN4 is associated with protein phosphatases and protein kinases and involved 
in cell proliferation, differentiation, apoptosis and transformation. 
PSMG1 PSMG1 encodes a chaperone protein. Little is known about the function of 
PSMG1, but the protein has been hypothesized to be involved in microbial 
processing in Crohn’s disease 
GPR35 GPR35 is one of the "metabolite-sensing" G-protein-coupled receptors that 
expressed on immune cells and some gut epithelial cells. Proteins in this family 
generally mediate an anti-inflammatory effect. 
TCF4 TCF4 is a transcription factor affecting cell proliferation and differentiation. It is 
important in T-cell, B- cell and plasmacytoid dendritic cell development. 
CCL20 CCL20 is the ligand of chemokine receptor CCR6 and strongly attracts immature 
dendritic cells and memory T cells. 
NFKB1 NFKB1 belongs to NF-κB family that controls genes regulating a broad range of 
biological processes including inflammation, cell growth, tumorigenesis and 
apoptosis. 
RFX4 
 
RIC8B 
RFX4 is a transcription factor belonging to regulatory factor X (RFX) family, 
which potentially contributions to brain development and disease.  
RIC8B has been identified as a G alpha(s)-binding protein, which catalyzes cAMP 
production and regulates many physiological aspects. 
FOXP1 FOXP1, which belongs to subfamily P of the forkhead box (FOX) transcription 
factor family, regulates lymphocyte expansion and differentiation processes, and 
might act as a tumour suppressor. 
CCDC88B CCDC88B is a member of the hook-related protein family and acts as a novel 
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regulator of maturation and effector functions of T cells during pathological 
inflammation. 
CLEC16A  
SOCS1 
CLEC16A is a novel regulator of mitophagy that maintains glucose homeostasis.  
SOCS1 is a negative regulator of cytokine signalling. It has an important role in 
Treg-cell integrity and function. 
UBASH3A UBASH3A belongs to a new type of protein tyrosine phosphatase family that 
negatively regulates T-cell signalling by promoting apoptosis. 
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Supplementary material 
 
 
Chapter 4: Factors associated with clinical outcome and the development of a 
risk scoring system for patients with PSC.  
 
 
 
Supplementary table 4.1. Univariate analysis using un-imputed data and multivariate 
analysis using 10 imputed data sets, of factors at diagnosis associated with 10-year risk of 
transplantation or death.  
 Univariable Analysis Multivariable Analysis 
Factor HR (95% CI) p-value HHR (95% CI) p-value 
Female 0.83 (0.64,1.07)   0.157     
Age at diagnosis 1.01 (1.01,1.02)   0.001 1.02 (1.01,1.03) 0.001 
Extra-hepatic disease 1.76 (1.34,2.31) <0.001 1.45 (1.09,1.92) 0.010 
IBD presence 0.94 (0.65,1.37)   0.766     
   UC      
   CD     
   IC     
Autoimmune disease 1.16 (0.84,1.60)   0.353   
Smoker 1.03 (0.79,1.34)   0.846   
Bilirubin     
   35 -49 2.92 (1.67,5.11) <0.001 1.92 (1.07,3.45) 0.030   
   50+ 4.88 (3.52,6.75) <0.001 2.50 (1.66,3.75) 0.000 
ALP ratio     
  1.5 - <2.5 1.15 (0.72,1.82)  1.15 (0.75,1.78) 0.519 
  2.5+ 2.04 (1.46,2.85) <0.001 1.70 (1.16,2.50) 0.007 
ALT  1.02 (1.00,1.03)   0.030   
Albumin 0.92 (0.89,0.94) <0.001 0.97 (0.94,1.00) 0.075 
Haemoglobin 0.85 (0.79,0.92) <0.001 0.99 (0.98,1.00) 0.037 
Platelets group     
  150 - 199 0.37 (0.21,0.66)   0.001 0.63 (0.36,1.11) 0.106 
  200 - 399 0.24 (0.16,0.37) <0.001 0.40 (0.25,0.63) 0.000  
  400+ 0.24 (0.14,0.41) <0.001 0.24 (0.13,0.45) 0.000 
Eosinophils 1.00 (0.82,1.21)   0.964   
Sodium 0.91 (0.87,0.96)   0.001   
Creatinine >120 1.75 (0.77,3.96)   0.181   
IgG 1.03 (0.95,1.12)   0.478   
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Supplementary Box 4.1 
Short-term UK-PSC Risk Score (RST) = 0.745 (Bili_t0 Group 1 [0/1] + 1.613 
(Bili_t0 Group 2 [0/1]) – 0.061 (Alb_t0 [g/l]) - 0.012 (Hb_t0 [g/l]) -0.476 (Plts_t0 
Group 1 [0/1]) – 0.698 (Plts_t0 Group 2 [0/1]) -0.962 (Plts_t0 Group 3 [0/1]).  
 
Long-term UK-PSC Risk Score (RSLT) = 0.015 (Age_t0[yrs]) + 1.022 (Bili_t2 
Group 1 [0/1]) + 1.156 (Bili_t2 Group 2 [0/1]) + 0.462 (ALP_t2 Group 1 [0/1]) + 
0.490 (ALP_t2 Group 2 [0/1]) +- 0.060 (Alb_t2[g/l]) – 0.414 (Plts_t2 Group 1) – 
0.420 (Plts_t2 group 2) – 0.623 (Plts_t2 Group 3 [0/1]) + 0.538 (disease type_t0 
[0/1]) + 0.987 (variceal bleed_t2 [0/1]).    
 
Bili_t0/t2  group 1; 0= Bili_t0<35 μmol/l or >50 μmol/l, 1= 35 to ≤ 50 μmol/l 
Bili_t0/t2  group 2; 0=Bili_t0 < 50 μmol/l, 1=Bili_t0 ≥50 μmol/l  
Plts_t0/t2 group 1; 0=Plts_t0<150×109/l, or ≥200×109/l, 1= Plts_t0 150 to <200×109/l  
Plts t0/t2 group 2; 0=<200 or ≥ 400×109/l, 1= 200 to <400×109/l 
Plts_t0/t2 group 3; 0=<400×109/l, 1= ≥ 400×109/l 
ALP_t2 group 1; 0=ALP_t2<1.5×ULN or ≥2.5×ULN, 1=1.5 to <2.5,  
ALP_t2 group 2; 0= ALP_t2<2.5×ULN, 1=≥2.5×ULN,  
Disease type_t0; 0=no extra-hepatic disease, 1=presence of extra-hepatic disease Variceal bleed_t2; 
0= no bleed by t2, 1=bleed by t2.   
 
Predicted survival rate at time t = (Baseline survival at time t) ^ exp (RSST or LT),  
 
RSST baseline survival at time t; 1 year: 0.0096612, 2 years: 0.0001109 
RSLT baseline survival at time t; 1 year: 0.8913371, 2 years: 0.7695844, 5 years: 0.4129811, 8 
years: 0.0218214.  
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Example 
An individual diagnosed at age 47 and with no evidence of extra-hepatic disease 
at diagnosis with the following biochemistry at t0: Bili 37μmol/l, Alb 34 g/l, Hb 
130 g/l and Plts 245×109/l, and the following biochemistry at t2: Bili 24μmol/l, 
ALP 2×ULN, Alb 30 g/l, Plts 152×109/l and no variceal bleed by t2, would score 
would score: RSST= (0.745 ×1) – (0.061 ×34)-(0.012 ×130)- (0.698×1)= -3.587.  
Predicted event free survival rate at 2 years = (0.0001109)^exp (-3.587)= 0.78= 
78%.  RSLT=(0.015 × 47) + 0.462 + (- 0.060 × 30)– 0.414 = -1.047.  Predicted 
event free survival rate at 5 years = 0.413 ^ exp (-1.047)  = 0.73 =73%.  
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Supplementary figure 4.1a): Harrell’s C- statistic per ALP cut-point at year 1 for 10-
year hazard of outcome. 
 
 
 
 
 
 
Supplementary figure 4.1b): Harrell’s C- statistic per ALP cut-point at year 2 for 
10-year hazard of outcome.  
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Chapter 5: Genetic association studies – key concepts. 
 
 
 
 
 
Supplementary figure 5.1. The statistical power for the allelic test in a case-control study 
according to (A) minor allele frequency (MAF), (B) disease prevalence, (C) linkage 
disequilibrium (LD), and (D) case-to-control ratio (M, MAF; P, prevalence; D, LD; R, case-
control ratio; A1=1.3, A2=1.5, A3=2, and A4=2.5 for heterozygous odds ratios) (figure 
shown is from Hong et al (158)).  
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Chapter 6: Replication and fine mapping of genetic risk loci in PSC. 
 
  
Supplementary Table 6.1. Association results for all the studied SNPs.   
Chr Locus SNP Position Alleles 
MAF 
(cases/controls) 
P-value 
(UK cohort) 
OR (95% CI) 
(UK cohort) 
2 BCL2L11 rs6720394 111,705,843 G/T 0.13/0.12 0.40 1.07 (0.92 - 1.23) 
2 GPBAR1 rs12612347 218,765,583 G/A 0.48/0.50 0.21 0.94 (0.85 - 1.04) 
3 MST1 rs3197999 49,696,536 A/G 0.33/0.28 1.9E-06 1.28 (1.16 - 1.42) 
13 GPC6 rs9524260 93,311,791 A/G 0.40/0.40 0.77 0.99 (0.89 - 1.09) 
4 IL-2/IL-21 rs12511287 123,797,981 A/T 0.31/0.27 3.0E-04 1.21 (1.09 - 1.35) 
4 IL-2/IL-21 rs6822844 123,728,871 T/G 0.15/0.17 1.9E-03 0.81 (0.70 - 0.92) 
4 IL-2/IL-21 rs13151961 123,334,952 G/A 0.15/0.17 3.2E-03 0.82 (0.71 - 0.93) 
4 IL-2/IL-21 rs13125087 123,238,043 T/A 0.16/0.19 3.9E-03 0.82 (0.72 - 0.94) 
4 IL-2/IL-21 rs11938795 123,292,459 C/T 0.23/0.26 5.9E-03 0.85 (0.76 - 0.95) 
4 IL-2/IL-21 rs6840978 123,774,157 T/C 0.18/0.21 8.5E-03 0.85 (0.75 - 0.96) 
4 IL-2/IL-21 rs6827444 123,352,628 G/C 0.22/0.19 0.02 1.15 (1.02 - 1.30) 
4 IL-2/IL-21 rs13143866 123,760,208 A/G 0.26/0.28 0.028 0.89 (0.79 - 0.99) 
4 IL-2/IL-21 rs7693745 123,455,033 G/A 0.29/0.26 0.034 1.12 (1.01 - 1.25) 
4 IL-2/IL-21 rs2137497 123,777,704 T/G 0.43/0.40 0.040 1.11 (1.01 - 1.22) 
4 IL-2/IL-21 rs12642902 123,727,951 A/G 0.32/0.34 0.066 0.91 (0.82 - 1.01) 
4 IL-2/IL-21 rs11722421 123,491,118 C/G 0.35/0.33 0.20 1.07 (0.97 - 1.18) 
4 IL-2/IL-21 rs6849146 123,545,541 C/T 0.39/0.38 0.21 1.06 (0.97 - 1.17) 
4 IL-2/IL-21 rs975404 123,740,742 C/T 0.35/0.36 0.28 0.94 (0.85 - 1.05) 
4 IL-2/IL-21 rs17454584 123,572,882 G/A 0.23/0.22 0.34 1.06 (0.94 - 1.19) 
4 IL-2/IL-21 rs1512971 123,744,785 T/C 0.28/0.27 0.36 1.05 (0.94 - 1.17) 
4 IL-2/IL-21 rs6534355 123,781,100 T/C 0.24/0.24 0.37 1.05 (0.94 - 1.18) 
4 IL-2/IL-21 rs4295278 123,766,991 C/T 0.06/0.05 0.38 1.10 (0.89 - 1.34) 
4 IL-2/IL-21 rs4833810 123,237,840 T/C 0.39/0.38 0.45 1.04 (0.94 - 1.15) 
4 IL-2/IL-21 rs4833834 123,685,801 G/A 0.09/0.10 0.45 0.94 (0.79 - 1.11) 
4 IL-2/IL-21 rs6534338 123,246,319 T/C 0.30/0.29 0.52 1.04 (0.93 - 1.15) 
4 IL-2/IL-21 rs13110000 123,797,510 C/T 0.44/0.43 0.52 1.03 (0.94 - 1.14) 
4 IL-2/IL-21 rs7678445 123,502,222 T/G 0.08/0.07 0.53 1.06 (0.89 - 1.27) 
4 IL-2/IL-21 rs13119723 123,437,763 G/A 0.15/0.15 0.65 0.97 (0.85 - 1.11) 
4 IL-2/IL-21 rs11931332 123,236,177 C/T 0.34/0.34 0.78 1.01 (0.92 - 1.12) 
4 IL-2/IL-21 rs6848868 123,369,736 C/T 0.08/0.08 0.81 0.98 (0.82 - 1.16) 
4 IL-2/IL-21 rs6419221 123,783,569 T/C 0.37/0.37 0.87 0.99 (0.90 - 1.10) 
4 IL-2/IL-21 rs1022234 123,782,528 G/A 0.31/0.32 0.91 0.99 (0.90 - 1.10) 
10 IL2RA rs4147359 6,148,445 A/G 0.39/0.34 2.6E-04 1.20 (1.09 - 1.33) 
10 IL2RA rs706778 6,138,955 T/C 0.44/0.40 4.3E-04 1.19 (1.08 - 1.31) 
10 IL2RA rs7090530 6,150,881 C/A 0.36/0.40 7.0E-04 0.84 (0.76 - 0.93) 
10 IL2RA rs10905718 6,154,862 G/A 0.35/0.31 1.0E-03 1.18 (1.07 - 1.31) 
10 IL2RA rs10905669 6,132,099 T/C 0.27/0.23 1.6E-03 1.20 (1.07 - 1.33) 
10 IL2RA rs11594656 6,162,015 A/T 0.21/0.24 2.8E-03 0.84 (0.74 - 0.94) 
10 IL2RA rs10905716 6,154,016 T/C 0.19/0.22 4.2E-03 0.84 (0.74 - 0.95) 
10 IL2RA rs706779 6,138,830 T/C 0.44/0.47 8.8E-03 0.88 (0.80 - 0.97) 
10 IL2RA rs7090512 6,150,835 C/T 0.27/0.30 0.011 0.87 (0.78 - 0.97) 
10 IL2RA rs706781 6,126,391 C/T 0.28/0.26 0.021 1.14 (1.02 - 1.27) 
10 IL2RA rs4749924 6,122,402 C/A 0.30/0.33 0.025 0.89 (0.80 - 0.99) 
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10 IL2RA rs11256456 6,120,718 C/T 0.23/0.21 0.032 1.14 (1.01 - 1.28) 
10 IL2RA rs2104286 6,139,051 C/T 0.26/0.28 0.044 0.89 (0.80 - 1.00) 
10 IL2RA rs2476491 6,135,416 T/A 0.27/0.29 0.053 0.90 (0.81 - 1.00) 
10 IL2RA rs11256497 6,127,800 A/G 0.35/0.37 0.072 0.91 (0.82 - 1.01) 
10 IL2RA rs12722563 6,109,567 A/G 0.10/0.12 0.085 0.87 (0.75 - 1.02) 
10 IL2RA rs2256774 6,137,171 C/T 0.32/0.34 0.11 0.92 (0.83 - 1.02) 
10 IL2RA rs12251307 6,163,501 T/C 0.11/0.12 0.11 0.88 (0.76 - 1.03) 
10 IL2RA rs12359875 6,091,113 T/C 0.23/0.25 0.14 0.92 (0.82 - 1.03) 
10 IL2RA rs6602392 6,118,085 A/C 0.10/0.09 0.18 1.12 (0.95 - 1.31) 
10 IL2RA rs791587 6,128,705 A/G 0.45/0.46 0.21 0.94 (0.85 - 1.04) 
10 IL2RA rs9663421 6,095,610 T/C 0.27/0.28 0.22 0.93 (0.84 - 1.04) 
10 IL2RA rs11598648 6,124,031 A/G 0.44/0.43 0.22 1.06 (0.96 - 1.17) 
10 IL2RA rs11256457 6,120,800 G/C 0.38/0.40 0.25 0.94 (0.86 - 1.04) 
10 IL2RA rs2076846 6,103,259 G/A 0.37/0.36 0.40 1.04 (0.94 - 1.15) 
10 IL2RA rs4749955 6,158,972 C/T 0.44/0.45 0.44 0.96 (0.87 - 1.06) 
10 IL2RA rs12722596 6,096,300 C/T 0.10/0.10 0.55 1.05 (0.90 - 1.23) 
10 IL2RA rs12722588 6,100,439 T/C 0.19/0.19 0.68 1.03 (0.91 - 1.16) 
10 IL2RA rs7093069 6,103,325 T/C 0.19/0.19 0.68 1.03 (0.91 - 1.16) 
10 IL2RA rs12722489 6,142,018 T/C 0.16/0.16 0.72 0.98 (0.86 - 1.11) 
10 IL2RA rs12244380 6,093,380 G/A 0.43/0.43 0.81 1.01 (0.92 - 1.12) 
Association results for all the 63 SNPs analysed in the UK cohort (992 PSC cases and 5162 controls) are shown with the 
method of genotyping used in the control population. All the 63 SNPs were genotyped in cases. Logistic regression analysis 
was performed in PLINK v1.07. Position refers to NCBI’s build 36. Bonferroni corrected P-value threshold for significance 
was determined to be < 7.9 x 10-4. SNPs with nominal association (P-value < 0.05) are shown in boldface.  
All the reported odds ratios are with reference to minor allele vs. major allele.     
Chr – chromosome, MAF – Minor allele frequency, OR – Odds ratio, CI – Confidence interval.  
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Supplementary Table 6.2. Association results for all the SNPs (nominally associated) analysed after excluding patients with auto-immune 
disease. 
Chr Locus SNP BP Alleles 
MAF 
(cases/controls) 
P-value 
(UK cohort) 
OR (95% CI) 
(UK cohort) 
P-value 
(AID excluded) 
OR (95% CI) 
(AID excluded) 
3 MST1 rs3197999 49,696,536 A/G 0.33/0.28 1.90E-06 1.28 (1.16 - 1.42) 1.20E-06 1.31 (1.17 - 1.46) 
4 IL-2/IL-21 rs12511287 123,797,981 A/T 0.31/0.27 3.00E-04 1.21 (1.09 - 1.35) 4.70E-04 1.22 (1.09 - 1.36) 
4 IL-2/IL-21 rs6822844 123,728,871 T/G 0.15/0.17 1.90E-03 0.81 (0.70 - 0.92) 6.50E-03 0.82 (0.71 - 0.95) 
4 IL-2/IL-21 rs13125087 123,238,043 T/A 0.16/0.19 3.90E-03 0.82 (0.72 - 0.94) 7.00E-03 0.83 (0.72 - 0.95) 
4 IL-2/IL-21 rs13151961 123,334,952 G/A 0.15/0.17 3.20E-03 0.82 (0.71 - 0.93) 0.01 0.83 (0.72 - 0.96) 
4 IL-2/IL-21 rs11938795 123,292,459 C/T 0.23/0.26 5.90E-03 0.85 (0.76 - 0.95) 0.023 0.87 (0.77 - 0.98) 
4 IL-2/IL-21 rs6840978 123,774,157 T/C 0.18/0.21 8.50E-03 0.85 (0.75 - 0.96) 0.012 0.85 (0.74 - 0.96) 
4 IL-2/IL-21 rs6827444 123,352,628 G/C 0.22/0.19 0.02 1.15 (1.02 - 1.30) 0.017 1.17 (1.03 - 1.32) 
4 IL-2/IL-21 rs13143866 123,760,208 A/G 0.26/0.28 0.028 0.89 (0.79 - 0.99) 0.042 0.89 (0.79 - 1.00) 
4 IL-2/IL-21 rs2137497 123,777,704 T/G 0.43/0.40 0.04 1.11 (1.01 - 1.22) 0.018 1.13 (1.02 - 1.26) 
10 IL2RA rs10905669 6,132,099 T/C 0.27/0.23 1.60E-03 1.20 (1.07 - 1.33) 5.10E-03 1.18 (1.05 - 1.33) 
10 IL2RA rs4147359 6,148,445 A/G 0.39/0.34 2.60E-04 1.20 (1.09 - 1.33) 1.20E-03 1.19 (1.07 - 1.32) 
10 IL2RA rs706778 6,138,955 T/C 0.44/0.40 4.30E-04 1.19 (1.08 - 1.31) 2.90E-03 1.17 (1.05 - 1.29) 
10 IL2RA rs7090530 6,150,881 C/A 0.36/0.40 7.00E-04 0.84 (0.76 - 0.93) 2.10E-03 0.85 (0.76 - 0.94) 
10 IL2RA rs10905718 6,154,862 G/A 0.35/0.31 1.00E-03 1.18 (1.07 - 1.31) 3.00E-03 1.18 (1.06 -1.31) 
10 IL2RA rs11594656 6,162,015 A/T 0.21/0.24 2.80E-03 0.84 (0.74 - 0.94) 7.10E-03 0.84 (0.75 - 0.95) 
10 IL2RA rs10905716 6,154,016 T/C 0.19/0.22 4.20E-03 0.84 (0.74 - 0.95) 0.015 0.85 (0.75 - 0.97) 
10 IL2RA rs706779 6,138,830 T/C 0.44/0.47 8.80E-03 0.88 (0.80 - 0.97) 0.019 0.88 (0.80 - 0.98) 
10 IL2RA rs7090512 6,150,835 C/T 0.27/0.30 0.011 0.87 (0.78 - 0.97) 0.024 0.88 (0.78 - 0.98) 
10 IL2RA rs706781 6,126,391 C/T 0.28/0.26 0.021 1.14 (1.02 - 1.27) 0.031 1.13 (1.01 - 1.27) 
A phenotype based sub-group analysis was performed against 5162 controls for PSC cases without autoimmune disease (AID) (n = 875). Results of this sub-group analysis 
is shown in the column marked as: P-value(AID excluded). Only SNPs with nominal association (P-value(AID excluded) < 0.05) are shown. Bonferroni corrected P-value threshold for 
significance was determined to be < 7.9 x 10-4 and SNPs reaching this threshold are shown in boldface. Position refers to NCBI’s build 36. All the reported odds ratios are 
with reference to minor allele vs. major allele. Chr – chromosome, MAF – Minor allele frequency, OR – Odds ratio, CI – Confidence interval. 
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Supplementary Table 6.3. Association results for all the SNPs (nominally associated) analysed for patients with or without IBD. 
Chr Locus SNP Position Alleles 
MAF 
(cases/controls) 
P-value 
(UK cohort) 
OR (95% CI) 
(UK cohort) 
P-value 
(PSC with IBD) 
P-value 
(PSC without IBD) 
3 MST1 rs3197999 49,696,536 A/G 0.33/0.28 1.9E-06 1.28 (1.16 - 1.42) 1.2E-05 7.2E-03 
4 IL-2/IL-21 rs12511287 123,797,981 A/T 0.31/0.27 3.0E-04 1.21 (1.09 - 1.35) 4.9E-03 9.0E-03 
4 IL-2/IL-21 rs6822844 123,728,871 T/G 0.15/0.17 1.9E-03 0.81 (0.70 - 0.92) 0.039 7.3E-03 
4 IL-2/IL-21 rs13151961 123,334,952 G/A 0.15/0.17 3.2E-03 0.82 (0.71 - 0.93) 0.038 0.016 
4 IL-2/IL-21 rs13125087 123,238,043 T/A 0.16/0.19 3.9E-03 0.82 (0.72 - 0.94) 0.019 0.04 
4 IL-2/IL-21 rs6840978 123,774,157 T/C 0.18/0.21 8.5E-03 0.85 (0.75 - 0.96) 0.10 0.017 
4 IL-2/IL-21 rs13143866 123,760,208 A/G 0.26/0.28 0.028 0.89 (0.79 - 0.99) 0.19 0.046 
10 IL2RA rs4147359 6,148,445 A/G 0.39/0.34 2.6E-04 1.20 (1.09 - 1.33) 1.3E-03 0.031 
10 IL2RA rs10905669 6,132,099 T/C 0.27/0.23 1.6E-03 1.20 (1.07 - 1.33) 2.8E-03 0.077 
10 IL2RA rs706778 6,138,955 T/C 0.44/0.40 4.3E-04 1.19 (1.08 - 1.31) 4.6E-03 0.020 
10 IL2RA rs10905718 6,154,862 G/A 0.35/0.31 1.0E-03 1.18 (1.07 - 1.31) 4.9E-03 0.036 
10 IL2RA rs706781 6,126,391 C/T 0.28/0.26 0.021 1.14 (1.02 - 1.27) 5.3E-03 0.55 
10 IL2RA rs7090530 6,150,881 C/A 0.36/0.40 7.0E-04 0.84 (0.76 - 0.93) 0.041 1.9E-03 
10 IL2RA rs11594656 6,162,015 A/T 0.21/0.24 2.8E-03 0.84 (0.74 - 0.94) 0.086 4.7E-03 
10 IL2RA rs10905716 6,154,016 T/C 0.19/0.22 4.2E-03 0.84 (0.74 - 0.95) 0.085 7.6E-03 
10 IL2RA rs706779 6,138,830 T/C 0.44/0.47 8.8E-03 0.88 (0.80 - 0.97) 0.11 0.016 
10 IL2RA rs7090512 6,150,835 C/T 0.27/0.30 0.011 0.87 (0.78 - 0.97) 0.25 4.8E-03 
10 IL2RA rs4749924 6,122,402 C/A 0.30/0.33 0.025 0.89 (0.80 - 0.99) 0.30 0.017 
10 IL2RA rs11256456 6,120,718 C/T 0.23/0.21 0.032 1.14 (1.01 - 1.28) 0.024 0.36 
10 IL2RA rs2104286 6,139,051 C/T 0.26/0.28 0.044 0.89 (0.80 - 1.00) 0.017 0.74 
A phenotype based sub-group analysis was performed against 5162 controls for PSC cases with IBD (n = 625); and PSC cases without IBD (n = 367). 
Results (P-values only) of these sub-group analyses are given in the last two columns marked as: P-value(PSC with IBD); and P-value(PSC without IBD) respectively.  
Only SNPs with nominal association (P-value(AID excluded) < 0.05) are shown. Bonferroni corrected P-value threshold for significance was determined to be < 
7.9 x 10-4 and the only SNP reaching this threshold is shown in boldface. Position refers to NCBI’s build 36. All the reported odds ratios are with reference 
to minor allele vs. major allele. Chr – chromosome, MAF – Minor allele frequency, OR – Odds ratio, CI – Confidence interval.  
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 Chapter 7: Genome wide association study in PSC.  
 
 
Supplementary Figure 7.1 (a). Individuals in the BBC control group with first principal component 
score < 0.16 and second principal component score < 0.072 were removed. 
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Supplementary Figure 7.1 (b). Individuals in the NBS control group with first principal component 
score < 0.16 and second principal component score < 0.072 were removed. 
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Supplementary Figure 7.2 (a). Histogram of missing data rate across all PSC cases. The vertical 
dashed line represents the threshold (3%) at which SNPs were removed from further analysis because 
of an excess failure rate.  
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Supplementary Figure 7.2 (b). Histogram of missing data rate across all BBC controls. The vertical 
dashed line represents the threshold (3%) at which SNPs were removed from further analysis because 
of excessive failure rate. 
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Supplementary Figure 7.2 (c). Histogram of missing data rate across all NBS controls. The vertical 
dashed line represents the threshold (3%) at which SNPs were removed from further analysis because 
of excessive failure rate. 
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Supplementary Table 7.1. Genetic association results for suggestive associations (p-value < 1 x 10-4) in the discovery panel.  
CHR SNP BP A1 F_A F_U A2 CHISQ P OR L95 U95 
1 rs10492966 8598005 A 0.2241 0.1846 G 18.81 1.45E-05 1.276 1.143 1.424 
1 rs11121182 8522553 A 0.2234 0.1849 C 17.88 2.35E-05 1.268 1.136 1.416 
1 rs10492965 8598127 A 0.2221 0.1837 G 17.8 2.46E-05 1.268 1.135 1.416 
1 rs9435739 17342924 G 0.2937 0.3388 A 17.24 3.30E-05 0.8113 0.735 0.8956 
1 rs11121203 8648240 G 0.2226 0.185 A 17.03 3.68E-05 1.261 1.129 1.408 
1 rs7553298 8770883 G 0.2361 0.1985 A 16.05 6.16E-05 1.247 1.119 1.39 
1 rs12087224 84130384 A 0.122 0.09476 G 15.51 8.21E-05 1.328 1.153 1.53 
2 rs1516637 112634339 G 0.2933 0.3491 A 25.92 3.56E-07 0.7739 0.7011 0.8543 
2 rs13389578 145216048 G 0.1063 0.08101 A 15.2 9.66E-05 1.349 1.16 1.568 
3 rs3197999 49721532 A 0.3336 0.2772 G 29.14 6.75E-08 1.306 1.185 1.439 
3 rs1131095 49714225 G 0.3398 0.2845 A 27.49 1.58E-07 1.294 1.175 1.425 
3 rs11130213 49712297 A 0.3395 0.2845 G 27.17 1.86E-07 1.292 1.173 1.424 
3 rs4283605 49678651 G 0.3398 0.285 A 27.05 1.98E-07 1.291 1.173 1.422 
3 rs11706370 49441091 A 0.3521 0.2987 G 25.02 5.67E-07 1.276 1.16 1.404 
3 rs17080528 49389842 A 0.3516 0.2988 G 24.49 7.48E-07 1.273 1.157 1.4 
3 rs10640 49454277 A 0.3516 0.2991 G 24.21 8.63E-07 1.271 1.155 1.398 
3 rs6997 49453834 A 0.3515 0.2991 G 24.02 9.53E-07 1.27 1.154 1.397 
3 rs11715915 49455330 A 0.3516 0.2993 G 23.99 9.66E-07 1.27 1.154 1.397 
3 rs6766131 49538932 G 0.3494 0.2975 A 23.74 1.10E-06 1.268 1.153 1.396 
3 rs4625 49572140 G 0.3516 0.2996 A 23.7 1.12E-06 1.268 1.152 1.395 
3 rs13070798 48705934 G 0.1402 0.1049 A 23.56 1.21E-06 1.391 1.217 1.591 
3 rs2286652 48689192 A 0.1396 0.1044 G 23.47 1.27E-06 1.391 1.217 1.591 
3 rs3811697 49590770 A 0.3538 0.3025 G 22.95 1.66E-06 1.262 1.147 1.389 
3 rs9836462 48712791 G 0.1427 0.1086 A 21.45 3.63E-06 1.367 1.197 1.56 
3 rs12107418 48689787 G 0.142 0.1085 A 20.67 5.46E-06 1.36 1.191 1.554 
3 rs13063312 48661985 A 0.1251 0.09551 G 18.08 2.11E-05 1.354 1.177 1.558 
3 rs11719291 48735706 G 0.151 0.1186 A 17.98 2.23E-05 1.321 1.161 1.503 
3 rs13324142 48669447 A 0.1247 0.09557 G 17.49 2.89E-05 1.348 1.171 1.551 
3 rs2276850 48669648 A 0.1247 0.09567 G 17.36 3.09E-05 1.346 1.17 1.549 
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3 rs3821876 48668394 A 0.1251 0.09608 C 17.32 3.16E-05 1.345 1.169 1.548 
3 rs2276852 48666923 G 0.1305 0.1009 A 17.2 3.36E-05 1.337 1.165 1.534 
3 rs2953130 128170341 A 0.1182 0.09041 G 16.72 4.34E-05 1.348 1.168 1.557 
4 rs345367 86754638 A 0.2612 0.3112 G 22.04 2.67E-06 0.7828 0.7067 0.8672 
4 rs7665833 131381117 A 0.1523 0.1174 G 21.1 4.36E-06 1.351 1.188 1.537 
4 rs11735471 189536624 G 0.4165 0.4657 A 18.23 1.96E-05 0.819 0.7472 0.8977 
4 rs2088131 11511291 A 0.3556 0.4006 G 15.94 6.54E-05 0.8254 0.7512 0.907 
4 rs4862251 184687644 A 0.2834 0.2435 G 15.88 6.76E-05 1.229 1.11 1.36 
4 rs11734090 123228113 G 0.2206 0.2598 A 15.23 9.52E-05 0.8063 0.7235 0.8985 
5 rs419119 6021846 A 0.172 0.2182 C 23.92 1.00E-06 0.7443 0.661 0.8381 
5 rs2029036 118275869 C 0.1049 0.07897 A 16.44 5.03E-05 1.367 1.175 1.591 
5 rs17648108 177831556 G 0.3128 0.2715 A 15.92 6.62E-05 1.222 1.107 1.348 
5 rs1567520 118159871 A 0.08692 0.06392 G 15.6 7.81E-05 1.394 1.181 1.645 
7 rs10951953 5510159 G 0.4512 0.5032 A 20.26 6.77E-06 0.8115 0.7409 0.8889 
7 rs10260121 115110126 G 0.1431 0.1117 A 17.76 2.50E-05 1.328 1.163 1.515 
7 rs2023702 114945308 G 0.08304 0.0604 A 15.9 6.69E-05 1.409 1.19 1.669 
7 rs1477216 155235978 A 0.4342 0.3894 G 15.65 7.63E-05 1.203 1.098 1.319 
8 rs9657390 2546665 G 0.3216 0.3677 A 17.22 3.32E-05 0.8152 0.7401 0.8979 
8 rs17070773 4463359 A 0.06409 0.09053 G 16.67 4.45E-05 0.688 0.5744 0.824 
8 rs2617094 4456167 A 0.09991 0.1298 G 15.31 9.10E-05 0.744 0.6413 0.8632 
9 rs12237858 33439738 A 0.1107 0.05898 C 78.67 7.36E-19 1.987 1.703 2.318 
9 rs7027092 95812707 G 0.2722 0.3223 A 21.82 2.99E-06 0.7863 0.7107 0.8699 
9 rs16931895 117609919 C 0.1493 0.1188 A 15.94 6.55E-05 1.301 1.143 1.481 
10 rs436207 61087914 C 0.2885 0.3647 A 47.28 6.15E-12 0.7062 0.6394 0.7801 
10 rs3118470 6101713 G 0.363 0.3164 A 18.56 1.65E-05 1.231 1.12 1.354 
10 rs953355 124515295 A 0.2125 0.1748 G 17.85 2.39E-05 1.274 1.138 1.425 
10 rs11255072 5806248 A 0.163 0.1302 G 17.12 3.51E-05 1.301 1.148 1.475 
10 rs990394 71347276 A 0.2524 0.2129 C 17.07 3.61E-05 1.249 1.124 1.388 
10 rs10885476 115330721 A 0.1308 0.1655 G 16.8 4.16E-05 0.759 0.6649 0.8663 
10 rs1658495 60280153 A 0.4965 0.4496 C 16.56 4.72E-05 1.207 1.102 1.322 
10 rs7099881 60316211 G 0.4908 0.444 A 16.49 4.88E-05 1.207 1.102 1.321 
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10 rs1649048 60324282 G 0.496 0.4494 A 16.42 5.09E-05 1.206 1.102 1.321 
10 rs1649031 60279742 A 0.4956 0.449 G 16.37 5.20E-05 1.206 1.101 1.32 
10 rs1904694 52905494 G 0.4451 0.4001 A 15.69 7.45E-05 1.203 1.098 1.318 
10 rs7072793 6106266 G 0.4535 0.4084 A 15.61 7.78E-05 1.202 1.097 1.316 
10 rs12252820 71351990 A 0.1646 0.1332 G 15.44 8.54E-05 1.282 1.132 1.452 
10 rs1413611 36466891 G 0.4214 0.3774 A 15.3 9.16E-05 1.202 1.096 1.317 
10 rs12412095 6113523 G 0.3528 0.3107 A 15.26 9.38E-05 1.209 1.099 1.33 
10 rs1451193 36461567 G 0.4583 0.5033 A 15.19 9.74E-05 0.8348 0.7623 0.9142 
10 rs1343065 54676411 G 0.3827 0.3398 A 15.15 9.94E-05 1.204 1.097 1.323 
11 rs11221265 128236936 A 0.14 0.1106 G 15.81 6.99E-05 1.309 1.146 1.496 
11 rs836141 34537316 A 0.4421 0.3975 G 15.4 8.72E-05 1.201 1.096 1.316 
11 rs7936255 38998451 A 0.294 0.3365 G 15.26 9.39E-05 0.8212 0.7439 0.9066 
12 rs10774625 111910219 G 0.4362 0.4974 A 28 1.22E-07 0.7818 0.7136 0.8566 
12 rs1265566 111716376 G 0.2676 0.316 A 20.47 6.06E-06 0.7911 0.7146 0.8757 
12 rs11065987 112072424 G 0.4692 0.4186 A 19.53 9.93E-06 1.228 1.121 1.345 
12 rs7134542 102339665 A 0.2572 0.2183 G 16.3 5.41E-05 1.241 1.117 1.378 
12 rs11066320 112906415 A 0.4736 0.428 G 15.84 6.91E-05 1.203 1.098 1.317 
12 rs11066301 112871372 G 0.4749 0.4292 A 15.83 6.95E-05 1.203 1.098 1.317 
12 rs770460 78132040 A 0.4855 0.4399 G 15.66 7.60E-05 1.201 1.097 1.315 
12 rs17696736 112486818 G 0.4772 0.4322 A 15.38 8.79E-05 1.199 1.095 1.313 
14 rs1824343 98920773 C 0.294 0.2392 A 30.05 4.22E-08 1.325 1.198 1.465 
14 rs1257641 99480395 A 0.08253 0.1163 G 21.76 3.09E-06 0.6834 0.5819 0.8026 
14 rs1015277 84438074 C 0.2076 0.1731 A 15.17 9.83E-05 1.252 1.118 1.402 
16 rs8047221 2897372 C 0.3041 0.3495 A 17.11 3.53E-05 0.8134 0.7374 0.8971 
16 rs3810801 2892370 A 0.3007 0.3458 C 17 3.74E-05 0.8136 0.7375 0.8975 
16 rs8060332 2892770 A 0.3409 0.3871 G 16.94 3.85E-05 0.819 0.7447 0.9008 
17 rs4405612 66733514 A 0.07784 0.055 G 17.52 2.84E-05 1.45 1.217 1.727 
17 rs10775405 45188090 A 0.3525 0.3098 G 15.62 7.75E-05 1.213 1.102 1.334 
18 rs470549 74747488 A 0.1078 0.05378 G 91.4 1.17E-21 2.125 1.815 2.488 
18 rs9952617 28881801 A 0.4947 0.4472 G 17.05 3.65E-05 1.21 1.105 1.325 
19 rs4897966 389873 A 0.2669 0.2275 G 16.18 5.77E-05 1.236 1.115 1.371 
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20 rs2064726 50715685 A 0.277 0.3258 G 20.55 5.82E-06 0.793 0.7172 0.8768 
20 rs1885082 17593984 G 0.2557 0.2178 A 15.45 8.46E-05 1.234 1.111 1.371 
21 rs2836881 40466299 A 0.2094 0.2699 C 35.51 2.54E-09 0.7166 0.642 0.7999 
21 rs2836878 40465534 A 0.2109 0.2699 G 33.89 5.82E-09 0.7229 0.6479 0.8066 
21 rs378108 40469520 G 0.5316 0.4789 A 20.76 5.22E-06 1.235 1.128 1.352 
21 rs1893592 43855067 C 0.2537 0.2997 A 19.11 1.24E-05 0.7946 0.7167 0.881 
A1 = minor allele; A2 = major allele; F_A = frequency of minor allele in cases; F_U = frequency of minor allele in controls; OR = odds ratio; L95 = lower 
limit of 95% confidence interval; U95 = upper limit of 95% confidence interval 
 199 
 
Supplementary Figures 7.3 (a – z). Regional association plots for all SNPs showing suggestive or genome 
wide significant association in the discovery panel. Plots were created using SNAP except for rs10774625 
(Figure 7.3r) which was plotted using Locus zoom plot. 
 
  
Supplementary Figure 7.3a. 
 
 
 
Supplementary Figure 7.3b. 
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Supplementary Figure 7.3c. 
 
 
 
 
Supplementary Figure 7.3d. 
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Supplementary Figure 7.3e. 
 
 
 
 
Supplementary Figure 7.3f. 
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Supplementary Figure 7.3g. 
 
 
 
 
 
Supplementary Figure 7.3h. 
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Supplementary Figure 7.3i. 
 
 
 
 
 
Supplementary Figure 7.3j. 
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Supplementary Figure 7.3k. 
 
 
 
 
Supplementary Figure 7.3l. 
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Supplementary Figure 7.3m. 
 
 
 
 
 
Supplementary Figure 7.3n. 
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Supplementary Figure 7.3o. 
 
 
 
 
Supplementary Figure 7.3p. 
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Supplementary Figure 7.3q. 
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Supplementary Figure 7.3u.  
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Supplementary Figure 7.3w. 
 
 
 
 
 
Supplementary Figure 7.3x. 
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Supplementary Figure 7.3y. 
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Supplementary Table 7.2. List of all SNPs considered for in-silico replication analysis 
(n = 96). 
CH
R 
SNP Position 
(GRCh37.5); 
build 19 
CHR SNP Position (GRCh37.5); build 19 
1 rs11121182 8522553 10 rs3118470 6101713 
1 rs7553298 8770883 10 rs10905669 6092093 
1 rs10492966 8598005 10 rs2387015 6215257 
1 rs10492965 8598127 10 rs3814195 6213960 
1 rs11121203 8648240 10 rs3763700 6181709 
1 rs7520572 8871690 10 rs11255072 5806248 
1 rs4908760 8526142 10 rs7072793 6106266 
1 rs1953827 8679848 10 rs12412095 6113523 
2 rs13389578 145216048 10 rs7090530 6110875 
2 rs16823732 145204758 11 rs7928323 38841059 
2 rs11883829 145519623 11 rs11034972 38860022 
2 rs12105918 145208193 11 rs2068461 38831942 
2 rs10192562 145184316 11 rs10837055 38845174 
2 rs13032840 145506108 11 rs836141 34537316 
3 rs13070798 48705934 11 rs7936255 38998451 
3 rs9836462 48712791 11 rs2555524 38881682 
3 rs13324142 48669447 11 rs2912573 38950513 
3 rs12107418 48689787 11 rs7116065 38979245 
3 rs13063312 48661985 11 rs11221265 128236936 
3 rs2276852 48666923 12 rs1265566 111716376 
3 rs2286652 48689192 12 rs17696736 112486818 
3 rs11719291 48735706 12 rs770460 78132040 
3 rs2276850 48669648 12 rs10774625 111910219 
3 rs3821876 48668394 12 rs11065987 112072424 
4 rs434193 86253489 12 rs11066320 112906415 
4 rs4693142 87252259 12 rs11066301 112871372 
4 rs7684187 123341159 14 rs1257641 99480395 
4 rs7689808 87254477 14 rs1015277 84438074 
4 rs345367 86754638 14 rs17119456 84485390 
4 rs11734090 123228113 14 rs1824343 98920773 
4 rs13132933 123010587 14 rs17119553 84509670 
4 rs11938795 123073009 16 rs8047221 2897372 
4 rs34135604 123283993 16 rs3810801 2892370 
4 rs6822844 123509421 16 rs8060332 2892770 
4 rs10027390 123368516 16 rs11076866 2898356 
4 rs11575812 123371049 18 rs9952617 28881801 
4 rs13151961 123115502 18 rs7229974 28890717 
5 rs17648108 177831556 18 rs11663134 28869498 
5 rs17132677 118175674 18 rs2114270 28885116 
5 rs12109252 118267633 19 rs4897966 389873 
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5 rs6874399 118225616 20 rs2064726 50715685 
5 rs419119 6021846 20 rs1885082 17593984 
5 rs2029036 118275869 20 rs4814628 17593315 
5 rs1567520 118159871 20 rs13734 17594729 
7 rs10951953 5510159 21 rs378108 40469520 
8 rs17070773 4463359 21 rs1893592 43855067 
8 rs2617094 4456167 21 rs2836881 40466299 
9 rs7027092 95812707 21 rs2836878 40465534 
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Supplementary table 7.3. Meta-analysis results for all SNPs (n = 86). SNPs reaching 
genome-wide significance (p-value < 5 x 10-8) are highlighted in bold. 
CHR BP SNP A1 A2 P-value 
(combined); 
random effects 
OR 
(combined)
; random 
effects 
Q I 
1 8648240 rs11121203 C T 0.0002113 1.212 0.2668 18.9 
1 8679848 rs1953827 A G 0.0004828 0.8734 0.648 0 
1 8526142 rs4908760 A G 0.0006915 0.8772 0.4838 0 
1 8770883 rs7553298 A G 0.001383 0.8378 0.2304 30.49 
1 8598127 rs10492965 A G 0.03827 1.1808 0.0963 63.85 
1 8598005 rs10492966 C T 0.04297 0.8447 0.0837 66.57 
1 8522553 rs11121182 A C 0.04574 1.1784 0.0885 65.53 
1 8871690 rs7520572 A G 0.07293 1.1304 0.1205 58.53 
2 145204758 rs16823732 A G 0.0006241 1.2897 0.3153 0.83 
2 145208193 rs12105918 C T 0.001232 1.297 0.284 12.89 
2 145184316 rs10192562 A G 0.001258 0.7837 0.3301 0 
2 145216048 rs13389578 C T 0.008451 1.2567 0.1881 42.27 
2 145519623 rs11883829 A G 0.5935 0.9468 0.014 83.42 
2 145506108 rs13032840 A G 0.6143 1.0544 0.0118 84.22 
3 48705934 rs13070798 C T 1.07E-08 1.3648 0.6451 0 
3 48712791 rs9836462 A G 2.73E-08 0.7406 0.7701 0 
3 48689787 rs12107418 A G 6.48E-08 0.7453 0.7364 0 
3 48735706 rs11719291 A G 2.10E-07 0.7599 0.917 0 
3 48661985 rs13063312 A G 1.30E-06 1.3165 0.5185 0 
3 48669447 rs13324142 C T 1.75E-06 0.7621 0.538 0 
3 48666923 rs2276852 A G 1.95E-06 0.7656 0.5831 0 
4 123010587 rs13132933 C T 3.04E-07 0.7666 0.5399 0 
4 123509421 rs6822844 G T 1.28E-05 1.3292 0.2397 27.65 
4 123115502 rs13151961 A G 9.61E-05 1.322 0.2001 39.09 
4 123073009 rs11938795 C T 0.0003023 0.8421 0.2929 9.61 
4 123228113 rs11734090 C T 0.003339 0.8451 0.2124 35.69 
4 123341159 rs7684187 A G 0.0116 1.1504 0.2073 37.1 
4 123368516 rs10027390 C T 0.01177 0.8691 0.2061 37.45 
4 86754638 rs345367 A G 0.0956 0.8552 0.0306 78.61 
4 87252259 rs4693142 A G 0.1232 0.9091 0.1789 44.65 
4 87254477 rs7689808 C T 0.1235 1.1001 0.1781 44.84 
4 86253489 rs434193 C T 0.1613 0.9154 0.1367 54.84 
5 6021846 rs419119 A C 0.03127 0.813 0.0596 71.82 
5 118159871 rs1567520 C T 0.5916 0.8871 0.0042 87.78 
5 118175674 rs17132677 C T 0.6138 0.9146 0.0074 86.08 
5 177831556 rs17648108 C T 0.652 1.0667 0.003 88.62 
5 118225616 rs6874399 C T 0.6595 0.9255 0.008 85.76 
5 118275869 rs2029036 G T 0.7511 1.081 0.0012 90.51 
5 118267633 rs12109252 C T 0.7683 0.9333 0.0025 89.04 
8 4456167 rs2617094 A G 0.4139 0.8733 0.0072 86.17 
8 4463359 rs17070773 A G 0.6219 0.8824 0.0006 91.56 
9 95812707 rs7027092 A G 0.6021 1.089 0.0017 89.89 
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10 6101713 rs3118470 C T 2.27E-09 1.2646 0.341 0 
10 6110875 rs7090530 A C 8.63E-07 1.2125 0.3597 0 
10 6092093 rs10905669 C T 1.08E-06 0.8108 0.8171 0 
10 6106266 rs7072793 C T 2.07E-06 1.247 0.2338 29.47 
10 6181709 rs3763700 C T 9.45E-06 0.8398 0.7899 0 
10 6113523 rs12412095 A G 0.0003783 0.7761 0.089 65.42 
10 6215257 rs2387015 C T 0.01449 0.8473 0.2063 37.39 
10 6213960 rs3814195 C T 0.01532 0.847 0.2099 36.39 
10 5806248 rs11255072 C T 0.4958 0.8964 0.004 87.93 
11 34537316 rs836141 A G 0.01898 1.1483 0.1806 44.21 
11 128236936 rs11221265 A G 0.4373 1.1307 0.0149 83.12 
11 38841059 rs7928323 A C 0.7299 0.9532 0.0006 91.44 
11 38831942 rs2068461 C T 0.7399 1.0461 0.0009 91.01 
11 38860022 rs11034972 C T 0.7483 0.9571 0.0007 91.2 
11 38845174 rs10837055 A C 0.7734 1.0374 0.0017 89.89 
11 38998451 rs7936255 A G 0.8812 0.9743 0 93.99 
11 38979245 rs7116065 C T 0.9041 0.9818 0.0003 92.42 
11 38950513 rs2912573 A G 0.9222 1.0166 0.0001 93.71 
12 111910219 rs10774625 A G 6.79E-10 1.2645 0.6726 0 
12 111716376 rs1265566 C T 4.46E-08 0.7932 0.929 0 
12 112072424 rs11065987 A G 3.08E-07 0.8232 0.694 0 
12 112486818 rs17696736 A G 2.79E-06 0.8382 0.8478 0 
12 112906415 rs11066320 A G 3.20E-06 1.1935 0.767 0 
12 112871372 rs11066301 A G 3.24E-06 0.8379 0.7705 0 
12 78132040 rs770460 C T 0.4487 0.9222 0.0073 86.13 
14 84485390 rs17119456 A G 0.05121 0.8712 0.1494 51.88 
14 99480395 rs1257641 A G 0.07703 0.7802 0.0361 77.23 
14 84438074 rs1015277 A C 0.08445 0.862 0.0883 65.57 
14 84509670 rs17119553 A G 0.1138 0.8796 0.0977 63.54 
14 98920773 rs1824343 G T 0.5856 1.1063 0.0001 93.49 
16 2892770 rs8060332 A G 0.02782 0.8644 0.1401 54.07 
16 2892370 rs3810801 A C 0.09511 0.873 0.081 67.15 
16 2897372 rs8047221 A C 0.1404 1.1362 0.0514 73.65 
18 28890717 rs7229974 A G 0.6075 0.9426 0.0037 88.14 
18 28881801 rs9952617 C T 0.6761 0.9442 0.0006 91.57 
18 28885116 rs2114270 G T 0.6823 0.9547 0.0049 87.38 
20 17593984 rs1885082 A G 3.62E-05 0.833 0.3604 0 
20 17593315 rs4814628 C T 0.0001539 0.8234 0.7811 0 
20 17594729 rs13734 A G 0.000516 1.1792 0.8332 0 
20 50715685 rs2064726 C T 0.608 1.0831 0.0003 92.29 
21 43855067 rs1893592 A C 1.19E-05 1.217 0.298 7.66 
21 40469520 rs378108 A G 0.0003878 0.8418 0.2169 34.41 
21 40465534 rs2836878 A G 0.0314 0.7973 0.0301 78.75 
21 40466299 rs2836881 G T 0.03502 1.2594 0.0246 80.22 
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Appendix 2 
 
The UK PSC Consortium 
 
Chief Investigator: 
Prof Gideon Hirschfield, University Hospitals Birmingham NHS Trust 
 
Steering committee group members: 
Dr Graeme Alexander Cambridge University Hospitals NHS Trust 
Dr Richard Sandford, Cambridge University hospital NHS Trust 
Dr George Mells, Cambridge University hospital NHS Trust 
Dr Roger Chapman, John Radcliffe Hospital NHS Trust 
Dr Mark Hudson, Newcastle upon Tyne Hospitals NHS Trust 
Prof David Jones, Newcastle upon Tyne Hospitals NHS Trust 
Dr Douglas Thorburn, Royal Free London NHS Trust 
Professor Massimo Pinzani, Royal Free London NHS Trust 
Dr Simon Rushbrook, Norfolk and Norwich University Hospital NHS Trust 
Martine Walsmsley, PSC Support group, Trustee and Chair 
 
Principal investigators at each recruitment site: 
 
Abertawe Bro Morgannwg University NHS Trust (Dr Chin Lye   Ch'ng, Dr Clement Lai, 
Dr Tom Yapp), Aintree University Hospitals NHS Foundation Trust (Dr Richard 
Sturgess), Airedale NHS Trust (Dr Chris Healey), Barnsley Hospital NHS Foundation 
Trust (Dr Kapil Kapur), Ashford and St Peter's Hospitals NHS Trust (Dr John Thornton), 
Barking, Havering and Redbridge University Hospitals NHS Trust (Dr Stephen Grainger, 
Dr Purushothaman Premchand), Barnet and Chase Farm Hospitals NHS Trust (Dr 
Stephen Mann, Dr Kalpesh Besherdas), Barts and The London NHS Trust (Dr Richard 
Marley, Prof Graham Foster), Basingstoke and North Hampshire NHS Foundation Trust 
(Dr John Ramage), Bedford Hospital NHS Trust (Dr Rory Harvey), Blackpool Teaching 
Hospitals NHS Foundation Trust (Dr Peter Isaacs), Bolton NHS Foundation Trust (Dr 
George Lipscomb),  Bradford Teaching Hospitals NHS Foundation Trust (Dr Sulleman 
Moreea), Brighton and Sussex University Hospitals NHS Trust (Dr Jeremy Tibble, Dr 
Nick Parnell), Bromley Hospitals NHS Trust (Dr Anthony Jenkins), Buckinghamshire 
Healthcare NHS Trust (Dr Sue Cullen, Dr David Gorard), Burton Hospitals NHS 
Foundation Trust (Dr Altaf Palejwala), Cambridge University Hospitals NHS Foundation 
Trust (Dr Graeme Alexander), Calderdale And Huddersfield NHS Foundation Trust (Dr 
Susan Jones, Dr Ashwin Verma), Cardiff and Vale NHS Trust (Dr Richard Aspinall, Dr 
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Sunil Dolwani),  Central Manchester University Hospitals NHS Foundation Trust (Dr 
Martin Prince), Chelsea and Westminster Hospital NHS Foundation Trust (Dr Karen 
Hawkins, Dr Priyajit Prasad), Chesterfield Royal Hospitals NHS Foundation Trust (Dr 
David Elphick), City Hospitals Sunderland NHS Foundation Trust (Dr Harriet Mitchison), 
Colchester Hospital University NHS Foundation Trust (Dr Ian Gooding), Countess of 
Chester Hospital NHS Foundation Trust (Dr Mazn Karmo), County Durham and Darlington 
NHS Foundation Trust (Dr Anjan Dhar, Dr Stephen Mitchell, Dr Sushma Saksena), 
Cwm Taf NHS Trust (Dr Minesh Patel), Dartford And Gravesham NHS Trust (Dr Roland 
Ede), Derby Hospitals NHS Foundation Trust (Dr Andrew Austin), Doncaster and 
Bassetlaw Hospitals NHS Foundation Trust (Dr Joanne Sayer), Dorset County Hospitals 
NHS Foundation Trust (Dr Chris Hovell), East and North Hertfordshire NHS Trust (Dr 
Martyn Carter, Dr Peter McIntyre), East Cheshire NHS Trust (Dr Konrad Koss), 
Medway NHS Foundation Trust (Dr Gray Smith-Laing), Maidstone and Tunbridge Wells 
NHS Trust (Dr George Bird), East Kent Hospitals University NHS Foundation Trust (Dr 
Kate Hill), East Sussex NHS Trust (Dr David Neal), East Lancashire Hospitals NHS Trust 
(Dr Vishal Kaushik), Epsom and St Helier University Hospitals NHS Trust (Dr Guan 
Lim), Frimley Park NHS Foundation Trust (Dr Aftab Ala), Gateshead Health NHS 
Foundation Trust (Dr Athar Saeed), George Eliot Hospital NHS Trust (Dr Sankara 
Raman), Gloucestershire Hospitals NHS Foundation Trust (Professor Jonathan Brown), 
Great Western Hospitals NHS Foundation Trust (Dr Ajeya Shetty), Guy's and St Thomas' 
NHS Trust (Dr Mark Wilkinson), Gwent Healthcare NHS Trust (Dr Miles Allison, Dr 
Marek Czajkowfki, Dr Peter Neville), Harrogate and District NHS Foundation Trust (Dr 
Butt, Dr Gareth Davies), Heart of England NHS Foundation Trust (Dr Theodore 
Ngatchu), Hereford Hospitals NHS Trust (Dr Rupert Ransford), Hinchingbrooke Health 
Care NHS Trust (Dr Richard Dickinson), Homerton University Hospital NHS Foundation 
Trust (Dr Ray Shidrawi), Hull And East Yorkshire Hospitals NHS Trust (Dr George 
Abouda), Hywel Dda Health Board NHS Trust (Dr Faiz Ali, Dr Mark Narain, Dr Ian 
Rees, Dr Imroz Salam),Imperial College Healthcare NHS Trust (Dr Ashley Brown), 
Ipswich Hospital NHS Trust (Dr Simon Williams), NHS Isle Of Wight (Dr Christopher 
Sheen), James Paget University Hospitals NHS Foundation Trust (Dr Matthew Williams), 
Kings College Hospital NHS Foundation Trust (Dr Michael Heneghan), Kingston Hospital 
NHS Trust (Dr Chris Rodrigues), Lancashire Teaching Hospitals NHS Foundation Trust 
(Dr Phillip Shields), Leeds Teaching Hospitals NHS Trust (Dr Mark Aldersley, Dr 
Mervyn Davies, Dr Charles Millson), Luton and Dunstable Hospital NHS Foundation 
Trust (Dr Sambit Sen), Mid Cheshire Hospitals NHS Foundation Trust (Dr Kevin Yoong), 
Mid Essex Hospital Services NHS Trust (Dr Cho Cho Khin), Mid Staffordshire NHS 
Foundation Trust (Dr Pradip Singh), Mid Yorkshire Hospitals NHS Trust (Dr Nurani 
Sivaramakrishnan), Milton Keynes Hospital NHS Foundation Trust (Dr George 
MacFaul), Newham University Hospital NHS Trust (Dr Matthew Guinane), NHS Ayrshire 
& Arran (Dr Chris Gillen, Dr James Rose, Dr Amir Shah), NHS Borders (Dr Chris 
Evans), NHS Dumfries & Galloway (Dr Subrata Saha), NHS Fife (Dr Sherzad Balta, Dr 
John Wilson), NHS Forth Valley (Dr Peter Bramley), NHS Grampian (Dr Andrew 
Fraser), NHS Greater Glasgow and Clyde (Dr Aidan Cahill, Dr G Curry, Dr Shouren 
Datta, Dr Ewan Forrest, Dr Neil Jamieson, Dr James McPeake, Professor Peter Mills, 
Dr Judith Morris, Dr Adrian Stanley), NHS Highland (Dr Dara De Las Heras, Dr Tim 
Shallcross), NHS Lanarkshire (Dr Stuart Campbell, Dr Richard Crofton, Dr Andrzej 
Prach), NHS Lothian (Dr Andrew Bathgate, Dr Kevin Palmer),  NHS Tayside (Dr Alan 
Shepard, Dr John Dillon), Norfolk and Norwich University Hospitals NHS Foundation 
Trust (Dr Martin Phillips, Dr Simon Rushbrook), North Bristol NHS Trust (Dr Robert 
Przemioslo), North Cumbria University Hospitals NHS Trust (Dr Babur Javaid, Dr Chris 
McDonald), North Tees And Hartlepool NHS Foundation Trust (Dr Jane Metcalf), North 
Wales NHS Trust (Dr Paulose George, Dr David Ramanaden), The North West London 
Hospitals NHS Trust (Dr Maxton Pitcher), North West Wales NHS Trust (Dr Jaber 
Gasem Dr Richard Evans), Northampton General Hospital NHS Trust (Dr Udi Shmueli), 
Northern Devon Healthcare NHS Trust (Dr Andrew Davis), Northern Lincolnshire and 
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Goole Hospitals NHS Foundation Trust (Dr Prabhakar Mysore, Dr Asifabbas Naqvi), 
Northumbria Healthcare NHS Trust (Dr Mark Welfare), Nottingham University Hospitals 
NHS Trust (Dr Steve Ryder), Oxford Radcliffe Hospitals NHS Trust (Dr Roger 
Chapman), Pennine Acute Hospitals NHS Trust (Dr Howard Klass, Dr Jimmy Limdi, Dr 
Bashir Rameh), Peterborough Stamford Hospitals NHS Foundation Trust (Dr Mary 
Ninkovic), Plymouth Hospitals NHS Trust (Dr Matthew Cramp), Poole Hospital NHS 
Foundation Trust (Dr Nicholas Sharer), Portsmouth Hospitals NHS Trust (Dr Patrick 
Goggin), Queen Mary’s Sidcup NHS Trust (Dr Howard Curtis), Royal Berkshire NHS 
Foundation Trust (Dr Jonathan Booth), Royal Cornwall Hospitals NHS Trust (Dr Hyder 
Hussaini), Royal Devon and Exeter NHS Foundation Trust (Dr Reuben Ayres), Royal Free 
Hampstead NHS Trust (Dr Douglas Thorburn), Royal Liverpool and Broadgreen 
University Hospitals NHS Trust (Dr Martin Lombard), Royal Surrey County Hospital NHS 
Trust (Dr Michelle Gallagher), Royal United Hospital Bath NHS Trust (Dr Duncan 
Robertson), Salisbury NHS Foundation Trust (Dr Sam Vyas), Sandwell and West 
Birmingham Hospitals NHS Trust (Dr Saket Singhal), Scarborough And North East 
Yorkshire Health Care NHS Trust (Dr Sathish Babu), Sheffield Teaching Hospitals NHS 
Foundation Trust (Dr Dermot Gleeson), Sherwood Forest Hospitals NHS Foundation Trust 
(Dr Sharat Misra), Shrewsbury and Telford Hospital NHS Trust (Dr Jeff Butterworth), 
South Devon Healthcare NHS Trust (Dr Keith George), South London Healthcare NHS 
Trust (Dr Alastair McNair), South Tees Hospitals NHS Trust (Dr Andrew Douglas), South 
Tyneside NHS Foundation Trust (Dr Colin Rees), South Warwickshire General Hospitals 
NHS Trust (Dr Jeremy Shearman), Southampton University Hospitals NHS Trust (Dr 
Kate Nash, Dr Mark Wright), Southend University Hospital NHS Foundation Trust (Dr 
Gary Bray), Southport And Ormskirk Hospital NHS Trust (Dr Graham Butcher), St 
George’s Healthcare NHS Trust (Dr Daniel Forton), St Helens And Knowsley Hospitals 
NHS Trust (Dr John McLindon), Stockport NHS Foundation Trust (Dr Debashis Das), 
Surrey and Sussex Healthcare NHS Trust (Dr Gary Mackenzie, Dr Azhar Ansari, Dr 
Gregory Whatley), Taunton and Somerset NHS Foundation Trust (Dr Stirling Pugh), 
Dudley Group of Hospitals NHS Trust (Dr Neil Fisher), The Hillingdon Hospital NHS Trust 
(Dr Deb Datta), The Lewisham Hospital NHS Trust (Dr John Odonohue), The Newcastle 
upon Tyne Hospitals NHS Foundation Trust (Dr Mark Hudson), The Princess Alexandra 
Hospital NHS Trust (Dr Rosemary Phillips), The Queen Elizabeth Hospital King's Lynn 
NHS Trust (Dr Andrew Douds), Rotherham NHS Foundation Trust (Dr Barbara 
Hoeroldt), Royal Bournemouth And Christchurch Hospitals NHS Foundation Trust (Dr 
Earl Williams), The Royal Wolverhampton Hospitals NHS Trust (Dr Matthew Brookes), 
Trafford Healthcare NHS Trust (Dr Chris Summerton), United Lincolnshire Hospitals NHS 
Trust (Dr Aravamuthan Sreedharan, Dr Sanjiv Jain, Dr Martin James), University 
College London Hospitals NHS Foundation Trust (Dr Stephen Pereira), University Hospital 
Birmingham NHS Foundation Trust (Professor David Adams), University Hospital of 
North Staffordshire NHS Trust (Dr Alison Brind), University Hospital of South Manchester 
NHS Foundation Trust (Dr Gill Watt), University Hospitals Bristol NHS Foundation Trust 
(Dr Fiona Gordon, Dr Jim Portal), University Hospitals Coventry and Warwickshire NHS 
Trust (Dr Esther Unitt), University Hospitals of Leicester NHS Trust (Dr Allister Grant), 
Walsall Hospitals NHS Trust (Dr Mark Cox), Warrington and Halton Hospitals NHS 
Foundation Trust (Dr Subramaniam Ramakrishnan), West Hertfordshire Hospitals NHS 
Trust (Dr Alistair King), West Suffolk Hospitals NHS Trust (Dr Simon Whalley), Western 
Sussex Hospitals NHS Trust (Dr Andy Li, Dr Mohammed Rashid), Weston Area Health 
NHS Trust (Dr Andrew Bell), Winchester And Eastleigh Healthcare NHS Trust (Dr Harriet 
Gordon), Wirral University Teaching Hospital NHS Foundation Trust (Dr Riyaz 
Faizallah), Worcestershire Acute Hospitals NHS Trust (Dr Ishfaq Ahmad, Dr Ian Gee), 
Wrightington, Wigan and Leigh NHS Trust (Dr Gurvinder Banait), Yeovil District 
Hospital NHS Foundation Trust (Dr Steve Gore, Dr James Gotto), York Hospitals NHS 
Foundation Trust (Dr Alastair Turnbull).  
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Appendix 3 
 
 
Participant Questionnaire (Version TWO) 
Research study into the genetic causes of Primary Sclerosing Cholangitis 
 
[Patient name] 
[Patient address] 
 
1) What is your date of birth? ______________________ 
 
2)   Sometimes the genes involved in causing a disease like PSC are different 
in different ethnic groups. Knowing your ethnic category will help us to analyse 
the results of this study. Please indicate your ethnic category by ticking the most 
appropriate box. 
 
NATIONAL CODE  YES 
   
WHITE   
A BRITISH  
B IRISH  
C ANY OTHER WHITE BACKGROUND  
   
MIXED   
D WHITE AND BLACK CARIBBEAN  
E WHITE AND BLACK AFRICAN  
F WHITE AND ASIAN  
G ANY OTHER MIXED BACKGROUND  
   
ASIAN OR ASIAN BRITISH   
H INDIAN  
J PAKISTANI  
K BANGLADESHI  
L ANY OTHER ASIAN BACKGROUND  
   
BLACK OR BLACK BRITISH   
M CARIBBEAN  
N AFRICAN  
P ANY OTHER BLACK BACKGROUND  
   
OTHER ETHNIC GROUPS   
R CHINESE  
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S ANY OTHER ETHNIC GROUP  
   
   
Z NOT STATED  
 
 
3) What is your sex (Please circle)                                 Male                         
Female 
 
4) Do you have Inflammatory Bowel Disease?    Yes           No           Not Sure 
  
      5)   If yes do you have:                Ulcerative Colitis              Crohn’s  Not 
Sure 
           (Please circle your response) 
       
      6)  Do you or have you ever smoked?                  Yes                No 
 
7) If you have smoked then please list the dates between which you smoked 
tobacco 
 
            
 
 
 
 
 
 
 
     8) Have you lived in accommodation that is occupied with pets?    Yes              No    
          
         If yes please could you indicate which pets and at what ages of your life? 
 
 
 
 
 
 
 
 
 
 
Please answer question 9 and 10 if possible, and in which format you are more 
familiar with. 
 
9) What is your current weight? (Either answer in stones and pounds or 
kilograms). 
 
…………………………………………………………………………………………
……….                                           
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10) How tall are you? (Either answer in meters/cms or feet and inches). 
 
 …………………………………………………………………………… 
………………………                                                                          
                                                                              
11) Please indicate the areas that you have ever lived in 
 
Country of Birth 
…………………………………………………………………………………. 
 
 
Areas Lived Location (Post Code) Duration of stay in that 
area 
   
   
   
   
   
   
 
12) If you had symptoms from your PSC how long did it take for you to be 
diagnosed? 
 
-------------------------------------------------------------------------------------------------------
------ 
 
13) Have you had adequate information regarding your condition         Yes     No     
Not sure  
      (Please circle) 
 
14a) Do other members of your family have PSC?                               Yes    No     
Not sure 
        (Please circle) 
14b) If yes, please indicate which other members of your family have PSC.  
 
RELATIVE        YES 
GRANDMOTHER  
GRANDFATHER  
FATHER  
MOTHER  
MATERNAL AUNT  
MATERNAL UNCLE  
PATERNAL AUNT  
PATERNAL UNCLE  
BROTHER  
SISTER  
OTHERS  
 
14c) How many brothers and sisters do you have (alive or dead)?      
__________________ 
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15a) Do other members of your family have Inflammatory Bowel Disease? 
                                  
 
Yes        No                   Not Sure  
 
 
15b) If yes, please indicate which other members of your family have Inflammatory 
Bowel disease 
 
RELATIVE        YES 
GRANDMOTHER  
GRANDFATHER  
FATHER  
MOTHER  
MATERNAL AUNT  
MATERNAL UNCLE  
PATERNAL AUNT  
PATERNAL UNCLE  
BROTHER  
SISTER  
OTHERS  
 
 
16) How many children do you have? 
 
17) Do they have any illnesses? If so please describe them all in the box below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18) Do you suffer from any of the following medical conditions (you’ll know if you 
have it!)? 
 
 YES 
DAUGHTERS (Please indicate how many) SONS (Please indicate how many) 
  
Illnesses your children have please detail: 
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A) SYSTEMIC LUPUS ERYTHEMATOSIS (SLE) 
 
 
 
B) OVERACTIVE OR UNDERACTIVE THYROID DISEASE 
 
 
 
C) INSULIN DEPENDANT DIABETES STARTING FROM YOUNG AGE 
 
 
 
D) SJOGREN’S SYNDROME 
 
 
 
E) SCLERODERMA 
 
 
 
F) COELIAC DISEASE 
 
 
 
19) Have you had any operations (If so please detail) 
 
 
 
 
 
 
20) How old were you when you were first told you had PSC?
 __________________ 
      (Please leave blank if not sure) 
 
 
21) If you have inflammatory bowel disease how old were you when you first had it? 
      (Please leave blank if not sure) 
 
      ---------------------------------------------------------------------------------------------------
----- 
 
22) When you were first told you had PSC, did you have any of the following 
symptoms? 
 
 YES 
 
A) ITCHING 
 
 
 
B) EXCESSIVE TIREDNESS 
 
 
 
C) DISCOMFORT IN THE LIVER AREA (THE RIGHT-SIDED, UPPER PART OF THE TUMMY) 
 
 
 
D) ACHING OF THE BONES 
 
 
 
E) ASCITES (FLUID INSIDE THE TUMMY) 
 
 
 
F) BLEEDING FROM VARICES (SWOLLEN VEINS AT THE BOTTOM END OF THE GULLET) 
 
 
 
G) JAUNDICE (YELLOW DISCOLOURATION AFFECTING THE WHITE OF THE EYE) 
 
 
 
H) HEPATIC ENCEPHALOPATHY (CONFUSION OWING TO LIVER DISEASE)  
 
 
 
I) NO SYMPTOMS (ONLY THE LIVER TESTS WERE ABNORMAL)  
 
 
J) OTHERS 
 
 
 
 
 
23a) Have you had a liver transplant?   Yes  No  
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23b) If you have had a liver transplant, when was it performed? ________________ 
 
Questions 24, 25 & 26: please only answer these questions if you have not had a 
liver transplant. 
 
24) If you have not had a liver transplant, do you have any of the following symptoms 
now? How long have you had them? 
 
 
 
YES DURATION 
 
A) ITCHING 
 
  
 
B) EXCESSIVE TIREDNESS 
 
  
 
C) DISCOMFORT IN THE LIVER AREA (THE RIGHT-SIDED, UPPER PART OF THE 
TUMMY) 
 
  
 
D) ACHING OF THE BONES 
 
  
 
E) ASCITES (FLUID INSIDE THE TUMMY) 
 
  
 
F) BLEEDING FROM VARICES (SWOLLEN VEINS AT THE BOTTOM END OF THE 
GULLET) 
 
  
 
G) JAUNDICE (YELLOW DISCOLOURATION AFFECTING THE WHITE OF THE EYE) 
 
  
 
H) HEPATIC ENCEPHALOPATHY (CONFUSION OWING TO LIVER DISEASE)  
 
  
 
I) NO SYMPTOMS  
 
  
J) OTHERS   
 
 
25) Are you receiving any of the following medications for PSC? 
 
 
MEDICATION 
 
 
YES  
 
A) URSODEOXYCHOLIC ACID  (URSO)? 
 
 
 
B) CHOLESTYRAMINE? 
 
 
 
C) RIFAMPICIN? 
 
 
 
D) HOW MUCH URSODEOXYCHOLIC ACID DO YOU TAKE? (PLEASE WRITE DOSE IN YES 
BOX IF TAKING IT) 
 
 
 
26) Are you waiting for a liver transplant?           Yes                  No
  
27) Have you ever from suffered from a cancer? 
 
If yes please detail 
 
 
 
 
No more questions. Thank-you for completing the 
questionnaire… 
 
Clinician’s Questionnaire (Version 1) 
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Research study into the genetic causes of Primary Sclerosing Cholangitis 
 
Dear [collaborating clinician] 
 
Re: [Patient name, date of birth, address] 
 
This patient has agreed to participate in a research study into the genetic causes of 
primary sclerosing cholangitis. As part of the study, please provide the following 
information about the patient: 
 
 
1) Is the patient under follow-up at [hospital]? Yes                              No    
 
2) Is the patient known to have PSC?   Yes   No 
 
3) Mode of diagnosis 
 
3.1) Investigations 
 
 YES NO DATE 
 
3.1 A) MRCP 
 
   
 
3.1 B) ERCP 
 
  
 
 
 
3.1 C) LIVER BIOPSY 
 
 
 
 
 
 
 
3.2) If ERCP or MRCP did the patient have 
 
 YES NO NOT 
CLEAR 
 
3.2 A) INTRAHEPATIC CHOLANGIOGRAPHIC CHANGES 
 
   
 
3.2 B) EXTRAHEPATIC CHOLANGIOGRAPHIC CHANGES 
 
  
 
 
 
3.2 C) BOTH INTRA AND EXTRAHEPATIC 
 
 
 
 
 
 
 
 
3.3) Does the patient have Inflammatory Bowel Disease                      YES          NO 
       Please circle 
IF YES, PLEASE INDICATE WHICH TYPE YES NO 
 
3.3 A) ULCERATIVE COLITIS 
 
  
 
3.3 B) INDETERMINATE COLITIS 
 
  
 
3.3 C) CHRONS COLITIS 
 
 
 
 
 
3.4) Regarding Liver biopsy 
 
 YES DATE 
 
3.4 A) LIVER HISTOLOGY COMPATIBLE WITH PSC 
 
  
 
3.4 B) LIVER HISTOLOGY NOT COMPATIBLE WITH PSC 
 
  
 
3.4 C) LIVER BIOPSY NOT UNDERTAKEN  
 
 
 
NA 
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4) Liver Biochemistry 
 
Please provide any abnormal liver biochemistry result 
Please ensure:  
1) The blood test was undertaken at the time of diagnosis, or since the diagnosis 
was made.  
2) When the blood test was undertaken, the patient had no intercurrent illness 
(e.g. sepsis).  
 
 
 RESULT DATE OF TEST 
 
4.A) TOTAL BILIRUBIN 
 
  
 
4.B) AST 
 
  
 
4.C) ALT 
 
  
 
4.D) ALP 
 
  
 
4.E) ALBUMIN 
 
  
 
 
5) Does the patient suffer from any of the following co-morbid hepatic disorders? 
  
 YES 
 
5.A) CHRONIC HEPATITIS B 
 
 
 
5.B) CHRONIC HEPATITIS C 
 
 
 
5.C) ALCOHOLIC LIVER DISEASE  
 
 
 
 
5.D) NON-ALCOHOLIC LIVER DISEASE 
 
 
 
5.E) AUTOIMMUNE HEPATITIS (AUTOIMMUNE OVERLAP) 
 
 
 
5.F) PRIMARY BILIARY CIRRHOSIS 
 
 
 
5.G) HAEMACHROMATOSIS 
 
 
 
5.H) OTHER CO-MORBID LIVER DISORDER (PLEASE SPECIFY) 
 
 
 
 
 
 
 
6) What is the patient’s ethnicity? _____________________________________ 
 
 
 
No more questions. Thank-you for completing the questionnaire. 
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Dr Gideon Hirschfield  
The UK PSC Study 
 
Research Centre: 
Dept. of Medical Genetics 
Lv 6, Addenbrooke’s Treatment Centre 
Cambridge Biomedical Campus 
Hills Rd 
Cambridge 
CB2 0QQ 
 
Research study into the genetic causes of Primary Sclerosing 
Cholangitis 
 
Clinician Questionnaire 
 
Question 1 
 
1.1)  What is the patient’s date of birth?................................................ 
 
1.2)  What is the patient’s gender?                         Male                       Female  
 
 
1.3) Is the patient under follow-up at your hospital? Yes                              No    
 
 
1.4) What is the name of your hospital? 
………………………………………………………. 
 
1.5) Was the patient under another NHS Trust before you started looking 
after them? 
 
                                                                                Yes                              No    
 
1.6) If the answer to 1.5 was yes, please name the trust and hospital that was 
looking after the patient 
 
............................................................................................................................
......................... 
 
Question 2 
 
2.1) Is the patient known to have PSC?        Yes                        No 
 
2.2) Date of Diagnosis of PSC (i.e confirmation on biopsy or cholangiography, 
if known)  
 
                                                                 
………………………………………………………... 
 
2.3) Was the patient initially diagnosed with another liver condition? 
        
Yes                              No  
 
 
 
Recruitment centre: XXXX 
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2.4) If yes, what was the name of this condition? 
………………………………….. 
 
 
2.5) What date was this diagnosis 
made?.................................................................................. 
 
 
Question 3 
 
3.1) Is the patient still alive?              Yes   No  
 
        
If yes, please go to Q.4. 
 
 
3.2) What is the cause of death documented on the death certificate or in the 
hospital notes (if known)? 
 
Ia…………………....................................................................................
............. 
                       
Ib…………………....................................................................................
............. 
                                    
Ic…………………....................................................................................
............................. 
 
 
3.3) What was the date of death?           
......................................................................................... 
 
 
Question 4 
 
4.1) Has the patient had a liver transplant?            Yes                       No        
 
 
4.2) Is the patient on the liver transplant waiting list? Yes                          No 
 
 If no, move straight to Question 5.  
 
 
4.3) Date the patient was listed for liver transplant (if known):         
………………………………... 
 
 
4.4) Date of actual liver transplant (if known):                                   
..…………..…………………... 
 
 
4.5) Name of transplant centre (if 
known)…………………….……………………….………………... 
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4.6) Does the patient have recurrent PSC post-transplant? Yes    No 
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Question 5 
 
5.1) Please provide the blood results at the time of the diagnosis  
 
 RESULT REFERENCE 
RANGE 
DATE OF TEST 
TOTAL BILIRUBIN    
AST    
ALT    
ALP    
ALBUMIN    
CREATININE    
SODIUM    
HAEMOGLOBIN    
PLATELETS    
WHITE CELL COUNT    
EOSINOPHIL COUNT    
PROTHROMBIN TIME    
APTT    
INR    
 
 
5.2) Please provide the results of the patient’s blood tests one year after 
initial diagnosis 
 
 RESULT REFERENCE 
RANGE 
DATE OF TEST 
TOTAL BILIRUBIN    
AST    
ALT    
ALP    
ALBUMIN    
CREATININE    
SODIUM    
HAEMOGLOBIN    
PLATELETS    
WHITE CELL COUNT    
EOSINOPHIL COUNT    
PROTHROMBIN TIME    
APTT    
INR    
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5.3) Please provide the blood results two years after initial diagnosis 
 
 RESULT REFERENCE 
RANGE 
DATE OF TEST 
TOTAL BILIRUBIN    
AST    
ALT    
ALP    
ALBUMIN    
CREATININE    
SODIUM    
HAEMOGLOBIN    
PLATELETS    
WHITE CELL COUNT    
EOSINOPHIL COUNT    
PROTHROMBIN TIME    
APTT    
INR    
 
 
5.4) Please provide the results of the patient’s most recent blood tests 
 
**IF THE PATIENT IS A TRANSPLANT RECIPIENT, THEN PLEASE PROVIDE 
BLOOD TEST RESULTS IMMEDIATELY PRIOR TO TRANSPLANTATION** 
 
 RESULT REFERENCE 
RANGE 
DATE OF TEST 
TOTAL BILIRUBIN    
AST    
ALT    
ALP    
ALBUMIN    
CREATININE    
SODIUM    
HAEMOGLOBIN    
PLATELETS    
WHITE CELL COUNT    
EOSINOPHIL COUNT    
PROTHROMBIN TIME    
APTT    
INR    
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Question 6 
 
6.1) Please provide the following immunology results (if multiple results 
available, please state the earliest result, post-diagnosis) 
 
 RESULT REFERENCE 
RANGE 
DATE OF TEST 
P-ANCA 
(POSITIVE OR NEGATIVE) 
  
N/A 
 
ANA 
(POSITIVE OR NEGATIVE) 
  N/A  
SMA* 
(POSITIVE OR NEGATIVE) 
*SMOOTH MUSCLE ANTIBODY 
RESULT: 
 
TITRE: 
N/A  
ANTI MITOCHONDRIAL 
ANTIBODY  
(POSITIVE OR NEGATIVE) 
 N/A  
LKM-1 ANTIBODY 
(POSITIVE OR NEGATIVE) 
 N/A  
IMMUNOGLOBULIN IGG  
(LEVEL) 
   
IMMUNOGLOBULIN IGA  
(LEVEL) 
   
IMMUNOGLOBULIN IGM  
(LEVEL) 
   
IGG4  
(LEVEL AND UNITS) 
   
CA19-9 
(LEVEL) 
   
 
 
Question 7 
 
7.1) Please indicate which of the following was used as the initial diagnostic 
investigation: 
 
 YES NO DATE 
MRCP    
ERCP    
 
LIVER BIOPSY   
 
 
 
 
 
7.2) Was ERCP or MRCP compatible with PSC?  Yes              No 
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7.3) If the patient has had an ERCP or MRCP, did it show: 
 
 YES NO UNCLEAR 
INTRAHEPATIC CHOLANGIOGRAPHIC CHANGES OF 
PSC 
   
EXTRAHEPATIC CHOLANGIOGRAPHIC CHANGES OF 
PSC 
   
BOTH INTRA AND EXTRAHEPATIC CHANGES  OF PSC    
NORMAL (NO EVIDENCE OF PSC)    
 
(Please note that extrahepatic biliary tree involves up to the point of 
bifurcation of the left   and right hepatic ducts i.e. everything up to, and 
including the common hepatic duct). 
 
7.4) Has the patient had a follow-up MRCP or ERCP?          Yes   No 
 
If yes, please provide the 
date:………………………………………………………………………… 
 
  
7.5)  Was this an ERCP or 
MRCP?:…………………………………………………………………….. 
 
7.6) Please indicate changes seen on most recent MRCP or ERCP: 
 
 YES NO UNCLEA
R 
INTRAHEPATIC CHOLANGIOGRAPHIC CHANGES OF 
PSC 
   
EXTRAHEPATIC CHOLANGIOGRAPHIC CHANGES OF 
PSC 
   
BOTH INTRA AND EXTRAHEPATIC CHANGES  OF PSC    
NORMAL (NO EVIDENCE OF PSC)    
 
 
7.7)  Are digital or DICOM copies of ERCP/MRCP images available?   Yes                           
No                                    
 
7.8) If the patient has had a Liver Biopsy, please indicate the following 
findings: 
 
 YES DATE 
LIVER HISTOLOGY COMPATIBLE WITH PSC   
LIVER HISTOLOGY NON-DIAGNOSTIC   
LIVER HISTOLOGY NOT COMPATIBLE WITH PSC   
 LIVER BIOPSY NOT UNDERTAKEN   NA 
 
7.9) Which stage of liver disease did the patient have (if known)? (Stage 1-4)      
......................... 
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7.10) Has the patient had a Fibroscan?                      Yes  
   No 
 
 If yes, please document the date…………..……..       kPa………..       
f=…………………….. 
 
**PLEASE INCLUDE AN ANONYMISED COPY OF THE MRCP/ERCP AND LIVER 
BIOPSY REPORTS CITED, STATING THE PATIENT UK-PSC STUDY ID** 
 
 238 
  
 
Question 8 
 
8.1) Has the patient had a colonoscopy to screen for Inflammatory Bowel 
Disease (IBD)?        
    
    Yes               
No 
 
8.2) Does the patient have Inflammatory Bowel Disease?                 
    Yes               
No  
               
 
If no, please 
proceed to Q. 8.6 
 
If yes to 8.2, please indicate which type: 
 YES NO 
ULCERATIVE COLITIS   
INDETERMINATE COLITIS   
CROHNS COLITIS   
 
8.3) Date of diagnosis of IBD (if known)                        
………..……………………………. 
 
 
8.4) If they have colitis is it:               MACROSCOPIC            MICROSCOPIC 
 
 
8.5) Distribution of the Colitis (Please tick all that apply)  
  
TERMINAL ILEUM       CAECUM  ASCENDING COLON  
TRANSVERSE 
COLON 
 DESCENDING 
COLON 
 SIGMOID COLON  
RECTUM  
 
 
 
**PLEASE INCLUDE AN ANONYMISED COPY OF THE INITIAL COLONOSCOPY  
REPORT STATING THE PATIENT UK-PSC STUDY ID** 
 
 
8.6) If patient has ever had dysplasia, was it; Low grade                                High 
grade    
 
 
8.7) Has the patient had a colectomy?                    Yes                               No 
 
 
8.8) If yes, what was the date of their colectomy (if known)?                
………………….. 
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8.9) Specify type of colectomy (if known):     Sub-total colectomy with ileo-
anal pouch     
 
 Pan-proctocolectomy with 
ileostomy    
    
 
 
 
8.10) What was the indication for the colectomy?    
 
Cancer                   Inflammation             
 
Low grade Dysplasia              High grade dysplasia 
 
 
 
 
Other (state)………………...…….... 
 
 
8.11) If patient has had colon cancer, please list the site       
………………………….…….……. 
 
Question 9 
 
9.1) Has the patient had any of the following:  
 
 Yes  Date of first diagnosis 
Cholangiocarcinoma   
Gallbladder cancer   
Hepatocellular carcinoma   
Pancreatic cancer   
Cholecystectomy   
Gallbladder dysplasia (on cholecystectomy report)   
Colorectal Cancer   
Bile duct dysplasia (from ERCP or surgery)   
  
 
9.2) Has the patient had a bone density/DEXA scan?        Yes              No 
          
 If no, proceed to Q.10 
 
9.3) If yes, provide details of the most recent scan: 
 
Date of the report ………………  T score of hip………….……   T score of 
spine………………      
 
Question 10 
 
10.1) Please put the details of the first liver ultrasound findings the patient 
had: 
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Date of ultrasound ………………………………….. 
 
Is liver heterogenous?  Yes    No    Not sure 
 
Is capsule of liver irregular?  Yes    No    Not sure 
 
Size of spleen (cm)…………………… 
 
If no size recorded, was the spleen:             Normal sized                  Enlarged  
 
Gallstones    Yes     No 
 
Gallbladder Polyps    Yes     No 
 
Ascites                                                Yes     No 
            
 
 
10.2) Please put the details of the most recent US the patient had  
 
Date of ultrasound ………………………………….. 
 
Is liver heterogenous?  Yes Y No    Not sure 
 
Is capsule of liver irregular?  Yes    No    Not sure 
 
Size of spleen (cm)…………………… 
 
If no size recorded, was the spleen:             Normal sized                  Enlarged  
 
Gallstones    Yes     No 
 
Gallbladder Polyps    Yes     No 
 
Ascites                                                Yes     No 
 
 
Question 11 
 
11.1) Does the patient suffer from any of the following co-morbid hepatic 
disorders? 
  
 YES 
CHRONIC HEPATITIS B  
CHRONIC HEPATITIS C  
ALCOHOLIC LIVER DISEASE   
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD OR NASH)  
AUTOIMMUNE HEPATITIS ( OR AUTOIMMUNE OVERLAP)  
PRIMARY BILIARY CIRRHOSIS  
HAEMOCHROMATOSIS  
OTHER CO-MORBID LIVER DISORDER (PLEASE SPECIFY)  
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11.2) Has the patient had any of the following complications/diagnoses? 
 
 
 
 
 
 
 
 
 
 
 
 
 
Question 12 
 
12.1) Does the patient suffer from any of these additional diseases? 
 
 YES 
TYPE 1 DIABETES  
PSORIASIS  
RHEUMATOID ARTHRITIS  
ANKYLOSING SPONDYLITIS  
SARCOIDOSIS  
MYAESTHENIA GRAVIS  
MULTIPLE SCLEROSIS  
COELIAC DISEASE  
SYSTEMIC LUPUS ERYTHEMATOSUS  
SJOGRENS SYNDROME  
HYPOTHYROIDISM  
HYPERTHYROIDISM  
 
Question 13 
 
13.1) Has the patient ever taken Ursodeoxycholic acid?             Yes            
No 
 
If no, proceed to Q.13.5 
 
 
13.2) If yes to 13.1, what date did they start?   ................................. 
 
 
13.3) What dose of Ursodeoxycholic Acid did they take (dose mg)………. 
(frequency)………. 
 
 
13.4) If the patient stopped taking Ursodeoxycholic acid, what date did they 
stop?....................... 
 YES  DATE OF FIRST EPISODE OR FIRST 
NOTED 
VARICES ON SCREENING 
ENDOCSOPY 
  
VARICEAL BLEED   
ASCITES   
ENCEPHALOPATHY   
CHOLANGITIS (BILIARY SEPSIS)   
 JAUNDICE   
CIRRHOSIS   
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13.5) Has the patient ever taken Azathioprine?          Yes     No 
 
13.6) If yes to 13.5, what date did they start?     
............................................................................. 
 
 
13.7) Has the patient ever taken a 5-ASA compound (e.g. 
mesalazine,‘pentasa’, ‘asacol’    ‘ipocol’,  ‘mesovant’, ‘octasa’, Balsalazide, 
‘colazide’and balsalazide, olsalazine)?  
 
                    Yes    No 
 
 
13.8) What is the patient’s most recent weight (please state units)? 
………………………….. 
 
 
 
 
No more questions. Thank you for completing the questionnaire. 
 
FINAL CHECKLIST 
 
Have you included an anonymised copy of the following, stating the patient’s UK 
PSC Study number? 
 
ERCP Report 
 
MRCP Report 
 
Liver Biopsy Report   
 
Colonoscopy report 
 
 
 
 
If you have any questions or queries regarding the completion of this 
questionnaire please contact: 
 
Bridget Bell (B.F.Bell@bham.ac.uk; Tel: 0121 371 8101). 
 
 
 
Please return completed questionnaires to:  
The UK PSC Study,  
Dept. of Medical Genetics 
Level 6 Addenbrooke’s Treatment Centre,  
Cambridge Biomedical Campus,  
Hills Rd, 
Cambridge, CB2 0QQ 
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